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Chapter 1 
Introduetion 
In 1907, Aloïs Alzheimer wrote on a disorder of the brain we now call Alzheimer's 
disease: 11ÜTI the whole, it is evident that we are dealing with a peculiar, little-k:nown 
disease process. In recent years these partienlar disease processes have been detected in 
great numbers. This fact should stimulate us to further study and analysis of this 
partienlar disease".1 Despite the extensive search for clues on the cause of Alzheimer's 
disease by scientists for over eighty years, the words 11peculiar'' and "little-knownu still 
apply to our current lrnowledge of the disease process. At present, Alzheimer's disease 
is already a major cause of disability in western populations and given the increase of the 
proportion of elderly people the number of patients is likely to rise in most populations.' 
Yet, remarkably little epidemiologie research into the etioiogy of the disease bas been 
performed to date.' 
The work presented in this thesis has been motivated by the Jack of knowledge of risk 
factors for Alzheimer's disease. It has been long recognised that genetic factors are 
implicated, in particular in early-onset Alzheimer's disease.4 But to what extent are 
genetic factors involved? Are all cases with Alzheimer's disease of genetic origin or is the 
disease in some cases primarily of envîronmental origin? If the latter is true, which 
envîronmental factors may lead to Alzheimer's disease and how do these factors interact 
with the genetic component? The research described in this thesis aimed at resolvîng 
these questions. 
The studies of Alzheimt;;r's disease presented bere have started very much from an 
epidemiologie point of view. Yet, the issues addressed in this thesis required 
methodologie and analytic techniques of the field of genetics. The schools of thought of 
bath epidemiology and genetics are also reflected in the design of the various studies on 
which this thesis is based. Same studies follow the traditional epidemiologie design as they 
deal with camparisans of cases and controls. Other are more compatible with genetic 
studies as relatives of cases and controls are the subject of investigation. 
In chopter 2 an overview is presented of the design of the studies reported. In chapter 
3 the role of genetics in Alzheirner's disease is studied. Chapter 4 gives the evîdence for 
l3 
Chapter 1 
the involvement of environmental risk factors and chapter 5 deals with gene-environment 
interaction. Finally, in chapter 6 the limitations of the studies are reviewed and the 
fmdings are discussed in the context of the present knowledge of the etiology of 
Alzheimer's disease and related disorders. 
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Chapter 2.1 
Genetie-epidemiologie study of 
early-onset Alz.heimer's disease 
In the period from 1982 to 1987 a study of risk factors for early-onset Alzheimer's 
disease was carried out: The aîm of the study was to investigate genetic and 
environmental determinants of AJzheimer's disease. Initially, the study was designed as 
a case-control study. In the second phase, the investigation was extended to fust degree 
relatives of cases and controls. The study was performed in the four narthem provinces 
of the Netherlands and the region of Rotterdam. Here we describe the ascertainment 
procedure of cases and controls, the data collection and some characteristics of the 
population. Details on the study design have been publisbed earlier.' 
Ascertainment of subjects 
Cases. For this study, patients were eligible in whom the diagnosis of Alzheimer's 
disease was made befare the age of 70 years in the period of January 1980 to July 1987. 
The study was population-based and aimed at a complete ascertainment of cases with 
early-onset Alzheimer's disease in two areas of the Netberlands, i.e., the four northern 
provinces (Groningen, Friesland, Drenthe and Overijssel), and the region of the city of 
Rotterdam. To obtain a full ascertainment of patients, all nursing homes, psychiatrie 
institutions, social-geriatric services, neurologists and facilities for computed tomography 
in the specified areas were asked for patients with dementia. The patients were then seen 
by Drs Tanja, Haaxma, or Schulte who independently confirmed the diagnosis of 
probable Alzheimer's disease using a standard protocol similar to the criteria of the 
National Institute of Neurological and Communicative Disorders and Stroke and the 
"The study was initiated by the Working Group Epidemiology of Dementia. At that time, memhers of this 
working group were: Drs R Haaxma, A Hofman, AJ Lameris, RJ Saan, W Scbulte, TA Tanja, with the 
support of Mrs V Otten. 
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Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).' Dementias 
other than Alzheirner's disease (e.g., multi-infarct dementia and dementia secondary to 
a1coholism, depression, metabo1ic d:isorders, and other conditions) were excluded on the 
basis of the clinical history, neurologie examination, and neuropsychologie and }aboratory 
tests. Patients with symptoms of Parkinson's disease befare the onset of Alzheimer's 
disease were also excluded. 
The înclusion criteria for patients were: a typically slow progressive decline of 
inteHectual function,z a score on the Clinical Dementia Rating scale of more than 0.5/ 
a score on the Short Portable Mental Status Questionnaire (SPMSQ) of less than 20 (out 
of 30)/ a score of seven or less on the Hachinski-scale,5 no evidence of abnormalities on 
computed tomography other than cerebral atrophy, nor offocal dysfunction on electro-
encephalography. Of the 278 patients brought to our attention, 201 satisfied these 
criteria. The family of one patient refused cooperation and for two ethers no informant 
could be found. In 198 (98%) patients, data on risk factors were obtained along with a 
serum sample. In all ten cases, whohad an autopsy, the diagnosis was confrrmed.1 
Controls. For each patient a reference subject was selected, matched for age (within 
five years ), gender and place of residence. These contra Is were dravm randomly from the 
popuiatien register of the municipality of the pa ti ent at the time of diagnosis. All control 
subjects had a SPMSQ score of20 or over. For controls, the first person asked consenled 
in 103 cases (52% ), in 68 (34%) it was the second selected person, in 23 (12%) the third, 
and in four (2%) the fourth. 
Data collection 
Case-control study. Informed consent was abtairred from the responsible family 
member for cases and àirect1y frorn the control subjects. Data on putative risk factors for 
Alzheimer's disease were assessed by a structured interview. Because of the cognitive 
decline of the patients, the history was taken from the next of kin of the patient. To 
assure symmetry of data collection, we also interviewed a next of kin for the control 
subject. For 174 cases (88%) and 188 controls (95%) the informant was the spouse ar 
an adult child. As etiologie factors were studied, questions referred to exposure of the 
patient befare the age of onset of dementia. Onset age of Alzheimer's disease was 
estimated as the age at which memory loss ar change in behavior was first noted by the 
next of kin or any other relative. For control subjects, a "reference age'1 was defined 
18 
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basedon the age of onset of Alzheimer's disease in the matebed case and only exposures 
befare this 11reference agen were cansidered. 
The interviews were dane by three interviewers, who :in general obtained the 
information in bath the patient and his ar her controL We aimed ta conduct the 
interview shortly after the diagnosis was made. In practice, patients were interviewed 
three months to three years fallow:ing the diagnosis of Alzheimer's disease. The interview 
included questions on (1) family history of dementia and related disorders, (2) parental 
age at birth, (3) medical history, including head trauma and psychiatrie history, ( 4) 
environmental factors inciuding smoking, alcohol and occupational history, and (5) life 
events. The disease history of patients and controls was evaluated by closed guestions 
with additional open ended questions a bout medica] treatrnent and actmission to hospita}. 
Pedigree studies. In the case-control study, full pedigree information on dementia was 
obtained from the next of kin as part of the structured interview. All first degree relatives 
were listed and we asked specifically a bout the occurrence of dementia, Down's syndrome 
and Parkinson's disease in them. Ta increase the validity, all data on family history were 
verified by a sibling ofthe participant. Verification was obtained in the period from 1989 
to 1990, as part of a follow-up study on mortality of the patients. Again, we asked a bout 
the occurrence of dementia and reJated disorders in all first degree relatives but in 
actdition we questioned siblings extensively on the cause and the course of the dementia 
in the affected relatives. If the patient had been admitted to hospita!, the diagnosis was 
checked in independent medica] records. 
The pedigree structure of 17 patients (9%) was consistent with autosoma1 dominant 
inheritance of Alzheimer's disease. The criteria for autosomal dominant inheritance were: 
(1) at least three patients with reported dementia in two genera ti ons; (2) at 1east two 
patients with detailed records with the clinical diagnosis of Alzheimer's disease. Within 
the 17 families in which the disease was apparemly inherited as an autosomal dominant 
disorder, all relatives (first to third degree) were screened for dementia. Data on risk 
factors for AJzheimer's disease were collected in affected and in unaffected relatives 
aiong with a blood sample for DNA extraction. Again, infonned consent was obtained 
from family merobers for affected relatives and directly from the non-demented rela!:ives. 
Population 
Tables 2.1.1 and 2.1.2 give a brief overview ofthe study population. Table 2.1.1 shows 
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Table 2.1.1 Age at disease onset and at diagnosis of the 198 clinically diagnosed Alzheimer 
patients 
Age at onset: 
-54 years (number) 
55-59 years (number) 
60-69 years (number) 
Mean (years and SD) 
Age at diagnosis: 
-59 years (number) 
60-69 years (number) 
Mean (years and SD) 
Men 
n~74 
22 
28 
24 
56.3 (6.0) 
21 
53 
61.1 (3.0) 
Wamen 
n~124 
34 
48 
42 
57.1 ( 4.8) 
38 
86 
61.3 (3.9) 
Table 2.1.2 Family history of dementia' and education in 198 patients with clinically 
diagnosed Alzheimer's disease and 198 age- and gender-matched controls 
Variabie 
Yes No OR+ OR+ 
F amily history: 
Cases 96 102 4.5 4.9 
[2.7-7.7] [2.8-8.4] 
Controls 37 161 
Less than 7 years education: 
Cases 112 86 1.4 1.7 
[0.9-2.1] [1.1-2.7] 
Controls 88 110 
"' In flrst degree relatives 
f Odds ratio, with 95% confldence interval within parentheses 
t Odds ratio adjusted for dementia in first degree relatives or educatîon 
20 
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the age at onset and age at diagnosis of the patients. Of the 198 patients, 74 were men 
and 124 were wamen. The mean age at onset was 56 years in men and 57 years in 
wamen. At the time that we interviewed the informants, 41 of the patients were living at 
home and 157 in nursing homes or other institutions. One hundred twenty-seven patients 
lived in the four narthem provinces of The Netherlands, whereas 71 lived in the region 
of the city of Rotterdam. Table 2.1.2 shows that Alzheimer's disease was associated with 
family history of dementia and education. Adjusted for education, the odds ratio for those 
with at least one first degree relative with dementia was 4.9 (95% confidence interval2.8-
8.4). Familial aggregation of Alzheimer's disease is further discussed in chapter 3.2. The 
odds ratio for those with less than seven years of education was 1.7 (95% confidence 
interval 1.1-2.7), when adjusting for family history of dementia. Possible explanations for 
the relation between education and Alzheimer's disease are addressed in chapter 6.3. 
Famîly history of dementia and education were always considered as putative 
confounders when studying other risk factors for Alzheimer's disease. 
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The EURODEM collaborative 
re-analysis of case-control studies of 
Alzheimer's disease 
A collaborative re-analysis was conducted basedon raw data of 11 case-control studies 
of risk factors for AJzheimer's disease to evaluate the evidence for the association of 
Alzheimer's disease with various putative risk factors.t:: The aim of the analysis was to 
study risk factors for Alzheimer's disease, with sufficient power to detect associations with 
relatively rare exposures and with specific subgroups of AJzheimer's disease. In addition, 
:individual studies were re-analyzed to see whether associations were consistently found 
across studies. Here we wiJl give a brief overview of the case-control studies that 
contributed data to the re-analysis:-.13 and discuss the strategy that has been foliowed in 
the analysis. 
Description of the individual studies 
All case-control studies of Alzheimer's disease conducted befare January 1, 1990, were 
traeed through medline search, review papers, and persarral contacts. Studies in which 
the patients did nat meet the NINCDS-ADRDA or DSM UI criteria for the clinical 
diagnosis of Alzheimer's disease were excluded. 14' 15 Thus, eleven studies were identified 
as eligible for the re-analysis. Table 2.2.1 gives an overview of studies included in the re-
anaiysis. The selection of cases and controls in each study is described in table 2.2.2. In 
the tables, the studies are ordered alphabetically by country and city of origin. In nine of 
the eieven studies data collection bas been symmetrical for cases and controls. In most 
studies, data were collected by interviewing a next of kin in person. There were three 
This chaptcr is based on: Van Duijn CM. Stijnen T. Hofman A Risk factors for Alzheimcr·s disease: 
Overview of thc EURODEM collaborative re-ana.Jysis of casc-control studies. Int J Epiderniol 1991;20 
(suppl 2):S4-Sl2. 
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Table2.2.1 Studies included in the EURODEM col/aborative re-analysis of case-control 
studies 
Country Principal Numbcr of Origîn Data eaUeetion 
învestigator Cases Con trol$ Casos Contra Is 
(response ratc) 
Australi311 Broe, 170 170 HospîtaVGP Populatîon Structured interview 
Hendcrson, (-) (·) at home with next of 
Jonn, Creascy kin 
Finbnd-' Soinînen 63 91 Population Populatîon Structured interview 
(61%) (50%) Nursîng home with ncxt of kin for 
cases and with 
controls in pcrson/ 
Parish records 
Ita!f Amaducci, 116 213 Hospita! Hospita!: 116 Structured interview 
Fratîglioni (79%) (·) Neîghborhood/ at home with next of 
friend:97 kin 
Japan!-' Kon do 34 68 Hospita! Neighborhood Structured interview 
(-) (-) with spouse for cases 
and with controls in 
pccson 
Tho Hofman 198 198 Populatîon Population Structured interview 
Netherlands10 (99%) (61%) at hOme with n~t of 
kin 
USA· Shalat 106 214 Hospit:ll Neighborhood Mailed questionnaire 
Bedford'~ (77%) (31%) (regi.s.tcrcd to ncxt of kin with 
votcrs) addîtional phone eaUs 
USA· Chandro. 64 64 Hospiwl Hospita! Structured interview 
Denver7 (100%) (100%) with ncxt of kin 
USA· Heyman 46 92 Hospit::ll Population Structured interview 
Durham4 (100%) (100%) random digit with ne:o..'t of kin 
dialing 
USA· Sehuman, 78 124 Hospita! Hospîta\:76 Structurcd with 
Minncapolii Mortimer (98%) (84%: Neighborhood:48 informant who \ived 
64%) >5 years with 
case/control 
USA· Kokmen 392 392 Register Register Medica! records 
Rochestc~ (·) (-) 
USA· Gr:lves 130 130 Hospita! Fricnd/Non· Structured interview 
Seattle12 (69%) (·) blood rclativc of with ncxt of kin by 
C3>0 tclcphone 
studies that differeà in this respect. In the study conducted in USA Bedford,8 data were 
collected by mailed questionnaires, in the USA Roehester studl only medical records 
were used and in the USA Seattle study1~ the data were collected by telephone interview. 
Four studies (Australia, 11 Finland/ The Netherlands, 10 USA Rochester~) can be considered 
as population-based, i.e., they airned at a full ascertainrnent of cases with AJzheimer's 
Chapter 22 
Table 2.2.2 Selection of cases and comrols in the 11 case-camrol studies 
Study Diagnosîs: criteria·; Exclusion criteria cases+ Ex.clusiof criteria Matching 
periOd;onset (years) contra IS variables 
Australiau NINCDS.ADRDA Not Englîsh speaking Asforcascs Gen der, 
possiblc/probablc; No suitablc informant :M:M:SE ~26 GP, age 
1986·1988 (± 3 ycars) 
Finland' NINCDS·ADRDA Oligophrenia, chromosoma! As for cases Gcoder, age, 
possib!e/probable; abnormality, MlD (HIS>7) Dementia, duration 
1979; onset > 65 sccondary dementias meningitis hospitalisa-
eocephalitîs tioo 
ltaif NINCDS-ADRDA No ncxt of kin availab!c As for cases Gcnder, age 
probab\e; Resîdencc outside study Dementia (Blesscd) (± 3 ycars). 
1982-1983 region Rcl:>tive of case rcsidence, 
onsct 40-80 hospita! 
Japan'-' DSM·III No suitoble informant Gender, agc 
Cercbrovascul:>r !esions (± 5 ycars), 
residence 
The NINCDS-ADRDA MlD (HIS>7), P:>rkioson's Dementia Gcnder, agc 
Netherlands10 prob:>b!e; 1980·1987 diseasc, secondary dcmcntias (SPMSQ) (± 5 ycars), 
onset <65 rcsidencc 
USA- DSM·III, A.lcoholîsm, severe head Household<2 Gcndcr, age, 
Bedford8 NINCDS-ADRDA; trauma, rcsidcncc outsidc Non.voters residencc 
1975·1982 Eastcro Massachusetts, 
remales 
USA- NINCDS·ADRDA No suitablc informant As for cases Gcndcr, :>ge 
Denver7 probable; 1975·1985 Dementia (::!::: 3 ycars), 
onsct >70 (SPMSQ) rcsidcnce, 
rclationship 
USA- NINCDS-ADRDA; Stroke, alcoholîsm :M:M:SE~21 Gender, age 
Durham4 onsct <67 Parkinsoa's disc3Sc (:!:: 5 years) 
USA· NINCDS·ADRDA Sccondary dementias As for cases Gcndcr, age, 
MinneapolW probablc; 1979·1982 Femalcs Dementia (± 3 yoars), 
residencc, 
race 
USA· NINCDS-ADRDA; Rcsidencc outsidc Roehester Symptoms Gender, age 
RoehesterP onset 1960·1974 Othcr dementîas dementia (± 3years) 
USA· DSM·III; MMSE>26, Stroke, As for cases Gcnder, agc 
Seattle11 NINCDS-ADRDA Parkinsoa's dîsease, major Memoryloss (± 10 years) 
possible/probablc; affectivc disorder, 
1980·1985 hypothyroidism 
No suitoble informant 
• NlNCOS-ADRDA denoto tbe ~nter!a for All:beimer'o di=x from tbc N~tionnl lnstitute of N~uroiOf.k and Cornmunk:oclvc DOOrden and S~ke and tb~ 
Ab:bdm~r'o 0~ nod Rebted Oioorden As.ooci:u.ton;l5 D$M·IIl denot"" tbe critetü for Alzheimer'• di>C.'151' frorn tb~ 0\Jl!?l<'•tk and Statioticol Man<U>I for 
+ ::;=;~~:~teo~l~~n~!o~:entl.a; HlS d~noteo Hacillnoi:J l..;b~mlc ScorcP MMSE denote> M;nJ-Mental State E>cmlnatiOIIIS; Bl=ed denotc> BJ~ 
infonna~on, m~mo'Y and oonccntt:>tlon teot;19 SPMSQ denoteo Sbort Poruble M"""'l S"'tu• Ouc•tlonn.air.:O 
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disease in a defined geographical area.4'9' 1o.11 An important feature of all case·control 
studies is that each is based on prevalent cases, who may have been diagnosed with 
Alzheimer's disease for several years, as well as incident ar newly diagnosed cases. 
Austral ia 
This study was conducted by Broe, Henderson, Creasey, Jorm and coworkers and 
comprised 170 cases and 170 population controls." The study aimed at a complete 
ascertainment of Alzheimer cases in a series of general practices in Sydney. 
Ascertainment was carried out through dementia clinics at two hospitals and the general 
practitioners in the catchment area of these hospitals. For cases, there were na inclusion 
criteria for onset age, but the large majority was of late-onset. Cases were diagnosed 
between 1986 and 1988. Controls were matebed for age, gender and general practice. 
Data collection was completely symmetrical for cases and controls, i.e., for bath cases and 
controls data were abtairred by a structured interview of a next of kin. 
Finland 
The study of Soininen and coworkers comprised 63 Alzheimer cases with an onset of 
disease of 65 years ar o!der.' This study was conducted in 1979 and aimed to ascertain 
all patients with the diagnosis of dementia in a defmed geographical area of eastern 
Finland. The response rate for cases was 61%. Contro!s (n;91) were randomly drawn 
from nursing homes and the general population. Cases and controls were matebed for 
gender, age and institutionalisation and length of stay. Data collection was nat 
syrnmetrical for cases and controls: control subjects were interviewed directly whereas the 
information of the cases was abtairred by interviewing an informant. 
Jtaly 
Amaducci, Fratiglion.i and coworkers conducted a hospital-based multi-centre study of 
116 Alzheimer cases.' Cases were diagnosed in 1982 and 1983. Patients with a disease 
onset between 40 and 80 years were eligible. Most cases were of early-onset: the onset 
of 91% of the sample was befare 70 years. The response ra te for cases was 79%. There 
were two control populations in this study: 116 hospita! controls and 97 neighborhood 
controls. Cases and controls were matebed for gender, age, area of residence and 
hospita!. Response rates for controls were unknown. For bath cases and controls an 
informant was interviewed. 
25 
Chapter 2.2 
Japan 
The study of Kondo et al comprised 34 cases and 68 neighborhood controls." Case 
selection was hospital~based and there were na inclusion criteria for onset age. 
Information for the cases was abtairred from the spouse. Cases and controls were 
matched for age and gender. Data collection was nat symmetrical for cases and controls. 
For cases an informant was interviewed whereas controls were interviewed directly. 
The Netherlands 
The study of Hofman et al comprised 198 cases with early-onset Alzheimer's disease 
and 198 population controls and has been described ex-tensive1y in chapter 2.1.10 The 
study aimed at a complete ascertainment of Alzheimer patients in whom the diagnosis 
was made befare the age of 70 years in four Narthem provinces of the Netherlands and 
the area of metropoEtan Rotterdam. Ascertainment was carried out through all 
neurologie, psychiatrie and geriatrie services in the study areas. All cases were diagnosed 
between 1980 and 1987 and the response rate for cases was 99%. Control subjects were 
drawn randomly from the same municipality as the cases. Cases and controls were 
matebed for age, gender and area of residence. The response rate for control subjects 
was 61%. For bath cases and controls an informant was interviewed. 
USA, Bedford, Massachusetts 
The stuáy of Shalat et al comprised 106 Alzheimer patients diagnose à between 1975 
and 1982.~> Since the cases were derived from a Veterans hospital, al1 cases were male. 
Although there were no restrictions for onset age, the onset of disease of the majority 
(61%) of the patients was befare the age of 65 years. Neighborhood controls (n=214) 
were drawn from lists of registered veters. The cases couid be matebed for gender and 
age to 162 contra Is. The response ra te was 77% for cases and 31% for comrols. Data 
were collected by self-administered questionnaires, mailed to a next of kin of cases and 
controls. Additional phone calls were made for verification and clarification of incomplete 
questionnaires. The study aimed to collect the data symmetrically for cases and controls 
in that informams of controls were asked not to consult the study subject for inforrnation. 
USA, Denver, Colorado 
Chandra and coworkers have studied 64 cases with late-onset Alzheimer's disease, i.e. 
onset age after 70 years.' Cases were diagnosed in the period 1975-1985. Cases and 
controls were derived from the same outpatient clinic. Cases were matebed to the 
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controls for gender, age and race. In addition, cases and controls were matched for 
relationship to informant. Information was collected symmetrically for cases and controls. 
The response rate was 100% for cases as well as controls. 
USA, Durham, North Carolina 
The study of Heyman et al included 46 cases with early-onset Alzheimer's disease and 
92 popuiatien controls.4 Case selection was hospital-based. The response rate for patients 
was 100%. Controls were selected from the population by random-digit dialing. Cases and 
contro!s were matebed for gender and age. The response rate was 100% for controls. For 
cases as well as controls, data were collected by a structured personal interview with a 
next of kin. 
USA, Minneapolis, Minnesota 
The study of Schuman, Mortimerand coworkers, was conducted in a Veterans hospita1.5 
The study comprised 78 male cases, diagnosed between 1979 and 1982. There were two 
control populations in this study: 76 hospita! controls and 48 neighborhood contro!s. 
Cases and controls were matebed for gen der, age, residence and race. For both cases and 
controls an informant was interviewed. The response ra te for cases was 98%. For hospita] 
cantreis and neighborhood controls, the response rates were 84% and 64% respective1y. 
USA, Rochester, Minnesota 
The study of Kokmen et al was based on the Roehester register.' The study included 
all patients with Alzheimer's disease with an onset of disease between 1960 and 1974. 
The register is considered to give a nearly complete ascertainment of Alzheimer patients 
admitted to hospitals and outpatient facilities in the Roehester area. Control subjects 
were also drawn from the register. However, since the register has been shown to cover 
over 95% of the Roehester population, the control subjects may be considered 
population-based. This is the Iargest case-control study conducted to date. The study 
comprised 392 cases and 392 control subjects. Since the data collection was completely 
based on medica! records, this study only yielded information on medica! history. 
USA, Seattle, Washuzgton 
The study of Graves et al was a hospital-based study of 130 cases diagnosed between 
1980 and 1985.12 For cases, there were na exclusion criteria for onset a ge. The response 
27 
Chapter 2.2 
rate was 69%. Cases were compared to 130 neighborhood controls, matched for gender 
and age. Furthermore, cases and controls were matched for relationship to informant. 
Data were collected by telephone interview. lnformation was collected symmetrically for 
cases and controls. 
Strategy of analysis 
The raw data of all el even studies were centralized at the Department of Epidemiology 
and Biostatistics of theErasmus University Medical School, Rotterdam, The Nether lands. 
The principa1 investigators of the studies were invited to a first workshop on the 
collaborative re-analysis and they all attended this meeting. During this workshop, the 
strategy of analysis was discussed with other invited epidemiologists and biostatisticians. 
In werking groups, the analyses for the putative risk factors were prepared. On the basis 
of these discussions, the data were re-analyzed and the results of these analyses were 
discussed during a secend workshop. 
In the re-analysis, only studies in which the data were collected symmetrically for cases 
and controls have been included. Two studies (Finland and Japan) did nat fulfil tbis 
crîterion, in that control subjects were interviewed personally but the pa tient's history was 
taken indirectly from an informantY3 A second restrietion concerned the control subjects. 
Only tbree studies in which the data were collected symmetrically included a group of 
hospita! controls,S·7 and two of these studies also had a popuiatien control group.5•6 To 
increase comparability with the other studies, the analysis was restricted to popuiatien 
controls for studies with two control groups. A separate analysis based on hospita} 
controls gave generally similar findings and did nat change any of the conclusions. Since 
we were interested in etiologie factors, only exposures more than one year befare the 
disease onset were included in the analysis. In control subjects, only exposures befare the 
age of onset of the matebed case were considered. 
The strength of the association between Alzheimer's disease and the putative risk 
factors was assessed by computing of the odds ratio as an estimate of the relative risk.16 
Odds ratios were estimated by maximum likelibood and the 95% confidence intervals 
were based on the asymptotic standard errors. Since all included studies were matebed 
for age and gender, odds ratios were estimated using conditional logistic regression 
analyses. 16 Thus, possible confaunding by a ge and sex was taken care of by the matebed 
design and the matebed analysis. Potential confaunding by family history of dementia and 
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education was controlled by entering these variables into the logistic regression modeL 
For family history of dementia, cases and controls with one or more first degree relatives 
affected with dementia were considered to have a positive family history. The number 
of years of education was available in ten studies:J.a.lCl-D and was added as a potential 
confaunder to the conditionallogistic regression model. Education was also considered 
as a dichotomous variabie (less than twelve years education versus twelve years education 
or more), to allow for a possible threshold effect. To test whether risks differed 
significantly across studies, covariables representing the interaction between the studies 
and the determinant were entered into the model. If the overall test for heterogeneity 
was significant, the study that differed was excluded and heterogeneity across the other 
studies was again tested. In case of heterogeneity, paoled odds ratios were estimated 
including and excluding the deviant studies. Stratified analyses were conducted based on 
gender, onset age and family history of dementia. For onset age, we did nat break the 
matching of the patients and controls. 
Two additional analyses were conducted to exclude some possible sourees of bias. First, 
since the studies were partly based on prevalent cases, selection bias may result from 
differential survival. The observed risk factors may therefore relate to predietors of 
survival, rather than to the risk of AJzheimer's disease. To evereome this problem, 
subgroup-analyses were conducted in incident cases, i.e. in patients who participated in 
the study within one year after diagnosis. Another subgroup-analysis was related to 
information bias, which may occur in particular when cases and controls are nat matebed 
for relationship to informant. To investigate the effect of this type of possible bias, we 
conducted analyses including only matebed pairs which were concordant for relationship 
to informant. These analyses gave results very similar to the overall analysis and did nat 
alter any of the conclusions. 
A great variety of risk factors has been studied intheel even case-control studies (table 
2.2.3). For this re-analysis, the risk factors were grouped into six categories: (1) family 
history of dementia and related disorders; (2) parental age at birth; (3) head trauma; ( 4) 
medica! history; (5) psychiatrie history; (6) environmental factors.For each risk factor, 
exposure definition and comparability of measurement across studies was evaluated 
befare re-analyzing the data. This procedure and the results of the collaborative re-
analysis are presented in seven separate papers publisbed as a supplement to the June 
1991 issue of the International Joumal of Epidemiology."·" 
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Table 2.2.3 Risk factors assessed in the EURODEM collaborative re-analysis of 
case-control studies 
Risk factor 
n=nurnbcr of studies 
Family history of: 
Dementia 
n=9 
Down's syndrome 
n=7 
Parkinsoa's discase 
n=2 
Patient history of: 
Parental agc 
n=7 
Head trauma 
n=11 
Anesthesia 
n=8 
Thyroid dîsease 
n=lO 
Epîlcpsy 
n=8 
Viral infections 
n=10 
Bactcrial infections 
n=7 
Atopy 
o=S 
Osteoarthritîs 
n=3 
Blood transfusion 
n=5 
Scvere headaches 
n=4 
Psychiatrie disorders 
n=8 
Alcohol intake 
n=9 
Smoking habits 
o=IO 
Occupational cxposurcs 
n=5 
Education 
n=lO 
30 
Studies that assesscd tbc risk factor 
Australia, Finland, It:lly, Japan, Thc Ncthcrlands, 
US~Bedford, US-Dcnvcr, US~Durham, US-Seattle 
Australia, Finland, ltaly, Japan, The Nethcrlands, 
US~Dcnver, US-Durham 
ltaly, Thc Netherlands 
Australia, Italv, Japan, The Nctherlands, 
US-Durham, trS-Minncapolîs, US-Scattle 
Austrnlia, Finland, Italy, Japan, Thc Netherlands, 
US-Bedford, US-Dcnver, US-Durham, US-
Minncapolîs, US-Rochestcr, US-Scattle 
Australia, Italy, Japan, The Ncthcrlan~ US-Durharn, 
US-Minoeapolis, US-Rochester, US-Scattle 
Australia, Finland, ltaly, Thc Netherlands, 
US-Bedford, US-Denver, US-Durham, 
US-Minncapolis, US-Rochester, US~Scattle 
Australîa, Finland, Japan, Tbc Nctherlands, US-
Bcdford, US-Durham, US-Minneapolîs, US-Rocbestcr 
Australia, Finland, ltaly, J3p::m, Thc Ncthcrl3nds, 
US-Dcnver, US-Durharn, DS-Minneapolis, 
US-Rochestcr, US-Semtlc 
Austra!ia, Finland, Japan, Thc Ncthcrl.:l.nds, US-
Durham, US-Minneapolis, US-Rochestcr 
Australia, Italy, Thc Ncthcrlan~ US-Minncapolîs, 
US-Sc:mlc 
Australia, US-Durham, US-Minncapolis 
Australîa, ltaly, Thc Ncthcrland::., US-Durham, 
US-Minneapolis 
Australia, Thc Ncthcrlands, US-Durham, 
US-Minneapolis 
Australia, Finland, Jap3n, The Ncthcrlands, US-
Bedford, US-Durham, US-Minncapolîs, US-Rochcstcr 
Australia, Finland, Italy, Japan, The Nethcrlands, 
US-Bcdford, US-Durham, US-Minneapolis, US-Scattlc 
Australia, Finl:md, lt;J.ly, Japon, Thc Nctherland·-, 
US-Bedford, US-Denver, US-Durham, US-
Minncapolîs, US-Seottle 
Australia, Japan, US-Bedford, US-Durham, US-
Minncapolîs 
Australia, Finland, Italy, Japon, The Netherlands, 
US-Bedford, US-Denvcr, US-Durhom, US-
Minnca olîs. US-Seattlc 
Nurnbcr of 
cases and 
contro\s 
883 cases 
1190 controls 
678 cases 
877 controls 
314 cases 
411 contro!S 
653 cases 
759 contro\s 
1385 cases 
1739 COntrO\s 
1145 cases 
1352 controls 
1350cases 
1668 controts 
1145 cases 
1401 controls 
1165 cases 
1321 contro\s 
975 cases 
1123 contro\s 
692 cases 
835 contro\s 
288 cases 
374 controls 
602 cases 
785 contro\s 
4S6 casos 
572 controls 
1145 cases 
1401 contro!s 
935 cases 
1288 controls 
991=os 
1300 contro!s 
428 cases 
656 controts 
996 cases 
1349 contro!s 
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Chapter 3 
Genetic factors 

Chapter 3.1 
Introduetion 
It is generally agreed upon that genetic factors are implicated in Alzheimer's disease.1 
Although there is evidence for autosomal dominant inheritance in a considerable number 
of families with multiple affecteà relatives/· the majority of cases appear to be sporadi2 
and there is stîll wide disagreement about the percentage of patients with Alzheimer's 
disease that may be explaineà by genetic factors.' 
This chapter aims to delineate the role of genetic factors in Alzheimer's disease. 
Firstly, chapter 3.2 addresses familial aggregation of Alzheimer's disease, Down's 
syndrome and Parkinson's disease. Secondly, chapter 3.3 deals with the genetics of early-
onset Alzheimer's disease. Risk of Alzheimer's disease and segregation of disease were 
studied in first degree relatives of 198 patients with early~onset Alzheimer's disease and 
198 age- and sex-matched controls. Thiràly, chapter 3.4 gives the results of a study of 100 
patients with early-onset of Alzheimer's disease, who were sereerred fora putative causa! 
rnutation in the amyloid precursor protein that has been reported by Goate et al.4 
The findings presented in chapter 3.2 are based on the collaboratîve re-analysis of 
case-control studies, as described in chapter 2.2. The other chapters (3.3-3.4) are based 
on the case-control study of early-onset Alzheimer's disease, which bas been described 
in chapter 2.1. 
References 
1. Haines JL. Invited editorial: the genetics of Alzhcimer's discase. A teasing problem. Am J Hum 
Genet 1991;4S:l021-1025. 
2. Farrer LA, Meyers RH. Cuppies LA. et aL Transmission and age-at-onset patterns in familial 
Alzheimer's disease: evidence for heterogeneity. Neurology 1990;40:395-403. 
3. Rocca WA,Amaducci LA Schoenberg ES. Epidemiology of clinically diagnosed Alzheimer's disease. 
Ann Neurol 1936;19:415-424. 
4. Goate A Chartier-Harlin MC, Mullan M, et aL Segregation of a missense mutation in the amyloid 
precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706. 
37 
Chapter 3.2 
Familial aggregation of 
Alzheimer's disease and related disorders 
AJthough the cause of Alzheimer's disease is still unknown, genetic factors seem to 
play an important role in its etiology.""' Tagether with age, a positive family history of 
dementia is one of the few established risk factors for Alzheimer's disease.6 Alzheirner's 
disease has also been linked with a family history of Down's syndrome and of Parkinson's 
disease.~"7 In this paper we present a re-analysis of case-control studies that examined 
familial aggregation of .Alzheimer's disease and ether disorders.7.16 The aims of this 
analysis were to campare risk estimates from the individual studies, to analyze the paoled 
data in order to obtain stable risk estimates, and to study subgroups in the paoled data 
set, based on gender and onset age. First, we will briefly review the evidence for an 
association of Alzheimer's disease with family history of dementia, Down's syndrome and 
Parkinson's disease. 
Familial aggregation of Alzheimer's disease bas been long recognised.11•16 In a number 
of families the disease is apparently inherited as an autosomal dominant disorder.2 It has 
been suggested that all cases of Alzhe.imer's disease may be due to autosomal dominant 
inheritance.l.1'~-22 Other studies have suggested a more complex mechanism, in whlch 
genetic as well as environmental factors may be implicated.::.:!:l-::s There is some evidence 
from genetic studies that the strengthof familial aggregation of Alzheimer's disease may 
vary with age of onset. Heston bas suggested that familial aggregation of Alzheimer's 
disease may be specific to early-onset patients.26 In his study, familial aggregation was 
observed only in early-enset patients. The risk in relatives of autopsy-proven patients 
diagnosed after the age of 70 years was nat statistically different from the risk in the 
general population. Thal and coworkers reported that nearly 50% of the patients with 
early-onset of disease (before 55 years) had a positive family history of dementia, as 
This chapter is based on: Van Duijn CM, Clayton 0, Chandra V, Fratiglionî L, Graves AB, Heyman A, 
Jorm AF, Kokmen E, KondoK Mortimer JA, Rocca WA, Shalat SL, Soininen H. Hofman A, for the 
EURODEM Risk Factors Research Group. Familîal aggregation of Alzbeimer's discase and related 
disorders: a collaborative re-analysis of case-control studies. Int J Epidemiol 1991;20 (suppl 2):Sl3-S20. 
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compared to only 25% of those with a !ate-onset.~ Although several studies have also 
supported this hypothesis, """""" these findings were nat supported by others."·n 
Family history of dementia has been studied in a variety of case-control studies, which, 
in contrast to the genetic studies, did nat adjust for the age of the relatives when 
assessing family history.7•9.n-LW,l6,35-36 Nine studies reported a significantly higher risk of 
Alzheimer's disease for relatives of patients with dementia. The only study that failed to 
show familial aggregation of Alzheimer's disease was of late-onset patients.12 In studies 
that comprised only early-onset cases, an increase in risk of Alzheimer's disease for 
subjects with a positive family history of dementia was consistently reported.7•9.:;s 
Family history of Down's syndrome has been associated with Alzheimer's disease. 
There is much evidence for a link between Alzheimer's disease and Down's syndrome. 
The Alzheimer type neuropathologie changes have been shown in patients with Down's 
syndrome37•39 and genetic linkage to chromosome 21 has been reported in a number of 
families in which AJzheimer's disease was apparently inherited as an autosomal dominant 
disorder.3-$ These observations have led to the hypothesis of familial aggregation of 
PJzheimer's disease with Down's syndrome. A higher frequency of presenile Alzheimer's 
disease than expected bas been observed in relatives of patients with Down's syndrome,4Q 
but this finding was nat confirmed by a study of the family history of dementia of 188 
patients with trisomy 21 and 185 contro1s.41 It cannot be excluded, however, that 
Alzheimer's disease is associated with family history of Down's syndrome due to 
translocations on cbramosome 21.41 Studies of the family history of Down's syndrome of 
patients with Alzheimer's disease have also yielded equivocal results. Family history of 
Down's syndrome has been studied in 10 studies.".ll.I~lt-.1<>.2().~.30.:<3'4~ Although seven studies 
observed more patients with a positive family history of Down's syndrome as compared 
to controls,"·1l.l:!.l6..>o.J3 a significant association was established in only three studiesY"'~ The 
study of Heston suggested that the risk was only increased for early-onset Alzheimer's 
disease.:y. In three studies that have examined family history of Down's syndrome, no 
patients or controls with a positive family history were found.1"·2()·4~ So far it has nat been 
possible to discern whether the negative findings of these studies reflect the low ra te of 
occurrence of Down's syndrome (1 in 700 in the general population) or a true lack of 
association. Another issue to resolve is whether familial aggregation of Alzheimer's 
disease with Down's syndrorne is found more in farnilial cases specifically, as would be 
predicted by a genetic link between Alzheimer's disease and Down's syndrome. This issue 
is addressed in chapter 5.4. 
Parkinson's disease is a neurologie disorder that has been associated -with Alzheimer's 
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disease. Alzheimer's disease and Parkinson's disease share several neuropathologie 
characteristics.(! and it has been suggested that Alzheimer's disease and Parkinson's 
disease may have a common etiology.M Two case-control studies of AJzheimer's disease 
have investigated family hlstory of Parkinson's disease.7•11 In both studies there were more 
Alzheimer patients with a first àegree relative with Parkinson's d:isease as compared to 
age- and sex-matched population controls. In the largest stuày, a significant increase in 
risk was observed, particularly in men with early-onset of Alzheimer's àisease.7 
Methods 
Family history data have been assessed inseven case-control studies in this re-analysis45 
in which the data had been collected symmetrically for patients and controls (table 
3.2.1).7'9.11-DJS,r6 Family history was obtained in five studies by a personal interview/·9•11.1::.16 
in one study by telephone interview15 and in one study by a questionnaire mailed to the 
infonnant.n In the Dutch study, family history data were always veri:6ed by a second 
informant who was a first degree relative of the participant. The analysis was restricted 
to disorders in frrst degree relatives. To increase comparability, we restricted the case-
control camparisans to control subjects derived from the population. 
All seven studies collected data on family hîstory of dementia. The analysis included 
all first degree relatives with a history of dementia, nat Alzheimer's disease specifically, 
because anamnestic information on the cause of dementia is nat likely to be reliable. In 
addition, affected relatives may have been diagnosed years before, when the diagnosis of 
Alzheimer's disease may have been less accurate. Family history ofDown's syndrome has 
been assessed in five studies eligible for the re-analysis.7·<>.n.u.t<>f!n two studies, no 
distinction was made between Down's syndrome and mental retardation.9·11 Family history 
of Parkinson's disease bas been studied in two investigations.7' 11 Bath studies have 
excluded patients with a history of Parkinson's disease befare the onset of Alzheimer's 
disease. In the Dutch study the diagnosis of Parkinson's disease was checked with 
independent medica! records.7 
Family history was considered positive for these who had at least one first degree 
relative with dementia. The number of first degree relatives, a putative confounder, was 
nat available in one of the seven elig~ble studies (USA Bedford"). The strength of the 
association was assessed by computing the odds ratio (OR) as an estimate of the relative 
risk. Conditiona11ogistic regression analysis was used to take the effects of education, the 
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Table 3.2J Family history of dementia in first degree relatives and the risk of Alzheimer's 
disease 
Study Cases Controls OR" 95% Cl 
Australia 16 58/170 21/170 3.8 2.1-6.9 
Italy11 29/116 12/97 2.6 1.0-7.5 
The Netherlands' 96/198 37/198 4.8 2.8-8.1 
USA, Bedford" 21/103 9/162 4.4 1.8-10.7 
USA, Denveru 21/54 18/50 1.0 0.5-2.2 
USA, Durham' 25/44 14/87 7.2 2.7-19.1 
USA, Seattle~ 55/129 29/130 2.5 1.4-4.4 
Overall analysis 305/814 140/894 3.5 2.6-4.6 
Excluding USA, Denver" 284n6o 122/844 3.6 2.7-4.9 
Odds ratio adjusted for age. gender, number of sîblings and education 
number of siblings and the matching variables age and gender into account.45 In this 
paper, we present the adjusted odds ratios with 95% confidence intervals (95% Cl). 
Stratified ana1yses were conducted based on gender and onset age. 
Results 
Family history of dementia 
Table 3.2.1 shows the odds ratios for family history of dementia in first degree relatives 
in the seven individua1 studies and in the paoled analysis. Overall, the odds ratio for 
those with at least one fust degree relative with dementia was 3.5 (95% Cl 2.6-4.6). The 
test for heterogeneity indicated na evidence for heterogeneity in odds ratios, except for 
the risk estimate observed in the Denver study.12 The latter study of late-onset 
Alzheimer's disease (onset age 70 years or over) deviated significantly (p=0.01) from the 
other studies in the overall analysis as well as in a subgroup analysis of late-onset 
Alzheimer patients. In the present study, the odds ratios were similar for men (OR 3.9; 
95% Cl 2.5-6.5) and wamen (OR 3.3; 95% Cl 2.3-4.6). Stratification according to age of 
onset of AJzheirner's disease showed that the odds ratio decreased with increasing onset 
age (table 3.2.2). Although there were still significantly more late-onset patients with a 
positive family history of dementia than contra Is, the odds ratio differed significantly from 
the odds ratio observed in early-onset patients (onset befare 70 years). Table 3.2.3 shows 
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Table 3.2.2 Family history of dementia in first degree relatives and the risk of Alzheimer's 
disease by onset age 
Onset a ge (years) Cases Controls OK 95% Cl 
-59 97/272 37/327 4.0 2.4--6.1 
60-69 76/183 31/205 5.3 2.8-10.0 
70-79 72/196 43/198 ?' 
--0 1.4-3.6 
80+ 41/122 20/123 2.6 1.3-5.2 
Odds ratio adjusted for age. gendcr. numbcr of siblings and education 
Table 3.2.3 Family history of dementia and the risk of Alzheimers disease by relatianship 
Family history dementia Cases Controls OK 95% Cl 
Parents 190/814 95/894 ? ' 
--0 1.8-3.1 
Siblings 101/814 23/894 4.8 2.9-7.8 
Onset case befare 70 years: 
Parents 115/453 43/528 3.5 2.3-5.2 
S:iblings 40/453 9/528 4.4 2.1-9.0 
Onset case at 70 years or over: 
Parents 63/308 47/307 1.4 0.9-2.1 
Siblings 571308 14/307 4.7 2.5-9.0 
Odds ratio adjusted for age. gender. number of sîblings and educa.tîon 
that for early-onset Alzheîmer's disease, similar risk estimates were found for parents and 
siblings. There was a lower risk for late-onset AJzheimer's disease for subjects with a 
demented parent observed. The percentage of patients of whom one of the parents was 
affected with dementia decreased with increasing onsetage (figure 3.2.1). The prevalenee 
of dementia in parents of control subjects did nat show a trend across the age strata. 
Figure 3.2.2 shows that the percentage of patients with one or more affected sîblîngs 
increased with increasing onset age. Table 3.2.4 gives the odds ratio accordîng to the 
number of first degree relatives with a history of dementia. Th ere were 49 patients with 
two or more first degree relatives as compared to 7 controls (OR 7.5; 95% Cl 3.3-16.7). 
The risk of Alzheimer's disease increased with the number of affected relatives (p-value 
for trend=0.008). This trend was observed in early-onset patients (p=0.013) as well as 
late-onset patients (p=0.005). 
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Figure 3.2.1 Percentage of Alzheimer cases and controls with a positive family history of 
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Figure 3.2.2 Percentage of Alzheimer cases and controls with a positive family history of 
dementia in the siblings 
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Table 3.2.4 Family history of dementia in first degree re/atives and the risk of Alzheimer's 
disease by number of affected relatives 
Number of relatives 
with dementia 
0 
1 
2+ 
Cases 
509 
206 
49 
Controls 
709 
103 
7 
Odds ratio adjusted for agc. gcnder. number of siblings and education 
Family history of Do\VD's syndrome 
OR' 
1 
2.6 
75 
95% Cl 
reierenee 
2.0-3.5 
3.3-16.7 
In all studies included in the re-analysis there were more patients with a posïtive family 
history of Down's syndrome in first degree relatives as compared to controls (table 3.2.5). 
The test for heterogeneity indicated that there was no evidence for heterogeneity across 
studies. Overall, the odds ratio was 2.7 (95% Cl 1.2-5.7) for family history of Down's 
syndrome. When excluding the studies which did nat differentlate between Down's 
syndrome and mental retardation/.1:: the risk estimate did notchange materially (OR 3.3; 
95% Cl 0.9-!2.1). Similar risk estimates were observed for men and wamen and for early-
enset and late-onset Alzheimer's disease (Table 3.2.6). 
Tab/e 3.2.5 Number of subjects wi.lh a family history of Down's syndrome in first degree 
relatives in Alzheimer cases and controTs 
Cases Controls OR' 95% Cl 
Australia lb 5/165 0/165 
ltaly" 1/116 0/97 
Netherlands' 5/198 3/198 1.7 0.3-13.0 
USA, Denver~ 2/64 0/64 
USA, Durham' 7/45 4/91 3.5 1.2-5.7 
Overall analysis 20/588 7/615 
Excluding USA, Denver" 11/479 3/460 
and USA, Durham' 
2.7 1.2-5.7 
3.3 0.9-12.1 
• Odds ratio adjusted for agc, gcnder. numbcr of siblings and cducation 
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Tahle 3.2.6 Down 's syndrome in first degree relatives and the risk of Alzheimer's disease: 
stratification by gender and onset age 
Cases Controls OR" 95% Cl 
Stratification by gender: 
Wamen 15/382 5/398 3.0 1.2-7.3 
Men 5/206 2/216 2.6 0.6-10.5 
Stratification by onset age: 
Befare 65 years 9/327 3/348 2.8 1.1-7.5 
65 years or over 9/243 4/241 2.6 0.7-10.0 
Odd.s ratio adjustcd for age, gender, numbcr of sîblings and cducation 
Family history of Parkinson's disease 
Family history of Parkinson's disease in first degree relatives was assessed in two 
studies (table 3.2.7). In bath studies, there were more patients with a positive family 
history of Parkinson's disease as compared to controls. Pooling of the studies yielded an 
odds ratio of 2.4 (95% Cl 1.0-5.8) for family history of Parkinson's disease in fust degree 
relatives. No significant differences in odds ratios were observed camparing men versus 
wamen (table 3.2.8). However, odds ratios tendeà to be higher for men. Risk estimates 
were very similar for patients with early-onset versus patients with late-onset Alzheimer's 
disease (table 3.2.8). 
Table 3.2.7 Number of subjects with a family history of Parkinson 's disease in first degree 
relatives in Alzheimer cases and controls 
Cases Controls OR" 95% Cl 
Italy11 6/ll4 3/96 2.0 0.4-14.8 
Nether1ands7 14/198 5/198 2.8 1.0-10.8 
Overall analysis 20/312 8/294 2.4 1.0-5.8 
Odds ratio adjustcd for agc, gcnder, numbcr of siblings and cducation 
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Table 3.2.8 Parkinson 's disease in first degree relatives and the risk of Alzheimer's disease: 
stratification by gender and onset age 
Cases Controls OR' 95% Cl 
Stratification by gender: 
Wamen 11/198 6/186 1.6 0.5-4.9 
Men 9/114 2/108 4.4 0.9-20.9 
Stratification by onset age: 
Befare 65 years 16/272 8/258 2.4 1.0-5.8 
65 years or over 4/29 0/25 
Odds ratio adjusted for agc, gender, number of siblings and educ:J.tion 
Discussion 
This re-analysis of case-control studies of Alzheimer's disease showed familial 
aggregation of dementia in bath early-onset and late-onset Alzheimer's disease. 
Significantly more Alzheimer patients than controls had a first degree relative with 
Down's syndrome. Purthermare the re-analysis supported a higher frequency of 
Parkinson's disease in first degree relatives of patients with Alzheimer's disease. 
These findings must be interpreled in light of the various problems encountered in 
case-control studies of Alzheimer's disease. As the majority of studies were hospital-based 
for case selection, selection bias may result from differentlal referral of patients according 
to family history of dementia.45 The paoled risk estimate, however, was very similar to the 
odds ratios observed in the population-based studies of Hofman et af and Broe et al.1" 
Another issue related to selection bias is that all studies inc1uded prevalent patients.45 
Observed associations may therefore relate to predietors of survival rather than to the 
risk of Aizheimer's disease. However, in a sub-ana1ysis of incident patients, i.e. patients 
included in the study within 1 year following diagnosis, risk estimates remained virtuaUy 
the same. As to information bias, non-differential misclassification may occur when 
assessing disease history in first degree relatives. A related issue is that we did nat 
distinguish the type of dementia in relatives, which may nat always have been of the 
Alzheimer type. This has most likely led to an underestimate of the strength of 
association between Alzheimer's disease and these disorders. Another problern in 
assessing fami1y history of late-onset disorders such as Alzheimer's disease and 
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Parkinson's disease is that rrrisclassification may also occur because relatives are still at 
risk of the disease after the study ar may have died befare the expression of the disease. 
Assuming that such a eensering mechanism bas been similar for fust degree relatives of 
patients and controls, this type of bias may dil u te a true association rather than to create 
a spurious one. Reeall bias may be another important souree of bias in these studies. 
Spurious associations may occur if relatives of patients pay more attention to the 
occurrence of other d:iseases intheir family than relatives of control subjects. This is more 
likely to occur in assessment of disease in relatives who are more distantly related. We 
have therefore restricted the re-analysis to first degree relatives. 
In this analysis of 814 patients with clinically diagnosed Alzheimer's disease~ and 894 
age- and gender-matebed control subjects we observed aggregation of dementia in the 
families of patients with early-enset as wel! as those with late-onset Alzheimer's disease. 
For early-onset Alzheimer's disease, the risk was about four times elevated, which was 
significantly higher than the 2.5 elevation in risk for Alzheimer's disease after the age of 
70 years. The lower risk estimate resulted from a Iower prevalenee of dementia in 
parents of late-onset patients. No difference was observed in risks for early-onset and 
late-onset Alzheimer's disease for history of dementia in siblings. An explanation for 
these findings may be related to the clustering of onset age within fami1ies.z.47 Relatives 
of late-onset patients are more likely to have a late-onset of the disease and may 
therefore have a higher chance of dying befare the disease onset. Since the life 
expectancy has most likely been higher for siblings than for parents, the chance of 
expressing the disease may have been higher in siblings of late-onset patients. 
Alternatively, if there is a true difference in risk for late-onset Alzheimer's disease 
between those who have an affected sibling and those who have an affected parent, this 
would suggest that familial a&,oregation of late-onset Alzheimer's disease may be of non-
genetic ar multifactorial origin. This finding is even compatible with a recessive disorder. 
A second finding which may point to heterogeneity is that the risk of Alzheimer's disease 
was significantly different for those with two or more first degree relatives with dementia 
as compared to those with one. 
There were significantly more patients with a first degree relative with Dàwn's 
syndrome than control subjects. A.lthough each of the individual studies showed a higher 
frequency of Down's syndrome in the family of patients, a significant increase in risk of 
Alzheimer's disease for subjects with a positive family history of Down's syndrome could 
only be shown after pooling of the data. This may be explained by the fact that Down's 
syndrome is a relatively rare disorder and large numbers of relatives are therefore 
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needed to establish an increase in risk. Our findings confirm earlier studies of family 
history of Down's syndrome.'u6.U The re-analysis of case-control studies did not confirm 
the hypothesis that the increase in risk was specific to early-onset patients.Z6 The risk 
estimates were very similar when stratifying by onset age. In etiologie terms, this finding 
may be of interest because if there is a true association between Alzheimer's disease and 
Down's syndrome, our finding would predict a link with chromosome 21 for bath early-
onset as well as late-onset Alzheimer's disease. However, to date, genetic linkage of 
Alzheimer's disease to chromosome 21 has been shown in families with early-onset 
Alzheimer's disease:>S but not in families with late-onset of disease:~49 It is important to 
note that matemal age at birth of the patients with Down's syndrome was not known and 
may have been an important confounder. Therefore we cannot rule out the possibility 
that the familial aggregation of Alzheimer's d:isease and Down's syndrome may be 
explained by a factor associated with the family history of both disorders, e.g. social class. 
ln this analysis we observed familial aggregation of Alzheimer's disease with 
Parkinson's disease, although patients with Parkinson's disease befare the onset of 
Alzheimer's disease were excluded in the case selection. The odds ratio tended to be 
higher in men as compared to wamen. In the interpretation of these findings it is 
important to note that the diagnosis of Alzheimer's disease was clinically assessed. Since 
the type of dementia was nat confirmed pathologically, we cannot exclude the possibility 
that the higher frequency of Parkinson's disease has occurred specifically in the family 
of patients who suffered from dementia caused by parkinsonism or Lewy body disease. 
In conclusion, this re-analysis confmned earlier studies that reported familial 
aggregation of early-onset Alzheimer's disease. In contrast to earlier studies, the re-
analysis also showed familial aggregation of late-onset Alzheimer's disease. The 
association between Alzheimer's disease and family history of dementia, however, was 
weaker in late~onset patients. Pooling of the data showed a significant increase in risk of 
Aizheimer's disease for subjects with a first degree relative with Down's syndrome. 
Individual studies may have Iacked statistica! power to assess an association. The re-
analysis also supported the hypothesis of familial aggregation of Parkinson's disease with 
Alzheimer's disease. However, this finding should be confirmed in a study of autopsied 
patients. 
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Genetics in early-onset Alzheimer's 
disease: risk and segregation of disease 
in first degree relatives 
Alzheimer's disease is a disorder w:ith a complex genetic etiology.1 Heterogeneity is 
evidenced by studies suggesting genetic linkage to chrornosome 19 as well as to 
chromosome 21.u Despite the evidence for autosomal dominant inheritance in a 
considerable number of familîes,7 the large majority of patients do nat have first 
degree relatives affected with dementia and for those the extent of genetic 
involvement is Iess clear!' Studies of the risk of Alzheimer's disease for fust degree 
relatives of cases have yielded risk estimates ranging from 5% to 50%.'~-16 Differences 
in methodology may underlie this wide range in risk estimates. However, it is a1so 
conceivable tbat these discrepancies rnay be due to heterogeneity.1 It has been 
suggested that genetics may differ between early- and late-onset Alzheimer's disease 
and that the early-onset form rnay be explained as an autosomal dominant trait. Ll<> 
Previous studies have been too small to yield precise risk estimates for early-enset 
AJzheimer's disease. Another problem in the interpretation of earlier investigations is 
that case-series have been hospital-based, which may have introduced selection bias 
when studying the extent of genetic involvement in the disease. As to the pattem of 
genetic transmission, to date only two studies on the segregation of Alzheimer's 
disease have been published, which have yielded contradicting results. 17' 1" 
We have studied the risk of early-onset AJzheirner's disease and the genetic 
transmission of disease in first degree relatives of 198 patients and in 198 age- and 
sex-matebed controls in a population-based study. 
This chaptcr is bascd on: 
Van Duijn CM, Farrer LA Cuppies LA. Hofman A Risk of dementia in first degree reiatives of 
patients with AJzheimer's disease. In: Iqbal K. McLachlan DRC, Winblad B. Wisnie'NSki HM (cds); 
Alzheîmer's discase: Basic mechanisms, diagnosis and thcrapeutic strategies. John Wîley & Sons. 
Chichester, 1991, 423-426. 
Van Duijn CM, Farrer LA. Cuppies LA. Hofman A Genetic transmission for Alzheimer's disease 
among patients identified in a Dutch population-based epidemioiogîcal study. Submitted. 
52 
Genetic transmission 
Methods 
Subjects. Patients were derived from an epidemiologie study of risk factors for 
clinically diagnosed Alzheimer's disease. The study aimed at a complete ascertainment 
of cases in whom the diagnosis was made befare 70 years and who were living in the 
four northern provinces of The Netherlands and the area of metropolitan Rotterdam. 
Ascertainment was carried out through all neurologie, psychiatrie, geriatrie services in 
the study areas. All cases were diagnosed in the period of January, 1980 to July, 1987. 
Control subjects were randomly drawn from the same municipality as the cases. Cases 
and controls were matebed for age (within 5 years), sex and residence. An extensive 
description of the design of the study, case diagnosis and response rates bas been 
given in chapter 2.1. The study comprised a total of 198 patients and 198 controls. 
Data collection. Detailed data on family history were collected by interviewing a 
next of kin of the patient ar controL All first degree relatives were Jisted and we 
asked specifically about the occurrence of dementia in them. Ta increase the validity 
of these data, the inforrnation was always verified by a sibling of the patient ar 
controL Because subjects were bom outside The Netherlands, we could not contact 
siblings in four cases and these subjects were excluded from the analysis. Por patients, 
we have assessed the onset age of dementia as the age at which memory loss or 
change in behavier was first noted. Por non-demented relatives, the eensering age was 
determined, i.e., the age at time of the study or the age at death. 
We questioned informants extensively on the cause and the course of the dementia 
in affected relatives. lf the patient had been admitted to hospita] the diagnosis was 
checked in independent medical records. Based on the reports of the informants and 
the :information derived from medica! records, we have classified relatives with a 
history of neurologie, psychiatrie ar roetabolie disorders that may also lead to 
dementia (e.g. stroke, Parkinson's disease, epilepsy, depression or alcoholism) as 
unaffected. Those subjects were considered at risk of Alzheimer's disease until the 
onset of the disorder that led to the censoring. As Alzheimer's dîsease may have been 
diagnosed years befare when the diagnosis was less accurate, aH other relatives with a 
type of dementia that was reported as being irreversible and progressive were 
classified as affected with possible Alzheimer's disease. 
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Data analysis. Risks of Alzheimer's disease and the age of onset distribution among 
fust degree relatives were estimated using a maximurn likelibood method.1? The 
maximum likelihoed estimates take into account the possibility that a proportion of 
relatives asymptomatic at the time of study may be susceptible and express the disease 
later in life and that some deceased relatives may have sneeurnbed to causes unrelated 
to Alzbeimer's disease although they may have developed symptoms had they 
survived. This metbod considers affected persons w:ith known onset ages, unaffected 
persons with known eensering ages and persons for whom onset age ar censoring age 
data are missing.1? Forthese latter relatives, a censoring age distribution was estimated 
based on the eensering distribution of the unaffected relatives with known data. The 
risk estimates are presented w:ith 95% confidence intervals. We tested differences in 
life time risks with the large sample z statistic, using the risk estimate and standard 
error of the aidest onset age camman to bath groups. 
Segregation analysis was carried out using a maximum likelihoed methad 
implemented in t."le computer program POINTER.2n The model parameters are: d, 
the degree of dominance, such that d=O corresponds to a recessive gene, d=l to a 
dominant gene, d=0.5 to a codominant gene and Ü<d<l corresponds to some 
additivity; t, the displacement at the major locus; q, the frequency of the high risk 
allele A; H, the polygenic heritability in offspring; Z, the parent to child heritability 
ratio; and rl, r2 and r3, the respective probabilities of genetypes AA, Aa, and aa 
transmitting the allele A. For Mendelian transmittance of a major locus, rl=l, 
r2=0.5 and T3=0, whereas the t's are equal if there is na transmission of a major 
effect. No families were ascertained through two ar more cases in the study. The 
ascertainment probability we have used for this population·based study is 0.01, 
corresponding to single ascertainment. Analyzing the data with an ascertairunent 
probability of 0.98 resulted in minor changes in the model parameters and did nat 
change the conclusions. Liability to developing dementia was assessed using the 
popuiatien risk of dementia, which was estimated as a cumulative incidence of 6.5 per 
1000." Based on the results of the survival analysis, we have adjusted the liability for 
age and sex (table 3.3.1). We have examined various models assuming: (1) Mendelian 
inheritance; (2) familial aggregation without an underlying major gene; (3) a mixed 
model postulating bath of the above; ( 4) no familial clustering. To campare the 
rnadeis the likelibood ratio test was used. 
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Table 3.3.1 Liability classes as defined for the segregation analysis 
Class A ge range (years) Cumulative 
Men Wamen Incidence 
1 0-50 0-45 0.000132 
2 51-65 46-62 0.000674 
3 66-75 63-70 0.001300 
4 76-80 71-78 0.002167 
5 81+ 79-80 0.002768 
6 8!-85 0.004285 
7 86-89 0.004971 
8 90+ 0.006500 
Results 
The 195 patients had 1,308 first degree re!atives compared with 1,219 in the 195 
controls. The risk of Alzheimer's disease in first degree relatives of patients is given in 
figure 3.3.1. The risk in relatives of the cases increased rapidly after age 55. By the 
age of 90 years the risk was 0.39 (95% Cl 0.27-0.51). Although this is Jower than the 
risk expected when the disease is to be explained solely as an autosomal dominant 
disorder, the 95% confidence interval included the predicted value of 0.50. The risk of 
Alzheimer's disease was significantly lower in relatives of control subjects (0.14; 0.06-
0.22). The relative risk for Alzheimer's disease for thase with an affected relative was 
2.8 (1.5-5.2). 
When stratifying the data for sex of the proband, onset age of the proband, sex of 
the relatives, re1ationship of the relatives to the case ar cantrol, the risk was 
significantly higher amang female relatives as campared to rnales when camparing risk 
estimates at the aidest camman onset age (table 3.3.2). Further stratification revealed 
that this was due to the 0.70 risk among fernale relatives of earlywonset cases (onset 
before the a ge of 58 years) by age 90. At the oldest common age (80 years ), the risks 
in male relatives of early-onset cases (0.16), male relatives of Jate-onset cases (0.20), 
female relatives of early-onset cases (0.29) and female relatives of Jate-onset cases 
(0.21) did not differ significantly. 
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Figure 3.3.1 Risk of dementia in first degree relatives of patients with Alzheimer's 
disease up to age 90 years 
Results of the segregation analysis are presented in table 3.3.3. The model assuming 
no famîlial aggregation of .t\.lzheimer's disease (model 1) was rejected when we 
compared this model to the most general Mendelian model (model 8; x.' 882.32; 
p<104 ) or the rnadeis assuming multifactorial inheritance (model 2; xi 853.54;p<W' 
and model 3; x,' 853.57;p<10'). When compared to the unrestricted mixed model 
(model 13), rnadeis postulating no Mendelian inheritance (model 2; x/ 3926;p<10'), 
no mu!tifactorial component (model 8; x,' 10.48;p=0.0012) and na transmission of a 
genetic defect (model 16; x,' 42.42;p< JO•) could be excluded. As to the mode of 
inheritance among the mixed rnadeis (models 9-12), recessive inheritance was rejected 
because the degree of dominanee (d) differed significantly from 0 (model 9 versus 
model 12; x,' 29.37;p=JO•). Since d was nat significantly different from 1 (model 11 
versus model 12; x,' O;p=1) or 0.5 (model 10 versus model 12; x.' 0.49;p=0.484), our 
data are compatible with the existence of a dominantly transmitted gene with reduced 
penetrance. While the multifactorial component was accounted for, more offspring 
was affected than expected based on Mendelian inheritance, i.e., r2 was significantly 
higher than 0.5 (model 12 versus model 13; x,' 9.89;p=0.0195). The best fit to our 
data was achieved in model 15. This model suggests that the penetrance of the 
Alzheimer's disease susceptibility allele at the major locus is 96%, 
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Tahle 3.3.2 Risk for Alzheimer's disease and age of onset distribution in first degree 
relatives of cases with Alzheimer's disease and age- and sex-matched controls 
Subgroup 
All 
Controls 
Male 
probands 
Female 
probands 
Onset .:s. 53 
years 
Onset >SS 
years 
Mal es 
relatives 
Females 
relatives 
Parents 
Siblings 
Number Relatives 
Affected Unaffected 
127 1181 
32 1187 
49 416 
78 765 
68 566 
59 615 
48 620 
79 561 
81 306 
46 875 
• 95% conGdence interv.ll within parentheses 
Life-time 
Risk" 
(years) 
0.39 
(0.27-0.51) 
0.14 
(0.06-0.22) 
0.39 
(0.21-0.57) 
0.38 
(0.24-0.52) 
0.48 
(0.30-0.66) 
0.32 
(0.18-0.46) 
0.22 
(0.14-0.30) 
0.56 
(0.36-0.76) 
0.42 
(0.30-0.68) 
0.18 
(0.08-0.28) 
Estimated 
Onset age· 
(years) 
77.7 
(74.6-80.8) 
81.4 
(77.9-84.9) 
77.8 
(72.7-S2.9) 
77.2 
(73.3-Sl.l) 
78.5 
(74.4-82.6) 
76.9 
(72.2-81.6) 
73.0 
(69.3-80.6) 
79.8 
(76.3-83.3) 
75.7 
(72.2-79.2) 
71.4 
(66.3-76.5) 
Oidest 
Onsetage 
90 
90 
90 
89 
90 
90 
86 
90 
90 
81 
Risk at Age 
Lowest Common 
Denominator· 
0.39 
(0.27-0.51) 
0.14 
(0.06-0.22) 
0.37 
(0.19-0.55) 
0.38 
(0.24-0.52) 
0.48 
(0.30-0.66) 
0.32 
(0.18-0.46) 
0.22 
(0.14-0.30) 
0.37 
(0.17-0.57) 
0.26 
(0.14-0.38) 
0.18 
(0.08-0.28) 
the frequency is 0.00097 and 35% of the transmission varianee is accounted for by 
Mendelian inheritance. When assuming an ascertainment probability of 0.98, the 
estimate was for penetrance 100% and for gene frequency 0.0084. In this case only 
9% of the transmission varianee could be accounted for by the major locus. 
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Table 3.3.3 Segregation analysis of Alzheimer's disease in first degree relatives of cases 
with Alzheitner's disease using an ascertainment probability of 0.01 and a cumulative 
incidence of 0.0065 
Model d q H z Tl T2 T3 -21n+c 
1 Sparadie (0) (0) (1.0) 672.91 
Multifactorial 
2 No cohort effect (0) 0.96 (1.0) -180.63 
3 Cohort effect (0) 0.97 0.99 (1.0) (0.5) (0) -180.66 
Single locus 
4 Recessive (0) 4.24 0.0680 (0) (1.0) (1.0) (0.5) (0) -2.91 
5 Co-dominant (0.5) 5.68 0.00076 (0) (1.0) (1.0) (0.5) (0) ·202. 70 
6 Dominant (1.0) 6.99 0.00390 (0) (1.0) (1.0) (0.5) (0) -132.93 
7 Unrestricted d 0.51 5.61 0.00076 (0) (1.0) (1.0) (0.5) (0) -202.70 
8 Unrestricted d+r 0.53 5.94 0.00060 (0) (1.0) 1.0 0.64 0 -209.41 
Mixed model 
9 Recessive (0) 5.07 0.06600 0.98 (1.0) (1.0) (0.5) (0) -180.63 
10 Co-dominant (0.5) 4.41 0.00180 0.67 (1.0) (1.0) (0.5) (0) -209.51 
11 Dominant (1.0) 2.16 0.00190 0.71 (1.0) (1.0) (0.5) (0) -210.00 
12 Unrestricted d 1.0 2.16 0.00!90 0.7! (1.0) (1.0) (0.5) (0) -210.00 
13 Unrestricted d+r 0.83 3.18 0.00089 0.79 (1.0) 1.0 0.69 0 -219.89 
General transmission 
14 Mendelian major 1.0 2.20 0.00220 0.46 2.13 (1.0) (0.5) (0) -224.33 
locus + cohort 
effects 
15 Unrestricted 0.96 2.62 0.00097 0.65 1.52 1.0 0.64 0 -229.23 
16 No cohort effect + 0.14 2.26 0.00!0 0.95 (1.0) (!.0) (!.0) (1.0) -177.47 
no transmission 
major gene 
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Discussion 
In this population-based study of early-onset Alzheimer's disease we observed that 
the risk of Alzheimer's disease was significantly higher for first degree relatives of 
patients with Alzheimer's disease as compared to relatives of controls. Among first 
degree relatives of patients the risk of Alzheimer's disease was lower than expected 
for an autosomal dominantly inherited disorder, although the risk estimate did nat 
differ significantly from the expected risk (i.e., 0.50). Segregation analysis suggested 
that familial aggregation of disease is most likely explained by a dominant major gene 
effect that acts tagether with a multifactorial component. 
A problern in the interpretation of our data may be that we have studied the 
occurrence of possible Alzheimer's disease in first degree relatives. The dementia may 
have been diagnosed years befare when the diagnosis of Alzheimer's disease and 
ether types of dementia was less accurate. Ta come to a diagnosis of possible 
Alzheimer's disease in relatives, we have questioned inforrnants extensively on the 
cause and the course of dementia and have classified relatives with a history of 
neurologie, psychiatrie ar roetabolie disorders that may lead to dementia other than 
Alzheimer's disease as unaffected. Furthermore, we have used multiple informants, 
which bas been shown to increase the reliability of data of family history.22 For aJ.l 
cases and controls, a sibling was interviewed who is likely to be the most 
knowledgable person about first degree relatives. 
Previous studies of the risk of Alzheimer's disease for relatives of patients have 
yielded risk estimates ranging from 5% to 50%."' Differences in methodology, e.g. 
ascertainment of patients and definition of age of onset may account for the 
cantroversial findings of these studies.L14 In addition, the growing evidence that genetic 
heterogeneity may be related to age of onset of Alzheimer's disease may explain part 
of the apparently contradicting findings. 1 The present study aimed at a complete 
ascertainment of cases with early-onset Alzheimer's disease in the two study regions to 
anticipate the problem of heterogeneity and selection bias. Among first degree 
relatives of patients the risk of Alzheimer's disease (0.39) was lower than ex-pected for 
an autosomal dominant inherited disorder (0.50), although the risk estimates did nat 
differ significantly. It is important to note, however, that we may have overestimated 
the risk because of the inclusion of relatives that suffered frorn other types of 
dementia than Alzheimer's disease. The risk arnong female relatives of early-onset 
cases by age 90 years was higher than expected for an autosomal dominant disorder. 
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This finding may be explained by (l) difficulties in assessment of Alzheimer's disease 
at old age; (2) the existence of cases with AJzheimer's disease of non-genetic origin; 
(3) the low number of wamen who sm·vive to such an old age leading to unstable risk 
estimates. When camparing the risk of relatives of cases and controls, this study 
confirms earlier findings of familial aggregation of Alzheimer's disease.5 
The segregation analysis indicates that familial aggregation of disease is most likely 
explained by a dominant major gene effect that acts tagether with a multifactorial 
component. Our findings suggest that a major gene for Alzheimer's dîsease accounts 
for no more than 35% of the total varianee in transmission of disease. Other genetic 
mechanisms ar environmental factors may account for the familial aggregation of 
disease in a considerable number of cases. As to the possibility of bias, the inclusion 
of relatives with ether types of demen6a would most likely lead to an overestimation 
of the extend of genetic transmission.17 Since no systematic bias in particular families 
is e:>.:pecteà, this type of misclassification has probably nat biased the data towards a 
specific model. A.nother methodological problem is related to eensering bias. Because 
the risk of Alzheimer's disease increases rapidly with age, genetic liability may have 
been underestimated. A final issue of concern relates to the statistkal analysis. 
Although we were able to reject several rnadeis postulating na transmission, recessive 
inheritance, na Mendelian inheritance and na multifactorial inheritance, we could nat 
àistinguish between several mixed and general transmission models. Moreover, despite 
the large number of observations, severa] models coulà nat be fitted easily because 
the likelihoed surfaces were re1atively flat or because of disturbances by locai maxima. 
The findings of the present segregation analysis are very similar to those reported 
by Farrer et al, who have studied first degree relatives of 232 patients affected with 
early- ar late-onset Alzheimer's disease. Bath studies show'îd: (1) Mendelian 
inheritance as wel! as a multifactorial component; (2) a higher number of offspring 
affected than expected based on autosomal dominant inher:itance in the mixed model, 
which takes into account the multifactorial component. There are several explanations 
possible for the latter finding." Firstly, this finding may be explained by the presence 
of non-genetic cases in the offspring, i.e., there may be subjects with disease but 
without the genotype (phenocopies ). Secondly, there may be reduced ascertainment of 
carriers among parents. Thirdly, there rnay be more than one dominant locus involved 
in early-onset Alzheimer's disease. Thus, some families woulà be expected to have 
more than 50% chance of affected offspring if this is nat a rare gene. In the only 
other stuày on segregation of Alzheimer's disease that has been reported to our 
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knowledge, two populations were studied. 18 No distinction could be made between the 
roodels postulating a single major locus, multifactorial inheritance and a mixed model 
using the data of one populationP In the other population, the multifactorial model 
was most likely. However, this population comprised a mixture of patients with 
Alzheimer's disease and Pick's disease.Z4 
In conc1usion, our findings are compatible with the view th·at multiple mechanisms 
may be involved in the transmission of early-onset Alzheimer's disease. Although our 
study confirms that a dominant gene may be implicated in early-onset Alzheimer's 
disease, the results suggest that other genetic factors as wen as environmental factors 
may account for the disease a considerable number of patients. 
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Amyloid precursor protein gene mutation 
in early-onset Alzheimer's disease 
A mutation within the amyloid precursor protein (APP) gene has recently been 
reported as the possible cause of Alzheimer's disease in two families in which the disease 
was apparently inherited as an autosomal dominant disorder.1 Thîs mutation in exon 17 
of the APP gene bas been shown to cause a valine-to-isoleucine substitution at amino 
acid 717 (transcript APP770). Recombination events between Alzheimer's disease and the 
APP gene in other families with early-onset Alzheimer's disease,u however, imply that 
other genes must be involved and that the role of the 717 APP mutation as a cause of 
early-onset Alzheimer's disease in the general popuiatien remains to be estab1ished.4 Ta 
assess the proportion of early-onset Alzheimer's disease that may be explained by the 717 
APP mutation, we have sereerred 100 familial and sparadie patients. 
Methods 
Patients were derived from a population-based epidemiologie study of early-onset 
Alzheimer's disease.5 The study aimeà at a complete ascertainment of prevalent and 
incident Alzheimer patients in whom the diagnosis was made befare the a ge of 70 years 
in four Nonhem provinces of the Netherlands and the area of metropolitan Rotterdam. 
For thïs study, the clinical diagnosis of Alzl1eimer's disease was independently confirmed 
using a standardised protocol according to the NINCDS-ADRDA criteria for A!zheimer's 
disease.6 The response rate was 99% for patients. An extensive description of 
ascertainment of these cases been given in chapter 2.1. Blood samples for DNA 
extraction were collected for a sample of 100 out of the 198 Alzheimer patients 
This chapter is based on: Van Duijn CM, Hendriks L, Cruts M, Hardy JA Hofman ~ Van Braeekhoven 
C. Frequency of mutation in the amyloid precursor proteîn gene (Letter). Lancet 1991;337:978. 
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participating in the study, who were still alive during the fol!ow-up in the period of 1989 
to 1990. The mean age of onset of dementia for the 100 patients was 57 years (SD=5). 
Of these patients, 48 were sporadic, i.e., there were no fust degree relatives known with 
Alzheimer's disease or dementia, and 52 patients had at least one first degree relative 
with dementia. Of these 52 familial patients, the pedigree structure of 14 was consistent 
with autosomal dominant inheritance of Alzheimer's disease. The criteria for autosomal 
dominant inheritance of Alzheimer's disease were: (1) at least three patients with 
reported dementia in two generations; (2) at least two patients with detailed medical 
records on the clinical diagnosis of Alzheimer's disease. Genea1ogy studies of second, 
third and fourth degree relatives of these 14 familial patients did not reveal evidence for 
a relationship between them. 
For the 100 patients DNA was extracted from total blood using the standard phenol-
chloroform extraction procedure. The DNA samples were screened for the 717 APP 
mutation. The mutation creates a Bcll restrietion site which allows detection of the 
corresponding polymorphism within the polymerase chain reaction (PCR) product. PCR 
was carried out using the intronic primers GTIGGGCAGAGAATATACTGA and 
GCCTAATICTCTCATAGTCT, generating a DNA fragment of 355 base pairs. The 
PCR reactions were performeà in a total volume of 50 1'1 containing 0.1 to 0.2 !Lg of 
genemie DNA, 1.5 Mm MgCJ~ 0.05 Mm KC!, 10 Mm Tris Ph 8.3, 0.001% (wfv) gelatine, 
0.2 Mm nucleotide triphosphates, 50 pmol of each primer and 2 U of Tag DNA 
polymerase (BRL, Bethesda, USA). The samples were covered with 50 1'1 mineral oil and 
30 three step cycles (1.30 min. 94°C; 1.30 min. 60°C, 2 min 72°C) were performed in a 
Cetus Thermocycler apparatus. The PCR products were digested with BeU (BRL) for 4 
hours at 50 oe. The digested PCR products were analyzed on a 3% agarose gel (2.5% 
Nusieve and 0.5% Seakem (FMC, Maine, USA)) at 2.5 V/cm during 5 hours. A sample 
of family F23 which showed the 717 APP mutation, 1 was used in each screening as a 
positive controL The proportion of screen positives were estimated for the total group 
ofpatients and for the subgroups offamilial and sparadie patients, separately. Exact 95% 
confidence intervals were calculated. 
Results and Discussion 
Screening of the 100 early-onset patients failed to show the mutation (table 3.4.1.). At 
a confidence level of 95%, this finding suggests that the APP mutation accounts for Jess 
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Table 3.4.1 Mutation in the amyloid precursor prorein gene in 100 patients with early-onset 
alzheimer's disease 
Number of fust Number Mean onset 
degree relatives patients age in years 
with dementia tested (SD) 
All 100 57 (5) 
0 48 56 (5) 
1 38 57 (5) 
> 2" 14 59 (5) 
* Consistent with autosoma\ dominant înhcrîtancc of Alzhcîmcr's discase 
Number 
screen 
positives 
(%) 
0 
0 
0 
0 
95% confidence 
interval 
0-3.6 
0-7.4 
0-9.3 
0-23.2 
than 3.6% of all cases with early-onset A.lzheimer's disease. Including only the 52 patients 
with a family history of dementia in first àegree relatives in the analysis, our study 
indicates that it is unlikely that more than 6.8% of the familial cases may be explained 
by thîs mutation. Restricting the analysis to the 14 patients deriveà from families in which 
the disease was apparently inherited as an autosomal dominant disorder. our negative 
findings yield a 95% confidence interval ranging from 0 to 23.2%. 
This study suggests that the 717 APP mutation is nat a camman cause of early-onset 
A.lzheimer's disease in the general Dutch papulation. To date, screening of patients with 
late-onset A.lzheimer's disease has also failed to show the 717 APP mutation.1 The 
preserree of this mutation in late-onset patients is less likely because families vv.ith late-
onset Alzheimer's disease do nat show linkage to cbramosome 21.7 Despite the 
significanee the 717 mutation in the APP gene may have for the undemanding of the 
pathogenesis of Alzheimer's disease, we conclude that for case diagnosis the mutation is 
at present of limited value. 
Acknowledgements 
This research was funded by the Flemish Bîotechnology Program, the National Fund for Scîentific 
Research (CVB) Belgium, the Eurodem EC COnccned Action of dementia, tbc SOOM Foundation and 
the Netherlands Organîsation for Scientific Research (NWO). We thank Hubert Backhavens and Dirk 
Goyvacrts for DNA extract ion, Drs Wim Schul te, Teun Tanja, Rob Haaxma. Arie Lamerîs. Rolf Saan for 
case diagnosis and Helen de Bruijn, Micheline de Haes. Jeanette Kamman, Hanncke van Meurs. Verona 
Otten, Carolinc Valkenburg for genealogy studies. 
65 
Chapter 3.4 
References 
1. Goate A, Chanier-Harlin MC, Mullan M, et at. Segregarion of a missense mutation in the amyloid 
precursor protein gene with familial Alzheimer's discase. Nature 1991;349:704-706. 
2. Van Broeckhoven C, Gcmhe AM, Vandenberghe A, et al. Failure of familial Alzbeimer's discase to 
segregate with the A4 amyloid gene in several European families. Nature 1987;329:153-155. 
3. Tanzi RE, St George.Hyslop PH, Haines JL, et al. The genetic defect in familial A.lzheimer's discase 
is not tightly linked to the amyloid 13 protein gene. Nature 1987;329:156--157. 
4. Wright AF, Goedert M, Rastie NB. Familial Alzheimer's disease: Beta amyloid resurrected. Nature 
1991;34%53-654. 
5. Hofman A, Schutte W, Tanja TA, et al. History of dementia and Parkinsoa's discase in fust degree 
relatives of patients with Alzheimer"s discase. Neurology 1989;39:1589-1592. 
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of 
Alzheimer"s disease: repon of the NINCDS-ADRDA Work Group. Neurology 1984;34:939-944. 
7. St George Hyslop PH, Haines JL, Farrer LA, et al. Genetic linkage studies suggest that Alzheimer's 
discase is nota single homogeneaus disorder. Nature 1990;347:194-197. 
66 
Chapter 3.5 
Decreased DNA repair capacity 
in inherited Alzheimer's disease 
Alzheimer's disease is a camman neurodegenerative disorder characterized by the 
premature death of neurons.' It has been reported that fibroblast and lymphoblastoid cell 
lines of patients with Alzheimer's disease have an increased sensitivity to the cell killing 
effects of alkylating agents and X-rays.'"' This phenomenon has been attnbuted to a 
defect in the capacity to remave DNA damages.'-'·' Comparison of DNA-damage levels 
in brain tissue of patients with Alzheimer's disease and controls indicated an at least 
twofold higber level of DNA breaks in patients with Alzheimer's disease as compared to 
controls.6 It is conceivable that in vivo such a defect will be pathogenie specifically in 
neuronal cells of Alzheimer patients, but that after exposure to certain DNA-damaging 
agents in vitro the defect may be detected in cells other than brain cells.' 
Decreased levels of DNA repair have been found in fibroblast and lymphoid celllines 
of patients with Alzheimer's disease after treatment with methyl methanesulfonate 
(MMS) or N-methyi-N'-nitro-N-nitrosoguanidine (MNNG),'-'·' although some of these 
results have been challenged.11).11 Thus far, DNA repair capacity bas nat been determined 
in freshly iso1ated cells of patients with Alzheimer's disease. Direct testing for general 
DNA repair defects wil! circumvent artifacts that may be introduced when using celllines 
and may be used for the diagnosis of Alzheimer's disease. 
In the present study a highly sensitive alkaline filter elution assay was used to 
determine the induction and disappearance of single-strand breaks in peripheral blood 
lymphocytes after exposure to N-ethyl-N-nitrosourea (ENU). We found that the mean 
percentage single-strand breaks disappearance was similar in patients with no ( 42.5%) 
or one first degree relative with dementia ( 43.0%) and controls ( 41.4% ). Single-strand 
breaks disappearance was significantly lower in patients with two or more affected 
relatives with dementia (23.6%) when compared to controls or the other patients. 
This chapter is based on: Boerrigter METI, Van Duijn CM, Mullaart E, Eikelenboom P, Van der Togt 
CMA, Knook DL, Hofman A, Vijg J. Decreased DNA repair capacity in familial, but not in sporadic 
Alzheimer's diseases. Neurobiol Aging 1991;12:367-370. 
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Methods 
Patients were derived from an epidemiologie study of risk factors for clinically 
diagnosed Alzheimer's disease. The study aimed at a complete ascertainment of cases in 
whom the diagnosis was made befare 70 years and who were living in the four northern 
provinces of the Netherlands or the area of metropolitan Rotterdam. Ascertainment was 
carried out through all neurologie, psychiatrie, geriatrie services in the study areas . .AJl 
cases were diagnosed in the period of January 1980 to July 1987. Control subjects were 
randomly drawn from the same municipality as the cases. Cases and controls were 
matched for a ge (within 5 years ), sex, and residence. An extensive description of the 
design of the study, case diagnosis and response rates bas been given in chapter 2.1. The 
study comprised a tata! of 198 patients and 198 controls. 
In the period 1989 to 1990, all patients and controls who were still alive were revisited. 
During 91 consecutive visits of 43 cases and 48 controls, blood was drawn for the present 
study of DNA repair capacity. Lymphocytes were isolated from 10 ml of coded blood 
samples, using Ficoll-Paque (Pharmacia) gradients" and washed tw:ice in RPMI 1640 
medium (Flow laboratories) plus 2% feta! calf serum. All steps were performed at 4"C. 
Viability of reeavered blood lymphocytes was always higher than 95% as measured by 
trypan blue dye exclusion. ENU (Sigma) was dissolved in dimethylsulfoxide (DMSO) 
immediately befare use. A constant number of cells (3x10'/ml) was used for each 
treatment :in order to exclude variations in the amount of damage in:itially induced. 
Lymphocyte suspensions were exposed to either 0.5 mM ENU (20 minutes) in RPMJ 
1640 medium plus 20 mM Hepes, 2mM glutamine and 5% feta! calf serum at 37 "C. The 
DMSO concentratien during ENU exposure was never higher than 1%. Control cells 
were treated w:ith RPMI containing the same DMSO concentration. At the end of the 
exposure period, cells were centrifuged and resuspended in RPMI 1640 supplemented 
with 10% fetal calf serum and glutamine and incubated for repair at 37 oe. For treatment 
w:ith 4Gy of "'Co-gamma-rays, lymphocytes were suspended in RPMl 1640 medium plus 
20 mM Hepes, 2mM glutamine and 5% fetal calf serum and were irradiated on ice in a 
Gamma-cel! 100 (Atomie Energy of Canada Ltd.) at a dose rate of 6 Gy/minute. After 
irradiation the cells were centrifuged and resuspended in RPMI 1640, 10 FCS, 2mM 
glutamine for repair incubation. 
The technique of alkaline filter elution, modilied for analyzing nonradioactively 
labelled cells,'' was used to measure ENU-induced DNA lesions, detected as single-strand 
breaks.'" In brief, cells were collected, centrifuged and resuspended in ice-cold PBS (8.1 
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mM Na,HPO., 15 mM KH,PO., 0.14 M NaCl and 2.6 mM KC!) at a final concentratien 
of 1.5x10' cells/ml; 0.8x10' cel!s were applied per filter. Loading and lysing of the cel!s, 
as wel! as the e!ution of the DNA, were performed under subdued lighting in order to 
minimize artificial in duetion of single-strand breaks. Elution was carried out at a flow rate 
of 0.03 mi/min. Six fractions were col!ected at 2.5 hour intervals. After the actdition of 
Hoechst 33258, DNA in each fraction was guantified spectrofluorometrically, as 
described.(, AH determ:inations and subsequent calculations were performed in a blinded 
marmer. The elution results were plotted as the log percent of DNA remairring on the 
filter as a function of elution time. Linear regression between the data points obtained 
at t=2Yz and t= 12Yz hour of elution time was used to determine the slope of the elutions. 
Mean slopes of elution curves were used to calculate the percentage single-strand break 
disappearance. In all experiments, mean slopes were based on at least triplicate 
determinations and standardized with reference to mean slopes of untreated control eens 
assayed in the same experiment. Variation between the triplicate detenninations of a 
single sample was typically less than 2%. 
Results 
Table 3.5.1 shows the general characteristics of bath the patients with Alzheimer's 
disease and contro1s. There were no significant diEferences in the mean age between 
patients and controls. Out of 43 patients, twelve (28%) had one first-degree relative with 
dementia, as compared to 13 out of 48 controls (27% ). Fifteen of the 43 patients (35%) 
had two or more first-degree relatives with dementia. The pedigree structure of these 
patients was consistent with autosomal dominant inheritance of Alzheimer's disease. 
These patients were not related to each other in first, second, or third degree. None of 
the controls had two or more first-degree relatives with dementia. 
In a previous study on DNA repair in lymphocytes from normal human individuals we 
used the alkylating agent ENU at a dose of 0.5 mM, which induces approximately 4000 
single-strand breaks per cel! and has na significant effect on cel! survival." In that 
previous study we observed that lymphocytes of 10% of normal young subjects suffer 
from a low capacity to remave ENU-induced single-strand breaks." The low level of 
repair appeared to correlate with a low level of survival of these cells at ENU doses of 
1,2 and 5 mM.15 Figure 3.5.1 shows representative elution curves for lymphocytes from 
a normal control subject, a patient with sparadie Alzheimer's disease, and a patient with 
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Tahle 3.5.1 Percentage disappearance of single-strand breaks in peripheral blood 
lymphocytes from patients with Alzheimer's disease and age·matched controls after in vitro 
exposure to 0.5 mM ENU (20 min, 37 °C} followed by an I hour repair incubation in fresh 
medium 
Subjects Family Number 
histary· subjects 
Cases 0 16 
1 12 
2 15 
All 43 
Contra Is 0 35 
1 13 
All 48 
Number of affected rels.tivcs 
t Mean (S.E.M.) 
a ge Female 
(years)+ (%) 
67.1 88 
(1.47) 
69.3 83 
(0.82) 
68.8 75 
(1.74) 
68.3 81 
(0.84) 
68.2 72 
(1.15) 
70.0 70 
(1.55) 
68.9 71 
(0.93) 
Single-strand ENU 
breaks induction+ re pair+ 
t=O t=l (%) 
0.164 0.084 42.5 
(0.011) (0.009) (8.2) 
0.180 0.101 43.0 
(0.011) (0.009) (4.4) 
0.181 0.131 23.6' 
(0.017) (0.011) (5.8) 
0.176 0.105 36.1 
(0.008) (0.006) (4.0) 
0.181 0.096 40.8 
(0.011) (0.007) (3.4) 
0.173 0.100 44.3 
(0.013) (0.012) (5.5) 
0.179 0.097 41.4 
(0.0009) (0.006) (2.9) 
t Numbcr of single-strand breaks represented by the slope of the elution curve (mean and S.E.M.) at indicatcd time 
(hours) after 20 minute ENU treatment 
§ Significantly different from tbe 4S control subjects {p=O.Ol) and significantly different from the 28 othcr patîents 
(p~0.02) 
two or more affected relatives, directly after exposure to 0.5 mM ENU and aftera 1 hour 
repair incubation. The initia! amount of single-strand breaks in lymphocytes from these 
three selected subjects did nat differ significantly. However, following a 1 hour repair 
incubation the amount of single-strand breaks was significantly decreased in lymphocytes 
from the control subjects and the sparadie patient, where as the lymphocytes from the 
selected pa ti ent with two ar more affected relatives appeared incapable of removing the 
ENU-induced single-strand breaks (figure 3.5.1, panels A-C). For lymphocytes from these 
sameindividuals gamma-ray-induced single-strand breaks were removed efficiently; repair 
was virtually complete within 1 hour of repair incubation (figure 3.5.1, panels D-F). The 
number of single-strand breaks induced by ENU over the 20-minute treatment peri ad was 
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Figure 3.5.1 Representarive elution curves of lymphocytes from a normal control subject (A 
and D ), a sparadie Alzheimer parient (B and E) and a parient with inhenited Aizheimer's 
disease (C and F) exposed in vitro to 0.5 mM ENU for 20 min at 37 oe (A,B, and C) or 
irradiated with 4Gy of gamma-rays at 4 °C (D, E, and F). Untreated control cells ( ~); 
treated cells, no repair incubarion (lil); treated ce/Is followed by an 1 hour repair incubation 
(o) 
nat significantly different between patients and controls (table 3.5.1). In the 48 controls 
the percentage single-strand breaks disappearance was 41.4% (SE 2.9% ), which was nat 
significantly different from the 36.1% (SE 4.0%) found in the 43 patients (p;0.75). 
Patients whohad na or one first degree relative with dementia had a mean single-strand 
breaks disappearance of 42.5% (SE 8.2) and 43.0% (SE 4.4), respectively, which was very 
similar totherepair in the controls (41.4%). Patients with two or more affected first-
degree relatives had a significantly lower percentage single-strand breaks disappearance 
(23.6%; SE 5.8%) than controls (p;0.01) or the other patients (p;0.02). In lymphocytes 
from six patients with two ar more affected relatives that were checked at 2Yz hour 
posttreatment, the percentage ofENU-induced single-strand breaks was 34.9% (SE 6.7), 
indicating that the ra te rather than the total amount of repair was lower in these patients 
(results nat shown). A similar decrease in rate of single-strand breaks disappearance in 
lymphocytes from some normal young subjects exposed in vitro to ENU was reported in 
our previous study. 15 
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There was no statistically significant correlation between age and the percentage single-
strand breaks disappearance in patients with Alzheimer's disease, controls or all groups 
cornbined. No differences were observed between men and wamen among control 
subjects. The amount of single-strand breaks disappearance was nat associated with 
onset-age, severity or duration of disease in the cases. 
Discussion 
Our data suggest a delayed DNA repair in patients from families in which Alzheimer's 
disease is apparent1y inherited as an autosomal dominant disorder. No evidence for a 
decrease in DNA repair capacity was found in the other patlents. This study confirms 
earlier observations of a significantly lower survival of fibroblast and lyrnphoid celllines 
from patients with Alzheimer's diseasé and of DNA repair defic:iencies in Alzheimer's 
disease een lînes with regard to exposure to MMS or MNNGY-9 However, other studies 
reported conflîcting evidence.1o.11 There may be several explanations for these 
contradicting find:ings. The number ofpatient-derived celllines used in earlierstudies has 
been limited (n=7 to n=9) resulting in a 1ow statistica! power to show a decreasein 
DNA repair. Also, the application of long-term cel! culture instead of using freshly 
isolated cells may have introduced bias. Moreover, it cannot be exc!uded that (genetic) 
heterogeneity explains part ofthe contradictîng results. To evereome these problems, we 
have studied DNA repair capacity in freshly isolated cells of 43 patients with early-onset 
Alzheimer's and conducted stratified analysis by family history of dementia, age and sex. 
In a previous study, we have used the excision repair inhibitor 1-B-arabino-
furanosylcytosine to provide evidence that the most likely type of defect responsible for 
the 1ow ENU-induced single-strand breaks repair observed insome individuals is a lesion-
specific step in excision repair, e.g. glycosylation. 15 In this regard it should be noted that 
different alkylating agents induce a different spectrum of DNA les:ions, the remaval of 
which may require different repair pathways and possibly different glycosylases. 
Therefore, the previously reported DNA repair defect in cells from sparadie Alzheimer 
patients, detected after treatment with MMS/ is nat necessari1y in conflict with our 
present results but could be the consequence of the different alkylating agents used. 
A deficiency in the ability of cells to repair alkylating agent-induced single-strand 
breaks may imply a hypersensitivity to DNA lesions induced by those agents. There may 
be several explanations for a diminished DNA repair in patîents from families in which 
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the disease is apparently inherited as an autosoma1 dominant disorder but nat in the 
other patients. Firstly, a decrease in DNA repair may be related to medication. As 
treatment was very similar for all patients involved in this study, this explanation is not 
very likely. Secondly, our findings may be explained by misdiagnosis of Alzheimer's 
disease as within this group of patients the diagnosis bas nat been confirmed by 
pathological examination. Although for this study the clinical diagnosis of Alzheimer's 
disease was verified in all patients (chapter 2.1), it may be argued that the diagnosis may 
be more certain in patients with two or more ether affected relatives. As misdiagnosis 
among the other patients wili tend to attenuate relationships, a pattem suggesting genetic 
heterogeneity as observed in the present study rnay be expected. Thirdly, the difference 
among subgroups of patients may be a conseguence of a different pathogenesis. At 
present, it is nat clear how a detective DNA repair may be related to the etiology and/or 
pathophysiology of familial Alzheimer's disease. lt may be speculated that a decrease in 
DNA repair may aggregate within families. It remains to be resolved whether this may 
lead to an increased susceptibility for Alzheimer's disease for subjects from such families 
or whether this bas ledtoa mutation causing Alzheimer's disease in a progenitor, which 
subseguently bas been transmitted as an autosomal dominant trait within these families. 
In patients with na ar one affected relatives, DNA repair may nat be împlicated in the 
etiology ar there may be other DNA repair processes involved than we have examined 
in the present study. 
In conciusion, our finàings suggest a delayed DNA repair in lymphocytes of patients 
from families in which Alzheimer's disease is apparently inherited as an autosomal 
dominant disorder. However, as this is the first study to show an association to ENU-
induced single-strand breaks specifically in a rather small subgroup of patients, our 
findings remain to be confirmed by ether studies. 
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Chapter4.1 
Introduetion 
In this chapter, the evidence for environmental (non-genetic) risk factors for 
Alzheimer's disease is presented. Case-control studies have yielded few leads about the 
etiology of Alzheimer's disease.1 Although actvaneed age and a positive family history of 
dementia have been consistently associateà with Alzheimer's disease, studies on the role 
of ether putative risk factors have yielded contradicting results. A major concern in the 
interpretation of these findings is the low statistica! power of the individual case-control 
studies. Although the largest study comprised 392 cases and 392 age- and sex-matebed 
controls, the size of the other studies varled from 34 to 198 cases.~ Given an ex-posure 
frequency of 0.10 in contra Is, a significanee level of 0.05 (two-sided) and a power of 0.90, 
the largest detectable relative risk is 3.4 in a study of 100 cases and 100 controls and 2.5 
in a study of 200 cases and 200 controls.' The relatively smal! sample size of the 
individual studies may therefore explain some of the apparently conflicting results. 
In the collaborative re·analysis basedon raw data of case-control studies (see chapter 
2.2), we evaluated the evidence for the association of Alzheimer's disease with parental 
age, head trauma, medica! and psychiatrie history, and environmental factors. An 
overview of the findings is given in chapter 4.2. Chapter 4.3 deals with further evidence 
fora relationship between head trauma and Alzheimer's disease and chapter 4.4 presents 
the findings of a study of serum levels of interleukin·6 in patients with .Alzheimer's 
disease. The latter two chapters are based on the on the case-control study of early-enset 
Alzheimer's disease, which has been described in chapter 2.1. 
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Risk factors for Alzheimer's disease: 
The EURODEM collaborative re-an.alysis 
of case-control studies 
Case-control studies have yielded few leads about the etiology of Alzheimer's disease.U 
Although actvaneed age and a positive family histmy of dementia have been consistently 
associated with Alzheimer's disease, studies of other putative risk factors have yielded 
contradicting results. These contradicting findings may in part be explained by the 
relatively small sample size of the individual studies. Although the largest study comprised 
392 cases and 392 controls, the size of the other studies varied from 34 to 198 patients.J-14 
The low statistica! power of such studies to detect a significant association with rare 
exposures may explain some of the apparently conflicting results. 
In this paper, we present a re-analysis of case-control studies of Alzheimer's disease. 
The aim of this analysis was (1) to re-analyze the data in order to campare risk estimates 
from the individual studies, (2) to estimate risks of Alzheimer's disease using the paoled 
data-set, and (3) to study subgroups of Alzheimer's disease, based on onset age and 
gender. The risk factors considered in this collaboratîve analysis were matemal age at 
index birth, head trauma, medical and psychiatrie history and environmental factors. 
Methods 
For this analysis, the original data of eleven case~contro1 studies were sent to the 
Department of Epidemiology and Biostatistics of theErasmus University Medica! School 
Rotterdam, Tbe Netherlands. An extensive description of the individual studies and the 
re-analysîs is given in chapter 2.2. In all studies, the diagnosis of the patients met the 
NINCDS-ADRDA or DSM-lll criteria."·" 
This chapter is based on: Van Ouijn CM, Hofman A, for the EURODEM Risk Factors Research Group. 
Risk factors for Aizheimer"s disease: The EURODEM collaborativc re-analysis of case-control studies. 
Neuroepidemiology. In press. 
78 
Environmental risk factors 
In the re-analysis, we excluded two studies in which the data were nat collected 
symmetrically for patients and controls. Three studies can be considered population-
based, i.e., they aimed to detect all patients in a defined geographical area.'u1u2 All studies 
comprised prevalent as well as incident patients. 
The strength of association between Alzheimer's disease and the putative risk factors 
was assessed by computing of the odds ratio (OR) as an estimate of the relative risk. 
Since all included studies were matebed for age and gender, odds ratios were estimated 
using conditionallogistic regression analysis.17 Confaunding by family history of dementia, 
number of siblings and education was evaluated by entering these variables into the 
Iogistic regression modeL For family history of dementia, a dichotomous variabie was 
created, categorizing individuals by ha ving at least one first degree relative with dementia. 
In this paper, the adjusted odds ratios are presented with 95% confidence intervals (95% 
CI). Stratified analyses were conducted based on gender and onset age. Age of onset was 
categorized in two groups: onset befare 70 years and at age 70 or older. For controls, a 
"reference age11 was defined based on the onset age of the matebed case. 
Results 
Parental age 
Of the nine studies that were included in this re-analysis, seven studies assessed 
parental age as a putative risk factor.4-1..S.l<~-l:: Of those studies, three (USA Denver/1 USA 
Durham' and USA Minneapolis') were excluded because data were available of Iess than 
60% of either the cases or the controls. Thus, only four studies contributed data to the 
analysis of parental age."'1a.12 As there is evidence for an increase in risk of Alzheimer's 
disease for young as wellas late matemal age, subjects whose mother was aged 25 to 29 
years at birth were taken as the reference category in the paoled analysis.18 
A.n increased risk of Alzheimer's disease was observed for these whose mothers age 
was 40 years or older at the time of the subjects birth (table 4.2.1). The increase in fisk 
was mainly determined by the Italian study' (OR 4.8; 95% Cl 1.2-19.3), while the other 
studies showed a non-significant small increase in the odds ratio (Australian study12 OR 
1.4; 95% CI 0.5-3.7; Dutch study'" OR 1.4; 95% Cl 0.6-3.4; USA, Seattle" OR 1.2; 95% 
Cl 0.3-4.5). Although the association was strengest in wamen, odds ratios were nat 
statistically significant different when camparing men and wamen and early- and late-
onset Alzheimer's disease. 
79 
Chapter 4.2 
Table 4.2.1 Matemal age" and the risk of Alzheimer's disease 
Matemal age Number of: 
(years) Cases Controls OR+ 95% Cl 
15-19 25 17 1.5 0.8·3.0 
20-24 87 97 0.9 0.6-1.4 
25-29 130 135 1 reference 
30-34 104 114 0.9 0.6·1.3 
35-39 53 55 1.0 0.6-1.6 
40+ 47 28 1.7 1.0·2.9 
·Studies included in the analyses are Australia./2 Italy.0 The Netherl:mds10 :md USA, Sea.ttlef! 
+ Odds ratio adjusted for age. gender. family history of dementia.. number of siblings and educ:~.tion 
The risk was also increaseà for very young matemalagein three studies,6.10·11 although 
the associat:ion àid nat reach statistica! significanee in the overall analysis (table 4.2.1). 
In the Dutch Studyl0 of early-onset Alzheimer's disease, the odds ratio was significantly 
increased for those whose mother was 19 years or younger at birth (OR 6.5; 95% Cl1.4· 
30.3). However, in the Seattle study11 an inverse association was found (OR 0.3; 95% CI 
0.1-1.3). When stratifying for onset age, an association with young matemal age was 
found only with early-onset Alzheimer's disease (OR 4.2; 95% Cl 1.4-13.0), but this 
finding was mainly determined by the Dutch study. 
There was no evidence for an association between early- ar late-onset Alzheimer's 
disease and paternal age at birth, when maternal age was adjusted for. 
Head trauma 
Only studies which collecteà information on head trauma with lass of consciousness 
that occurred more than one year befare the onset of dementia or the reference age in 
controls were considereà in the re-analysis (table 4.2.2). 19 In all these studies, the odds 
ratio exceeded one (table 4.2.2). The paoled odds ratio estimated from these studies was 
1.8 (95% Cl 1.3-2.7). Subgroup analysis showed a significant (p=0.005) difference 
between men and wamen. The odds ratio was for wamen 0.9 (95% Cl 0.4-1.7) and for 
men 2.7 (95% Cl 1.6-4.4). No significant difference was observed when stratifying for 
onset a ge. S.ince patients with Alzheimer's disease may have a higher risk of head trauma 
due to the dementia, odds ratios were estimated for head trauma aceuiTing more and less 
than ten years prior to the disease onset. The highest odds ratio was observed for head 
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Tahle 4.2.2 Head trauma and the risk of Alzheimer's disease 
Study Exposure frequency 
Cases Controls OR' 95% Cl 
Australia u 7/152 6/152 1.2 0.3-4.2 
ltaly' 6/95 3/95 2.0 0.4-12.4 
The Netherlandsw 22/197 17/197 1.3 0.7-2.8 
USA, Denver' 6/48 1/48 6.0 0.7-276.0 
USA, Minneapolis' 16/45 7/45 2.8 1.0-9.9 
USA, Rochester' 11/392 8/392 1.4 0.5-4.4 
USA, Seattle" 19/130 8/130 2.4 1.0-6.3 
Overall analysis 87/1059 50/1059 1.8 1.3-2.7 
Odds :ratJ.O adJUSted for age, gender, family h1story of dementia, number of s1blings and educatJOn 
trauma that occurred within ten years befare onset (OR 5.5; 95% Cl 1.6-18.3). A 
significant elevation in odds ratio (OR 1.6; 95% Cll.0-2.57) was also observed for head 
trauma that occurred more than ten years befare disease onset, which are nat likely due 
to the dementia. 
Medica! histocy 
Several disorders have been assessed as putative risk factors in the case-control studies 
(table 4.2.3).~ In the paoled analysis, only disorders that occurred more than one year 
befare the onset of Alzheimer's disease or the reference age in contro1s were considered. 
No association was found between Alzheimer's disease and thyroîd disease, when the 
type of thyroid disorder was unspecified. A significant association with hypothyroidism 
was observed (OR 2.3; 95% Cll.0-5.4). Although numbers were toa small to stratify for 
lag-time between diagnosis of hypothyroidism and onsetage of dementia, in most cases 
hypothyroidism was diagnosed long befare the onset of dementia (median time 20 years ). 
An increased risk was found for those with and without a family history of dementia. 
No association of Alzheimer's disease was found with neurotropic viruses. Since in 
most studies data were collected by interview, no distinction could be made between 
encephalitis ar meningitis. Tnere was no association of Alzheimer's disease with ex-posure 
to either of these disorders. The paoled analysis of epilepsy yielded a small, non-
significant increase in the odds ratio. The increase in risk was highest for epilepsy which 
first occurred within ten years befare the onset of Alzheimer's disease (OR 2.5; 95% Cl 
0.4-13.9), suggesting the seizures may have been an early symptom of the disease. 
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Table 4.2.3 Medica/ history and rhe risk of Alzheimer's disease 
Risk factor Exposure freguency 
Cases Controls OR+ 
All thyroid disease4-6.".to.t:: 110/994 115/991 LO 
Hyperthyroidism().tl,U 14/408 12/390 1.2 
Goitre(),ll,t:: 12/408 18/390 0.6 
Hypothyroidism7·"·1:: 17/655 8/732 2.3 
N eurotropie virus es: 
Herpes zoster4-6,9-t:: 100/1103 105/1110 0.9 
Herpes simplex I1>.to 94/314 78/295 1.2 
Polio myelitis4.s.to.n 5/451 7/467 0.8 
Encephalitis/meningitis4.7·"·10·1::.+ 7/1081 5/1167 1.6 
Epilepsl<.o.to.t:: 11/459 6/538 1.6 
Atopf·7.to.t:: 172/670 190/684 0.9 
Hay fever·7'10'11 3]/445 38/454 0.8 
Arthrosis/arthritiS4'5' 1::.+ 131/277 168/302 0.7 
Migraine/severe headaches4.S.to.t::.+ 68/463 101/490 0.7 
Blood transfusions4-t..w.t:: 71/523 112/562 0.6 
General anaesthesia4.5 .... 1:: 827/1098 838/1114 1.0 
• Reference to studies included in tbe analysis 
++ Odds ratio adjusted for agc, gcnder,_ family history of dementia, number of siblings and education 
Bascd on the anamncstic data, no dtstinction could bc made bet-.vcen these disorders 
95% Cl 
0.8-1.3 
0.5-2.6 
0.3-1.4 
1.0-5.4 
0.6-1.2 
0.8-1.8 
0.3-2.7 
0.5-5.3 
0.7-3.5 
0.6-1.2 
0.5-1.2 
0.5-1.0 
0.5-1.0 
0.4-0.9 
0.8-1.3 
There was no association of Alzheirner's disease with allergies nor with general 
anaesthesia. Inverse associations were observed with several chronic disorders 
( arthrosis/arthritis, migraine/severe headaches) and with blood transfusions. For migraine 
and severe headaches, subgroup analysis showed a significant (p;0.05) difference 
between men and wamen. The odds ratio for men was 1.1 (95% Cl 0.6-2.0) and for 
wamen was 0.6 (95% Cl 0.4-0.9). 
Bistory of depression 
Four studies have assessed episodes of depression disorder occurring more than one 
year befare the onset of Alzheimer's disease or the reference age in controls (table 
4.2.4).~1 In three out of the four studies there were more patients with a history of 
depression as compared to controls. It is important to note, that the association was 
observed in the Roehester studl, which is based on medica} records. A significant 
association was observed for episodes of depression more than ten years befare disease 
onset (OR 1.9; 95% CI 1.1-3.3), suggesting that the association may be a true risk factor 
rather than rnerely be the result of the dementia. There was na difference in risks 
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Tlible 4.2.4 History of depression and the risk of Alzheimer's disease 
Study Exposure freguency 
Cases Controls OR' 95% Cl 
Australia 12 11/170 4/170 2.8 0.9-8.6 
USA, Bedford' 4/103 6/162 0.8 0.3-3.1 
USA, Minneapolis' 4/78 1/48 3.0 0.3-28.6 
USA, Rochester' 36/392 21/392 1.8 1.0-3.3 
Overall analysis 55/743 32/772 1.8 1.2-2.9 
Odds ratio adjustcd for agc. gcndcr. family history of dementia. number of siblings and education 
observed after stratifying for gender. An increase in risk of Alzheimer's disease for history 
of depression was only observed in late-onset patients (OR 2.4; 95% Cl 1.4-4.4). The 
odds ratio in early-onset patients was 1.0 (95% Cl 0.5-2.3). Data on anti-depressant 
treatment (unspecified) were available on1y in two stuàies.5·12 No association with 
Alzheimer's disease could be establisheà. 
Data of life events have been assessed in six stuàies.<k>.s.lo.I~ A paoled analysis of these 
studies did nat show a significant association of Alzheimer's disease with death of a 
spouse, death of a child or divorce. 
Environmentai factors 
Table 4.2.5 gives the odds ratios for smoking (ever smoked yes/na).~ With the 
exception of two studies/·7 there was a consistent trend towards an inverse relationship. 
The paoled analysis of the studies showed a borderline significant decrease in the odds 
ratio (OR 0.8; 95% Cl 0.6-1.0). When smokers were classified according to the number 
of pack-years (number of cigarettes smokeà a àay (packs) x smoking duration (years)), 
the odds ratio decreased with increasing number of pack-years (p=0.0003). The odds 
ratio was 0.7 (95% Cl 0.5-1.1) for smoking less than 15.5 pack-years, 0.6 (95% Cl 0.4-1.0) 
for smoking 15.5-37.0 pack-years and 0.5 (95% Cl 0.3-0.8) for smoking more than 37 
pack-years. There was na evidence for effect modification by onset age or gender. 
Data on alcohol consumption were available from five studies.5~10 Odds ratios were 
estimated for low (0.6-3.2 ounces pure alcohol per week), moderate (3.2-6.0 ounces/week) 
or high intake (more than 6.0 ounces/week).:!Z The odds ratios were for Iow intake 1.1 
(95% Cl 0.7-1.6), for moderate intake 1.0 (95% Cl 0.6-1.7) and high intake 0.8 (95% Cl 
0.5-1.3). 
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Tahle4.2.5 Smoldng and the risk of Alzheimer's disease 
Study Exposure frequency 
Cases Controls OR' 95% CI 
Australia 12 80/168 89/169 0.8 0.5-1.3 
Italy' 51/116 52/97 0.6 0.3-1.4 
The Nether1ands10 89/193 102/195 0.7 0.5-1.2 
USA, Bedford' 85/102 127/161 1.5 0.7-32 
USA, Denver' 17/63 23/63 0.6 0.2-1.4 
USA, Durham' 25/46 50/91 1.0 0.5-2.1 
USA, Minneapolis' 54/78 37/48 0.5 0.2-1.7 
USA, Seattle" 66/129 75/129 0.7 0.4-1.2 
Overall analysis 467/895 555/953 0.8 0.6-1.0 
Odds ratio a.djusted for a,ge. gcnder. fumily history of <.icmentia, number of sîblings and OOucation 
Occupational exposures to solvents and lead have been studied in four investigations 
included in this re-analysis.4.s'7'8 The paoled risk estimate was for occupational ex-posure 
to solvents 0.8 (95% Cl 0.5-1.2) and for exposure to lead 0.7 (95% Cl 0.4-1.4).~ 
Discussion 
This collaborative analysis of case-control studies of patients with clin:ically diagnosed 
AJzheimer's disease suggests that the risk for Alzheimer~s disease :is increased for late 
matemal age, head trauma, hypothyroidism and history of depression. Th ere were inverse 
associations with smoking, arthrosis/arthritis, migraine/severe headaches and blood 
transfusions. No evidence was observed for a roJe in AJzheimer's disease of alcohol, 
occupational exposures to solvents and lead, general anaesthesia, neurotropic viruses, 
encephalitis or meningitis, atopy or hay fever. 
Th ere are several ways in which the findings of the re-analysis of case-controls studies 
of Alzheimer's disease may be biased.~4,Z5 Selection bias in the case-series may have 
occurred, since the studies were generally based on prevalent patients. The observed risk 
factors may therefore relate to predietors of survival, rather than to the risk of 
Alzheimer's disease. Another issue related to selection bias is that spurious associations 
may occur in studies which are nat population-based. Patients with certain conditions, e.g. 
head trauma, hypothyroidism and depression rnay have a higher chance to be included 
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in the study. As to the possibility of information bias, case-control studies relying on 
reports of informants are prone to misclassification and reeall bias. In chapter 6.2 the 
possibilities of bias will be discussed in depth and in chapter 6.3 the results of the re-
analysis will be reviewed in light of the findings of previous studies. Here, we will discuss 
the evidence for the association between Alzheimer's disease with parental age, head 
trauma, medical and psychiatrie history, and environmental factors based on the findings 
of the re-analys:is of case-control studies. Case-control studies of Alzheimer's disease 
conducted to date have been hampered by small sample size. Pooling of data into a 
single risk estimate may be an efficient way to overcome this problem. Yet, it is well 
recognized that case-control studies are prone to bias.24 Consistency of fmdings across 
studies that have been conducted at different locations with different methodology, 
however, may strengthen the evidence fora causa! relationship. Therefore, an important 
aim of the re-analysis bas been to test for heterogeneity across studies ( chapter 2.2). 
Parental age 
The association to matemal age derives limited support from this re-analysis. The 
majority of the individual studies showed a weak non-significant association of 
Alzheimer's disease with late matemal a ge ( 40 years and over), although all studies 
showed a consistent increase in risk. The increase in risk foryoung matemal age (age 19 
years or younger) was less consistent since one study showed an inverse association. No 
association could be shown with paternal age. Weak associations as observed bere may 
be explained by bias or confounding. On the other hand one may argue that true weak 
associations may be blurred by error in exposure measurement. Therefore, studies in 
which matemal age is verified in birth records are needed to discern whether matemal 
age is indeed a risk factor for AJzheimer's disease. 
Head trauma 
The association between Alzheimer's disease and head trauma was consistently shown 
across studies. In this analysis we were able to show a significant elevation in risk of 
Alzheimer's disease for head trauma that occurred more than ten years befare disease 
onset. Such events are not likely due to the dementia. However, we cannot exclude the 
possibility of reeall bias that may have operated in a similar way in all studies as 
informants for patients may be more eager to reealleet head trauma than informants for 
control subjects. The interaction with gender was unexpected and ît is difficult to fmd a 
biologie explanation for the absence of an association in wamen. Although we only 
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included head trauma with loss of consciousness, the explanation may be related to the 
head trauma generally being more severe in men. However, the possibility of reeall bias 
and the unexpected effect modification by gender indicate that the association between 
head trauma and Alzheimer's disease should be treated with caution. In chapter 4.3, the 
role of head trauma will be discussed further. 
Medica! history 
It is difficult to interpret the findings on medica] histmy. Methodological pitfalls such 
as selection bias, inforrnation bîas, confounding, multiple testing and data dredging apply 
particularly tothese analyses." A negative indication when interpreting the findings may 
therefore be an association contradicting the a priori hypothesis. Although the association 
with hypothyroidism is of interest because of a possible role of the thyroid horrnone on 
neuritic outgrowth.'" a priori this association was not expected and since hypothyroidism 
can be a cause of secondary dementia, eautien is warranted in the interpretation of this 
finding. From a statistkal point of view skepticism on a relatîonship toa specîfic kind of 
thyroid disease results from the Jack of an association to all thyroid disease combined. 
Also the inverse associations with several chronic disorders ( arthrosis/arthritis, 
migraine/severe headaches) and with blood transfusions were unexpected. One may argue 
that these inverse associations may be artifacts due to bias in the control popu1ation. 
Control subjects, who suffer from chronic diseases may have been more willing to 
participate in epidemiologie studies. An issue to consicter when interpreting the findings 
on viral infections is, that one may argue that rneasurement of exposure has been too 
crude to piek up an association to a specific virus. 
Psychiatrie history 
Perhaps one of the most interesting findings is the association with h:istory of 
depression as: (1) the association was observed in the Roehester study9, which îs based 
on medical records; (2) a significant association was observed for episodes of depression 
more than ten years befare disease onset, suggesting that the association may be a true 
risk factor rather than merely be the result of the dementia. However, in a slowly 
progressive disorder as Alzheirner's disease, the underlying disease process may already 
be in progress although no clinical symptoms can be detected. Therefore, we cannot fully 
exclude the possibility that the depression maybe a prodrome of Alzheimer"s disease and 
it may be concluded that the association between Alzheimer's disease and history of 
depression requires further research. In particular, the role of prior medicatien with 
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anticholinergic effects neects to be addressed. The data on medication in the present 
analysis did nat allow such an analysis. 
Environmentai factors 
The inverse association to smoking was an une>.:pected finding. With the exception of 
two studies, the association was consistently found across studies and there was evidence 
for a dose-response relationship. In the interpretation of these fmdings it :is important to 
note that prevalent cases were included in the studies. Patients that survived langer, i.e. 
non-smekers, may have been overrepresented in the study. The association to smoking 
will be discussed more extensively in the chapters 5.3 and 5.4. The absence of an 
assoc.iation with alcohol intake should be treated with eautien as cases with high intake 
may have been excluded in each study when applying the criteria for possible or probable 
Alzheimer's disease.15•16 This may have led to an underestimation in risk. This re-analysis 
does nat support an association with occupational exposure to lead or solvents. However, 
frequency of exposure was low and exposUre definition may have been toa crude to 
detect an association with Alzheimer's disease. 
Ta date, a great variety of risk factors have been associated with Alzheimer's disease. 
Many of these associations appeared in one ar two studies and were nat replicated by 
others.2 In the present analysis we tried to review the evidence for an association of 
Alzheimer's disease with matemal age at birth, head trauma, medical and psychiatrie 
h.istory and environmental exposures by re-analyzing the data of nine case-control studies. 
Although the study has supported an association of Alzheimer's disease with a number 
of these risk factors, prospective studies are needed to discern whether the observed 
associations are of true etiologie relevance. Case-control studies nested within prospective 
follow-up studies of Alzheimer's dîsease, are probably the most efficient way to overcome 
the problems encountered in retrospective case-control studies. 
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Chapter4.3 
Head trauma and the risk of 
early-onset Alzheimer's disease 
Repeated head trauma in boxers bas been linked to dementia pugilistica (punch drunk 
syndrome).' Although na classica! seni!e plaques were observed in patients with this 
syndrome, 1 neurofibrillary tangles indistinguishable from those seen in Alzheimer's disease 
are found.: These findings have led to the hypothesis that head trauma may be implicated 
in Alzheimer's disease. In four case-control studies a significant increase in risk of 
Alzheimer's disease was observed for those with a history of head trauma."' With the 
exception of two small studies/·8 each of the previous studies reported an excess of head 
trauma :in patients with Alzheimer's disease, although no significant association could be 
established.'" Little is known of the mechanism through which head trauma may be 
implicated in Alzheimer's disease. Graves et al reported that the risk of Alzheimer's 
disease increased when the periact between the head trauma and the onset of disease 
decreased.s As ether studies have been toa small to consicter the timing of the head 
trauma relative to the onset of disease, this inverse trend remains to be confirmed. 
Another issue to resolve is the interaction of head trauma w:ith other risk factors for 
Alzheimer's disease, in particular genetic factors. 
The emphasis of this study of the relationship between head trauma and Alzheimer's 
disease was on the lag-time between the head trauma and disease onset and on the 
interaction with ether risk factors, i.e. family history of dementia, gender and education. 
Metlwds 
Patients were derived from an epidemiologie study of risk factors for clinically 
diagnosed Alzheimer's disease. The study aimed at a complete ascertainment of cases in 
This chapter is based on: Van Duijn CM, Tanja TA, Haax:ma R. Schultc W, Saan RJ, Lamcris .AJ, 
Antonides-Hendriks G, Hofman A Head Trauma and the risk of Al;..hcimer's diseasc. Am J Epidcmiol. 
In press. 
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whom the diagnosis was made befare 70 years and who were living in the four northern 
provinces of The Netherlands and the area of rnetropolitan Rotterdam. Ascertainment 
was carried out through all neurologie, psychiatrie, geriatrie services in the study areas. 
All cases were diagnosed in the period of January 1980 to July 1987. Control subjects 
were randomly drawn from the same municipality as the cases. Cases and controls were 
matebed for age (within 5 years), sex, and residence. An extensive description of the 
design of the study, case diagnosis and response rates bas been given in chapter 2.1. The 
study comprised a total of 198 patients and 198 controls. 
Data collection. We assessed data on head trauma and other putative risk factors for 
Alzheimer's disease by a structured interview. Because of the cognitive decline of the 
patients, the history was taken from the next of kin of the patient. To assure symmetry 
in data collection, we also interviewed a next of kin for the control subject. For 174 cases 
(88%) and 188 controls (95%) the informant was the spouse or an adult child. As 
etiologie factors were studied, questions referred to exposure of the patient befare the 
age of onset of dementia. Age of onset of Alzheimer's disease was estimated as the age 
at which memory Ioss or change in behavier was first noted by the next of kin ar any 
other relative. For control subjects, a ''reference age" was defined based on the age of 
onset of Alzheimer's disease in the matched case and only events occurring befare the 
"reference age" were considered. Head trauma was assessed in closed questions with 
additional open-ended questions a bout: 1) Ioss of consciousness and duration of 
unconsciousness; 2) a ge at the time of the head trauma; 3) circumstances surrounding the 
event; 4) medica! treatment. 
Full pedigree information on dementia was obtained as part of the structured 
interview.15 Ta increase the validity of these data, we verified the information about the 
family history through an additional interview of a first degree relative. If the patient had 
been admitted to hospita!, the diagnosis was checked in independent medica! records. 
Patients were considered to have a positive family history of dementia when there was 
at least one first degree relative with dementia. 
Data analysis. We have restricted the analysis to head inj:1ries with loss of 
consciousness. The duration of the unconsciousness varied from one minute to two hours. 
According to the informant, all patients had regairred normal intellectual cognitive 
function after the head trauma. We assessed the strength ofthe association between head 
trauma and Alzheimer's disease by the odds ratio (OR) as an estimate of the relative 
risk. Conditional logistic regression analysis was used to take the matebed design into 
account.~ The odds ratio was estimated by maximum likelibood and the 95% confidence 
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interval (Cl) wasbasedon the asymptotic standard error. Possible conleunding by family 
history of dementia and education was adjusted for by adding these variables to the 
conditionallogistic regression model. To control for bias which may result from the fact 
tbat cases and controls were nat matebed for informant, we perfonned a separate 
ana1ysis basedon the 111 matebed case-control pairs that were concordant for informant. 
The results of this analysis were very similar to those of the overall ana1ysis and did nat 
change any of the conclusions. Modification of the relationship between head trauma and 
Alzheimer's disease by gender and education was studied by stratified analysis. For family 
history of dementia, interaction was tested as described by Ottman.~1 Those without a 
head trauma and without a family history of dementia were taken as a reference 
category. Risks were then estimated simultaneously for those with a head trauma but 
without a family history of dementia, for those with a positive family history but without 
a head trauma and for those with a head trauma as well as a positive family history. 
Results 
There was a non-significant increase in risk (OR 1.3; 95% Cl 0.7-2.6) for those. with 
a history ofhead trauma with lossof consciousness (table 4.3.1). When we restricted the 
analysis to case-control pairs that were concordant for informant, the risk estimate 
virtually did notchange (OR 1.4; 95% Cl 0.5-4.1). In the overall analysis, the OR for 
head trauma adjusted for family history of dementia and education was 1.6 (95% Cl 0.8-
3.4). When stratifying for gender, an increase in risk was observed only in men (p-value 
for interaction 0.17). There was na evidence for effect-modification by education (p-value 
for interaction 0.56). 
The mean period of time between the occurrence of the head trauma and the onset 
of dementia or the reference age was 16.8 years (50=16.3) for patients and 29.9 years 
(SD=12.9) for controls. Stratification for the time-lag until the onset of A!zheimer's 
disease showed that those wîth a head traumawithinten years befare the occurrence of 
Alzheimer's disease had eight times the chance of having Alzheimer's disease (table 
4.3.2). The odds ratio was 3.0 (95% Cl 0.3-28.8) in wamen. In men, five cases and no 
controls had a head trauma within ten years befare disease onset (p=0.03). There was 
na significant increase in odds ratio for head trauma that occurred more than ten years 
befare the disease onset or the reference age in men (OR 1.2; 95% Cl 0.3-4.7) or in 
wamen (OR 0.4; 95% Cl 0.1-1.7). 
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Table 4.3.1 Head trauma with loss of consciousness in 198 patients with clinica/ly 
diagnosed Alzheimer"s disease and 198 age- and gender-matched controls: The Netherlands, 
1980·1987 
Head trauma 
OR+ OR+ Yes No OK 
All (n=198): 
Cases 22 176 
1.3 1.8 1.6 
Contra Is 17 181 
[0.7-2.6] [0.8-3.8] [0.8-3.4] 
Men (n=74): 
Cases 16 58 
2.0 2.7 2.5 
Controls 9 65 
[0.8-5.0] [1.0-7.4] [0.9-7.0] 
Wamen (n=124): 
Cases 6 118 
0.8 1.0 0.9 
Controls 8 116 
[0.3-2.2] [0.3-3.2] [0.3-2.8] 
• Odds ratio, with 95% confidencc interval within parentheses. + Odds ratio adjusted for dementia in fl.fSt degrce rel:itives 
Odds ratio adjusted for dementia in fl.fSt degrec rdatives and education 
Table4.3.2 Timing of head trauma wilh /oss of consciousness relative toonset of dementia 
in 198 patients wilh clinically diagnosed Alzheimer's disease and 198 age- and gender-
matched controls: The Netherlands, 1980-1987 
Timing of head trauma Number of: 
relative to onset" Cases Controls ORt 
No head trauma 176 181 1.0 
reference 
Head trauma 8 1 8.0 
~ 10 years [1.0-64.0] 
Head trauma 12 15 0.8 
> 10 years [0.3-1.8] 
• Data are missing for 2 ~es and 1 control 
+ Odds ratio, with 95% eonfidence interval within parentheses + Odds ratio adJusted for -dementia in fiTSt dcgree relatives 
? Odds ratio adjusted for dementia in fl.fSt degrce reb.tives and edueation 
OR+ OR' 
1.0 1.0 
reference reference 
8.8 10.0 
[1.0-76.9] [1.0-96:8] 
1.0 0.9 
[0.4-2.6] [0.4-2.2] 
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Table 4.3.3 shows the interaction with family history of dementia. For those with a 
head trauma and a first degree relative with dementia the risk of Alzheimer's disease was 
nine times elevated. On a multiplicative scale, there was no evidence for effect-
modification by family rustory (p=0.90). The odds ratio for head trauma was 1.7 (95% 
CI 0.8-4.0) for those without a first degree relative with dementia and 2.0 (95% Cl 0.4-
10.0) for those with a positive family history. The risk estimates did nat change materially 
when actjusring for education. 
Tahle 4.3.3 Head trauma with loss of consciousness and Alzheimer's disease, effect 
modification by family history of dementia in first degree relatives: The Netherlands, 1980-
1987 
Component Number of: OK OR+ 
Cases Cantreis 
Head trauma - 89 147 1.0 1.0 
Family history - reference reierenee 
Head trauma - 87 34 4.7 4.9 
Family history + [2.7-8.1] [2.8-8.6] 
Head trauma + 13 14 1.7 1.5 
Family rustory - [0.8-4.0] [0.6-3.6] 
Head trauma + 9 3 9.2 9.5 
Family history + [1.8-48.3] [1.8-48.8] 
t Odds ratio, with 95% confidence interval within parentheses 
Odds ratio adjusted for cduca.tion 
Discussion 
In this study the association between Alzheimer's disease and head trauma with loss 
of consciousness was confined to head trauma that occurred within a period of ten years 
befare the onset of dementia. Although overall no relationsrup could be established in 
wo men, there was an excess of head trauma among female patients within this ten year 
periact as compared to control subjects. The association was nat modified by family 
history of dementia, as measured on a multiplicative scale. 
Ten previous studies consistently showed a higher frequency of head trauma in patients 
with Alzheimer's disease than in controls . .)...{"~ 14 Four studies reported the risk of 
Alzheimer's disease to be significantly elevated." Pooling of the data from all forma] 
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case-control studies of head trauma with loss of consciousness showed a significant 
association (OR 1.8, 95% Cl1.3-2.7).'-'·'·'"·""·""' lt is important to note that in the only 
prospective follow-up study based on data obtained from medica! records of the 
Roehester registeru a slight elevation in risk of 1.3 (p~0.70) was reported, similar to the 
risk unadjusted for family history of dementia observed in our study. Family history of 
dementia, however, was nat assessed as a putative confaunder in the Roehester study and 
the data did nat allow stratification by timing of the head trauma relative to the onset of 
disease. In the re-analysis of case-control studies the association between Alzheimer's 
disease and head trauma could only be establisheà in men." Althougb the association was 
strengest for head trauma that occurred within ten years befare disease onset, a 
significant elevation in risk (OR 1.6; 95% Cl 1.0-2.6) was also observed for head trauma 
that occurred more than ten years befare the onset of disease.r.. Such an inverse trend 
has been shown earlier by Graves et al/ who reported an assocîation between 
Alzheimer's disease and head trauma (with or without loss of consciousness) that 
occurred one to nine years (OR 9.7; 95% Cl1.1-83.3) and ten to 29 years (OR 5.0; 95% 
Cl 1.3-9.8) before the onset of disease. ln contrast, our study of head trauma with loss 
of consciousness suggests that the risk of Alzheimer's disease was increased oniy withîn 
the ten year period befare the disease onset. The finding of this association in men and 
wamen argues against effect-modification by gender. As to the interaction with family 
history of dementia, it has been suggested that head trauma may play a role only în those 
whoare genetically susceptible,z:. while atbers have reported that such environmental risk 
factors may be associated wiL-, sparadie Alzheimer's disease rather than with the familial 
farm of the disease.:z.24 Using family history of dementia as an indicator for genetic 
susceptibility/1 a sim:ilar odds ratio for Alzheimer's disease was obsetved in those with 
and without an increased genetic risk. This suggests that head trauma may influence the 
risk of Alzheimer's disease in those who are nat genetically susceptib]e and that there is 
na evidence for synergy ar antagonism in a multiplicative model. One may argue, 
however, that the power to show interaction in our study has been Iow. 
The type of study reporteà bere may suffer from bias. A first problem to be discussed 
is reeall bias. Sirree relatives of patients may be eager to find an explanation for the 
disease of the pa ti ent, they may overreport the exposure to factors such as head trauma 
which are thought to be associated with the disease. We have therefore restricted the 
analyses to severe head trauma with loss of consciousness. These events are less 
vulnerable to reeall bias since it is unlikeiy that relatives of patients report serieus events 
which did not occur and that relatives of controls have forgotten such a severe head 
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trauma. A second methodologie problem to be discussed concerns the diagnosis of 
Alzheimer's disease, which was in most cases based on clinical data. Although we finnly 
applied the criteria for the clinical diagnosis of Alzheimer's disease and the diagnosis was 
confirmed in all ten cases who had an autopsy,15 misclassification may have occurred in 
disease status in some cases. This type of misclassi:fication tends to diminish a true 
association. Misclassification may also bias the comparison of sparadie and familial 
Alzheimer's disease. In the absence of a genetic marker for popuiatien studies,25 we have 
classified tbe patients on tbe basis of their family history of dementia assuming that tbose 
with a positive history are most likely of primarily genetic origin and those with na frrst 
degree relatives with dementia are most likely of primarily environmental origin. Indeed, 
relatives of patients without a family history may carry the gene and express the disease 
later in life, whereas fam.:ilial aggregation of Alzheimer's disease may be due to clustering 
of non-genetic disease. This has perhaps led to non-differential misclassification," which 
may have reduced the power to show effect-modification. As to the possibility of selection 
bias, case selection aimed to be population-based in the two study areas. Although 
selection may have occurred in the control series because of the higher non-response as 
compared to tbe cases, it is unlikely that this was associated witb a history of head 
trauma. Finally, confaunding bias may have occurred because of the fact that putative 
risk factors may nat have been measured ar may have been measured with so much error 
that effective control for confaunding was impossible. 
Two interpretations of a relationship between recent head trauma and Alzheimer's 
disease are possible: 1) the head trauma may be a consequence of an early stage of the 
dementia; and 2) head trauma may be implicated in the pathogenesis of .PJzheimer's 
disease. As to the first explanation, there is evidence for an increase in risk of head 
trauma and falls for Alzheimer patients as compared to non-demented subjects.:.s-zs It is 
difficult in a case-control study to distinguish events preceding or following the disease 
onset, in particular when studying a disorder like Alzheimer's disease in which the onset 
age is nat easily assessed. However, we questioned relatives extensively about symptoms 
of the disease prior to the occurrence of the head trauma and excluded those patients 
with changes in behavior or memory loss befare the head trauma occurred. 
The second explanation, that head trauma may lead to .PJzheimer's disease, is 
supported by the finding of the Alzheimer type neurofibrillary degeneration in patients 
with dementia pugilistica.~ This type of pathology has been associated with repeated 
head trauma in boxers.1~'\(l Although initially no classica} senile plaques were observed/ 
recent studies of patients with dementia pugilistica have shown diffuse plaques.31<13 
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Because of the similarity in patho1ogy, a camman pathogenesis of Alzheimer's disease 
and dementia pugilistica bas been suggested."' The mechanism through which head 
trauma may be implicated in dementia is still unclear. Head trauma may induce changes 
in the blood brain barrier, which may lead to Alzheimer's disease.u On the other hand, 
it is conceivable that head trauma may cause rupture of brain vessels, which are already 
weakened by amyloid deposits.' Tbus, the trauma may trigger a subclinical pathological 
process and provake early-enset of dementia. This hypothesis is supported by the finding 
of an earlier onset of disease in patients with a history of head trauma3-1·3s and by the short 
lag-time between the head trauma and disease onset observed in the present study. 
Although the findings of our study are compatible with a rele of head trauma in early-
enset Alzheimer's disease, we interpretour findings with caution. Despite the apparently 
consistent findings of case-control studies,:z we cannot exclude the possibility that all 
studies may have been biased in a similar way. The validity of case-control studies of 
Alzheimer's disease conducted to date is limited by the possibility of confaunding by 
reeall bias and selection bias. To determine the etiologie significanee of the relarion 
between head trauma and Alzheimer's disease, the association remains to be confirmed 
in a prospecrive follow-up study. 
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Serum levels of interleukin-6 in patients 
with early-onset Alzheimer's disease 
In patients with Alzheimer's disease, extracellular amyloid fibrils accuroulate in the 
cores of the senile plaques and in cerebral and meningeal microvessels.1 Two lines of 
evidence suggest that the formation of amyloid deposits in Alzheimer's disease may be 
accompanied by an acute-phase response, the reaction of the body to tissue damage 
and inflammatory processes. First, the amyloid in the senile plaques has been 
demonstraled to be tightly associated with the acute-phase protein cd-
antichymotrypsin.::j Second, increased serum levels of the acute-phase proteins have 
been reported in patients with Alzheimer's disease.4.s 
Recently, it bas been demonstrated that the production of acute-phase proteins is 
at least in part mediated by two lymphokines, interleukin-l (IL-l) and interleukin-6 
(IL-6)."' These lymphokines are produced by a variety of cells and have several 
functions inside and outside the immune systern.10 The increased serum levels of IL-6 
that have been demonstraled in patients rejecting their kidney transplantant/1 patients 
with serieus skin injury,6 and in patients with rheumatoid arthritis13'14 indicate that 
inflammatory processes can be sensitively monitored by an IL-6 bio-assay. Therefore, 
we have used this assay to study serum levels of IL-6, as a serologie marker of disease 
and severity of dementia in 97 patients with clinically diagnosed A.lzheimer's disease, 
and in 79 population control subjects. 
Methods 
Patients were derived from an epidemiologie study of risk factors for clinically 
diagnosed A.lzheimer's disease. For this study all early-onset patiems (diagnosis ..::;_ 70 
years) living in Rotterdam or the four northern provinces of the Netherlands in whom 
This chaptcr îs bascd on: Van Duijn CM. Hofman A Nagelkerken L. Scrum levels of imcrlcukin-6 are 
nat clcvarcd in parienrs wi!h AJzheimer's diseasc. Ncuroscience Letters 1990;108:350-354. 
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the diagnoses was made in the period of January 1980 to July 1987 were ascertained. 
Ascertainment was carried out through all neurologie, psychiatrie, geriatrie services in 
the study areas. Control subjects were randomly drawn from the same municipality as 
the cases. Cases and controls were matebed for age (within 5 years), sex, and 
residence. An ex1:ensive description of the design of the study, case diagnosis and 
response rates has been given in chapter 2.1. The study comprised a total of 198 
patients and 198 controls, of whom 127 patîents and 127 controls were derived from 
the four Nartbern provinces. The latter patients participateà in this study of IL-6. 
Serum samples were available for 97 patients (76%) and 79 controls (62% ). 
Serum levels of IL-6 were determined in stared serum samples (-80 °C) with the 
use of a bio-assay.~ IL-6 dependent B9 hybridoma cells as well as human recombinant 
IL-6 were kindly provided by Dr. L. Aarden, Central Labaratory of the Blood 
Transfusion Service, Amsterdam. The cells were cultured in Iscoves' rnodified 
Dulbecco's medium (Seromed, Berlin, FRG), supplemented with penicillin (100 
U/ml), streptomycin (100 ,ug/ml), 2 Mm L-glutamin, 5x10·' M 2-mercapto-ethanol and 
5 % (v/v) foetal calf serum (Seralab, Crawley Down, UK). Sera from patients wjth 
Alzheimer's disease and from control subjects were ser:ia1ly diluted in duplicate in the 
same medium in flat-bottorn microtiter plates (Greiner, Nürtingen, FRG). Five 
thousand B9 cells were added to each wel! and the final volume was adjusted to 200 
,ul. After 66 hours of culture, the cells were pulsed with 0.25 ,uCi 'H-methyl-thymidine 
(specific activity 2 Ci/mMol; Radiochemical Center, Amersham, UK). Six hours later, 
the cultures were terminaled by harvesting the DNA on nitrocellulose filters (Skatron, 
Tranby, Norway). Filters were counted in toluene, containing 4 gil PPO and 0.05 gil 
POPOP. One unit IL-6/ml was defined as the concentration at which half-maximal 
proliferatîon was found; recombinant IL-6 served as a standard. 
As appears from figure 4.4.1, the B9 assay is highly sensitive to IL-6. The B9 cells 
proliferated in a dose-dependent manner in response to riL-6. The assay detected 
levels of RIL-6 as low as 0.1 U/ml. Maximal proliferation of the cells occurred in the 
presence of approximately 5 U/ml. Parallel dose response curves were obtained when 
positive sera were diluted. These three individual sera numbered 1052, 2063 and 2082 
were found to contain 25, 96 and 650 U !L-6/ml, respectively. 
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Figure 4.4.1 Measurement of IL-6 in serum Several amounts of human recombinant 
IL-6 (o), serum from one parient with Alzheimer's disease (o), and serum from two 
controls (o and .. ; were compared with regard to their ability to induce proliferation by 
B9 ce/Is 
Results and Discussion 
Median concentrations of serum IL-6 did nat differ significantly (p=0.40) between 
Alzheimer patients (8.6 U/ml, range:4.6-34.0) and controls (8.4 U/ml, range:5.S..650.0). 
Five patients with Alzheimer's disease as well as :five controls had a history of 
rheumatoid disease. In two subjects with rheumatoid arthritis increased IL-6 levels 
(94.0 U/ml and 650 U/ml) may have been due to tbe fact that these patients suffered 
from rheumatoid arthritis. Upon exclusion of all patients with rheumatoid arthritis 
median levels of serum IL-6 were 8.6 U/ml (range:4.6-34.0) for patients with 
Alzheimer's disease and 8.2 U/ml (range:5.8-30.0) for the controls (figure 4.4.2). In 
5% ( 4/74) of the controls the concentra ti on of serum IL-6 was above 13.0 U/ml; 
serum levels over 13.0 U/m1 were found in twice as many Alzheimer patients 
(11 %=10/93; p=0.17). Serum levels of IL-6 were similar for the 43 sparadie patients 
(those withno family Iristory of dementia) and the 50 familial patients (those with one 
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Figure 4.4.2 IL-6 in serum of patients with Alzheimer's disease and age- and sex-
matched controls 
or more first degree relatives with dementia). Median levels of serum IL-6 were 8.6 
U/rnl (range:4.6-34.0) for speradie patients and 8.2 U/ml (range:4.8-28.0) for familial 
patients (p=0.42). High concentrations of IL-6 were nat associated with the severity 
of the dementia as measured by the Clinical Dementia Rating-scale ar with the 
duration of the disease since the first symptoms. 
Earlier studies have reported increased serum levels of acute-phase proteins in 
patients with Alzheimer's disease.45 In the present study of weH-defined patients with 
clinically diagnosed Alzheimer's disease we do nat obtain evidence for elevated serum 
levels of IL-6, one of the mediators of the acute-phase response, as compared to age-
and sex-matched population controls. In sorne patients and controls elevated levels of 
IL-6 were found in serum. Since na obvious symptoms accounted for these findings, it 
is likely that subclinical intlammatory processes were responsible. Our findings do nat 
exclude of course tbe possibility that the concentratien of IL-6 is locally elevated 
within the central nervous system. Recently an increased number of IL-1 positive cells 
have been reported in patients with AJzheimer's disease and Down's Syndrome.JS 
Support for a local synthesis of IL-6 is provided by observations in mice." lt has been 
suggested that IL-6 may be involved in repair mechanisms by increasing the secretion 
of nerve growth factor by astrocytes.1b Therefore it is conceivable that IL-6 production, 
like IL-1, may be altered in Alzheirner's disease and further studies of levels of IL-6 
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within autopsy material will certainly be of interest. 
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Gene-environment interaction 

Chapter 5.1 
Introduetion 
Alzheimer's disease is a disorder with a complex genetic etiology.1 There is some 
evidence that genetic and environmental mechanisms may be implicated in Alzheimer's 
disease.24 Little is known of how these genetic and environmental factors may interact. 
Risk factors may merely modify the expression of a disorder of primarily genetic origin. 
It is aiso conceivable that non-genetic risk factors may increase the risk of Alzheimer's 
disease independently. 
This chapter deals with gene-environment interaction. Chapter 5.2 addresses the 
question which factors determine the onset-age in familial early-enset Alzheirner's 
disease. For this study, data of families in which the disease was apparently inherited as 
an autosomal dominant disorder were used. In chapter 5.3 a study of the relationship 
between smoking and family history of Alzheirner's disease and Parkinson's disease is 
presented. This chapter is based on the case-control study of early-onset Alzheirner's 
disease (see chapter 2.1) and on a study of risk factors in families in which the disease 
was apparently inherited as an autosornal dominant disorder. In chapter 5.4, interaction 
between genetic and environrnental risk factors is studied using data from the 
collaborative re-analysis of all case-control studies (see chapter 2.2). 
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Onset age in familial early-onset 
Alzheimer's disease 
There are over 100 reported families in whlch Alzheimer's disease segregates as an 
autosomal dominant disorder.1-4 Three studies have shown genetic linkage between 
early-onset Alzheimer's disease and polymorphic DNA markers on the proximal long 
ann of chromosome 21.5-7 Although age of onset of Alzheimer's disease may differ 
considerably between families, similar ages of onset of dementia have been reported 
previously within several large families in which Alzheimer's disease is apparently 
inherited as an autosomal dominant disorder. 1's.9 The crigin of the family resemblance 
in onset age of dementia is nat yet clear. The age of onset within a family may be 
determined by one ar more genetic loci. But on the other hand, given a camman 
genetic predisposition environmental factors shared by relatives may be involved in 
the onset of Alzheimer's disease. In addition, selection bias may account for the family 
specific onset age sirree relatives with similar ages of onset are more likely to be 
detected for genetic studies. 
To investigate which factors determine the age of onset of familial Alzheirner's 
disease, we have exarnined 30 families mu1tiply affected by Alzheimer's disease. These 
families were selected for molecular linkage studies or were ascertained for an 
epidemiologie study with complete ascertainment of patients with early-onset 
Alzheimer's disease. Thus the analysis was performed in two groups of pedigrees of: 
(1) families with known linkage to chromosome 21, and (2) a population-based 
unbiased sample of families for which no linkage data were available. Although early-
and late-onset Alzheimer's disease are considered as one neuropathological entity, we 
have excluded late-onset patients because inaccuracies in diagnosis of Alzheîmer's 
disease in this group may seriously bias the analysis. Moreover, there is some evidence 
that genetics may differ between early- and Jate-onset Alzheimer's disease.::.'o 
This chapter is bascd on: Van Duijn CM, Van Broeckhoven C, Hardy JA, Goatc AM, Rossor MN, 
Vandenberghe A, Martin J-J, Hofman A, Mullan MJ. Evidcnce for allelic heterogencity in familial 
early-onset Alzhcimcr's discase. Br J Psychiat 1991;158:471-474. 
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Methods 
Patients. We have studied age of onset of Alzheimer's disease within and betvveen 
30 families derived from Belgium,' Great Britain' and The Netherlands" (table 5.2.1). 
The families from these three studies contained totals of 62, 72 and 80 affected 
individuals respectively. All families had a pedigree structure consistent with 
autosomal dominant inheritance of Alzheimer's disease. The criteria for including a 
family in the study were: (1) at least three individuals with clinically diagnosed 
Alzheimer's disease in two ar more generations; 1~ (2) detailed medical records 
available on the clinical diagnosis of Alzheimer's disease of at least two affected 
relatives; (3) mean age of onset below 60 years :in the Belgian and British families and 
( 4) age of onset of the proband befare the age of 60 years in the Dutch study. The 
cutoff point of 60 years to select families with early-enset Alzheimer's disease was 
based on the findings of a study of risk for familial Alzheimer disease using age of 
onset data of 70 families.~ In the Belgian and British studies, families were ascertained 
for genetic Iinkage analysis. Therefore the mean age of onset of all affected relatives 
was used to select early-onset families. Different inclusion criteria were used for the 
Dutch epidemiologie study because individual patients, nat families, had been 
ascertained. Moreover, using the age of onset of probands to select families from this 
population-based study did nat put any restrictions on the onset age of the relatives. 
The Dutch study comprised aU patients diagnosed with early-onset Alzheimer's 
disease during the periact 1980-1987 in two areas of the Netherlands;" in the families 
of 17 patients there were at least three affected individuals known in two generations. 
All molecular genetic analyses conducted with the Belgian and British pedigrees were 
consistent with linkage to chromosorne 21.''·7 Although in one British family, a cross-
over between the dise2.se locus and one of the markers (D21S1/S11) was inferred, 
there was na significant evidence for heterogeneity. Data of onset age of Alzheimer's 
disease were determined through a personal interview of the next of kin of each 
patient, sa that in each family there were multiple informants. Age of onsd: was 
estimated as the age at which memory loss or change in behavior was first noted. 
Information of onsetage of dementia was available for 139 (67%) of the 214 affected 
individuals. 
Data analysis. Analysis of varianee was used to campare the age of onset among 
and within families. D To see whether the onset a ge changed over genera ti ons, the 
difference in age of onset was calculated for all possible combinations of sibships in a 
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Tahle5.2.1 Clinical characteristics of families multiply affected with Alzheimer's disease. 
Family Country Onsetage (years) Number of: 
number ~ean range Pathological Cases 
confmnations 
ADA" Belgium 35 26-45 38 11 
ADB" Belgium 35 30-39 24 6 
14 Great Britain 60 55-65 3 
15" Great Britain 52 45-70 3 
23" Great Britain 55 51-62 14 
32" Great Britain 54 47-59 6 
34 Great Britain 44 37-52 3 1 
53 Great Britain 52 43-60 5 
74" Great Britain 43 39-50 6 2 
75 Great Britain 51 44-58 10 
105 Great Britain 38 36-39 7 
121 Great Britain 37 35-39 4 
126 Great Britain 54 48-63 4 
127 Great Britain 46 41-48 7 
1005 Netherlands 60 50-78 9 
1025 Netherlands 56 52-60 3 
1034 Netherlands 63 59-70 4 
1049 Netherlands 55 50-61 4 1 
1066 Netherlands 41 38-49 9 2 
1068 Netherlands 55 50-67 4 
1070 Netherlands 59 52-67 4 
1072 Netherlands 60 55-75 6 1 
1085 Netherlands 57 50-63 4 
1097 Netherlands 56 48-60 3 
1100 Netherlands 39 35-42 7 
1104 Netherlands 53 47-58 6 
1125 Netherlands 53 49-58 5 
1230 Netherlands 55 49-60 6 
1264 Netherlands 61 56-66 4 
1270 Netherlands 58 47-65 4 
Families with cvidcncc of linkagc to chromosome 2.1"· 7 
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family. In the case of first degree relatives (genetic distance of 1/2), the difference in 
mean onset age of a sibship and the onset age of the affected parent is given. The 
camparisen of secoud degree relatives (genetic distance of 1/4) comprised the 
differenee between the mean onset age of a sibship and the mean onset age of all 
secend degree relatives of this sibship (i.e., uncles, aunts and grandparents). In the 
same way, the differences were calculated between third (genetic distance of 1/8), 
fourth (genetic distance of 1/16), fifth (genetic distance of 1/32), sixth (genetic distance 
of 1/64), seventh (genetic distance of 1/128) and eighth (genetic distance of 1/256) 
degree relatives. 
Results 
The age of onset of Alzheimer's disease was more similar within than between 
families. 77% of varianee in age of onset of dementia was due to differenees between 
families (table 5.2.2). Restrietion of the analysis to the pedigrees which we have 
previously reported linkage data on gave essentially similar results: 81% of varianee 
was aecounted for by between family differenees. In the Duteh data, based on 
complete aseertainment of patients, 67% of the varianee was due to differenees 
between families (table 5.2.2). Unaffected siblings of these patients, however, are still 
at risk of Alzheimer's disease. Sinee ages of siblings tend to be similar, bias may oecur 
Tahle 5.2.2 Analysis of varianee between and within families multiply affected with 
early-onset Alzheimer's disease 
Families Souree of Degrees Mean sum p-value lntra-class 
varia ti on freedom of squares correla ti on 
All Between 29 407.20 0.0005 0.77 
families Within 109 24.46 
Families with 
evidenee of Between 5 663.04 0.0005 0.81 
Iinkage to Within 39 22.20 
ehromosome 21 
Population-based Between 15 184.91 0.0005 0.67 
families Within 42 25.11 
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towards a limited varlation in age of onset of dementia. Upon exclusion of siblings of 
the probands, the intra-class correlation did nat change materially (intra-class 
correlation 0.63; p<0.005). 
Table 5.2.3 shows that the onset age has remained constant over generations and is 
independent of the genetic distance. The differences in onset age between sibships are 
given stratified for degree of relationship. The two extensive Belgian pedigrees with 
affected persons in 6 generations show that the age of onset remairred constant in 
seventh and eighth degree relatives who may have no more than 1/128 and 1/256 of 
their genes in common. Essentially similar results were obtained if the mean age of 
death of affected individuals was used. Although data on environmental toxins were 
Tahle 5.2.3 Difference (±SD) in age of onset between sibships by degree of relationship' 
Relationship 
(genetic 
distance) 
First 
(1/2) 
Second 
(1/4) 
Third 
(1/8) 
Fourth 
(1/16) 
Fifth 
(1/32) 
Sixth 
(1/64) 
Seventh 
(1/128) 
Eighth 
(1/256) 
Belgian 
Families 
6.0+4.4 
n=3 
4.0+3.2 
n=7 
5.5±2.8 
n=lO 
4.2±2.7 
n=8 
3.3±2.3 
n=8 
4.7+3.8 
n=12 
4.7+3.2 
n=10 
3.3+2.7 
n=8 
Dutch 
Families 
4.8+3.3 
n=19 
7.6+3.0 
n=10 
5.0 ... 
n=1 
British 
Families 
5.9+5.8 
n=14 
3.8+3.6 
n=18 
3.0±2.3 
n=14 
1.7±2.9 
n=3 
All 
Families 
5.3+4.5 
n=36 
4.9+3.7 
n=35 
4.1+2.7 
n=25 
3.5+2.9 
n=Jl 
3.3+2.3 
n;:-8 
4.7+3.8 
n=12 
4.7+3.2 
n,;;-10 
3.3+2.7 
n=8 
Families 
linked to 
cbramosome 
21 
5.4+3.2 
n=7 
4.3±3.5 
n=12 
5.1+2.7 
n=12 
4.2+2.7 
n=8 
3.3+2.3 
n=8 
4.7+3.8 
n=12 
4.7+3.2 
n=10 
3.3+2.7 
n=8 
The diffcrcnce in agc of onset between sibships of two different generations WüS calculated for all pos~ible 
combinations of sib~hips within a family. Thc avcrage of thc diffcrcnces (absolute values) are given by genetic 
distance. In thc case of a genetic distancc of 1/2, thc diffcrcncc in mc:m onsct agc of a sibship and thc onsct age of 
thc affected parent is given. The genetic distance of 1/4 cernprises the differencc between thc mcan onset age of a 
sibship and thc mcan onsct agc of all secend degrec relatives (i.e., uncles, aunts and grandparcnts). Esscntially 
~imilar results were obuined ifthc mcan agc of dcath of affected individuals was used. 
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nat available, we compared onset ages of relatives raised apart to see whether there 
was evidence for a modifying role of environmental factors. The average difference in 
onset age between sibships of a family bom more than 50 km apart (3.7 years; 
SD=3.0; n= 13) was sirnilar to the difference found for sibships barn less than 50 km 
apart ( 4.4 years; SD=3.0; n=54). 
Discussion 
These data show that age of onset of Alzheimer's disease is more similar wîthin 
families multiply affected with Alzheimer's disease than between families. The analysis 
of the population-based data indicates that this finding is nat due to ascertainment 
bias. Indeed, determination of onset ages may still be subject to error and collecting 
data of age of onset through interviews of relatives may have led to artifactual 
clustering of onset ages within families. However, in our study onset age was always 
obtained through taking of a family history of the next of kin of each patient, i.e., 
there were multiple informants within a family. Since in the large pedigrees, onset 
ages were abtairred from informants who did nat know of the relationship to other 
patients in the pedigree, this information can be considered as independent. The 
finding that the age of onset remairred constant even in eighth degree relatives 
strongly supports the existence of a family specific onset age within decades. 
Moreover, an analysis of age of death, dates which were always checked in 
independent medica! records, demonstrated the same effect. 
Our findings do nat support a predominant role of non-genetic factors. Similarity in 
ex-posure to environmental factors and lifestyle are likely to decrease if merobers of a 
family are more distantly related. Onset age, however, did nat differ significantiy wîth 
distance in relationship or birth place in our analysis. In accordance with our findings, 
a constant age of onset has been reported within a large Italian pedigree although 
relatives have !ived as far apart as France, Italy and the USA. 14 These findings suggest 
that genetic rather than environmental factors determine the family specific onset age 
within decades. However, within families in which the disease appears to be inherited 
as well as within sets of twins, !$ differences in onset a ge may vary from 3 to 30 years. 
Therefore, it is conceivable that non-genetic factors may be implicated in that they 
may alter the genetically determined onset age or that there may be phenocopies in 
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such families, i.e., patients who do nat have the genotype, but in whom the disease 
may be primarily of non-genetic origin. 
The data of families with linkage to chromosome 21 support the view that the 
characteristic age of onset of a family may have a genetic origin. There are two 
possible explanations for this: (1) other genes, which are coinherited with the locus on 
chromosome 21, may modify the onset age; (2) different loci on chromosome 21 ar 
different alleles at the same genetic locus ( allelic-heterogeneity) predispose to 
different ages of onset. The first e:: .. :p1anation would predict that within a family 
recombination between the Alzheimer's disease locus and the putative onset 
determining locus may occur. Thus would the varlation in age of onset increase when 
family merobers are more distantly related. Since age of onset appears to be constant 
within a family through different generations this explanation is less like1y. The family 
specific onset age of Alzheimer's disease observed in the analysis of families with 
evidence of linkage to the predisposing locus on cbramosome 21 suggests that there 
may be different mutations on cbramosome 21, either at various loci or at the same 
locus (allelic heterogeneity), which determine the onset age, 
These findings may have implications for scientific research as well as clinical 
practice. lt may be possible to detect those individuals who fall outside of the 
expected age of onset for a particular pedigree. Studies of these patients may reveal 
non~genetic risk factors for Alzheimer's disease because it is conceivable that such 
factors have modified the genetically determined onset age in these cases ar that 
these patients may represent non~genetic farms of Alzheimer's disease. In linkage 
studies, it may be of great value to detect the latter group of patients, as they will 
reduce the statistica] power of the study. As to genetic counselling, these findings 
imply that family specific age of onset curves should be used when assessing the risk 
to an individual to have inherited the disease. 
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Relation between nicotine intake, 
Alzheimer's disease and 
Parkinson's disease 
Alzheimer's dîsease and Parkinson's disease have been suggested to have a camman 
etiology.1·3 These neurodegenerative disorders share several patho!ogical and 
neurochemical characteristics. Lewy ba dies, one of the hallmarles of Parkinson's dîsease, 
are aften observed in Alzheimer's diseaseY The Alzheimer type pathology is found more 
aften in patients with actvaneed idiopathic Parkinson's disease than in the general 
population. In the most studies of Parkinson's disease, patients have been observed to 
smoke less than control subjects.4'5 There is some evidence that nicotine may imprave 
information processing and attention in Alzheimer patients,<'7 which suggests that nicotine 
may have a protective role in AJzhe:imer's disease. Totest this idea, we studieà smoking 
habits befare the onset of dementia in Alzheimer patients and population controls, as 
part of a genetie-epidemiologie study of Alzheimer's disease carried out in the 
Netherlands. 
Methods 
Risk factors for Alzheimer's disease were studied in 198 early-onset Alzheimer 
patients, 198 age- and gender-matched population controls, and in 17 families with a 
pedigree structure consistentwith autosomal dominant inheritance of AJzheimer's disease. 
The smoking history and the family history of dementia and of Parkinson's disease were 
assessed by a structured interview of the next of kin of the patient or control subject. 
Patients were derived from an epidemiologie study of risk factors for clinically diagnosed 
Alzheimer's disease.s.'} The study aimed at a complete ascertainment of cases in whom the 
This chapter is based on: Van Duijn CM and Hofman A Relation between nicotine intake and 
A.lzheimer's disea.se? Brit Mcd J 1991:302:1491-4. 
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diagnosis was made befare 70 years and who were living in the four narthem provinces 
of The Netherlands and the area of metropolitan Rotterdam. Ascertainment was carried 
out through all neurologie, psychiatrie, geriatrie services in the study areas. All cases were 
diagnosed in the period of January 1980 to July 1987. Control subjects were randomly 
drawn from the same municipality as the cases. Cases and contro1s were matebedfora ge 
(within 5 years ), gender, and residence. An extensive description of the design of the 
study, case diagnosis and response rates bas been given in chapter 2.1. The study 
comprised a total of 198 patients and 198 controls. 
Based on the information about the family history of dementia, patients with 
Alzheimer's disease were classified as sparadie (those with no first degree relatives with 
dementia) or familial (those with one or more first degree relatives with dementia). 96 
out of the 198 patients with Alzheimer's disease ( 48%) had one or more first degree 
relatives with dementia. The pedigree structure of 17 patients (9%) was consistent with 
autosomal dominant inheritance of Alzheimer's disease. The criteria for autosomal 
dominant inheritance were: (1) at least three patients with reported dementia in two 
generations; (2) at least two patients with detailed records with the clinical diagnosis of 
Alzheimer's disease." Within the 17 families in which the disease was apparently inherited 
as an autosoma1 dominant disorder, all relatives were screened for dementia.10'11 Data on 
smoking habits and risk factors for Alzheimer's disease were collected in affected and in 
unaffected relatives. 
Data collection. Information on putative risk factors for Alzheimer's disease was 
obtained by a structured interview of the next of kin of the patient. To assure symmetry 
in data collection, information on the control subject was also obtained from the next of 
kin. Since etiologie factors were studied, questions addressed exposures of the patient 
befare the onset of dementia. Age of onset was defined as the age at which memory 
failure or changes in behavier were first noted. For cantreis a ''reference age" was 
defined on the basis of the age of onset of Alzheimer's disease in the matebed case. 
Patients were classified as non-smokers if they had never smoked befare the disease 
onset and as smokers if they had ever smoked. Controls were classified similarly based 
on their smoking habits befare the reference age. Forsmokers the number of cigarettes 
smoked daily was asked for each periact they had smoked. As a measure of the life-time 
cigarette exposure, the number of pack-years was calculated by multiplying the number 
of cigarettes smoked a day (in packs) and the duration of cigarette use (in years). Data 
on the smoking histmy were nat available of five patients and three control subjects. 
The disease history of patients and contro1s was evaluated in close-ended questions 
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with additional open-ended guestions about medical treatment and hospitalization. Pull 
pedigree information on dementia and Parkinson's disease was obtained. All first degree 
relatives were listed and we asked specifically about the occurrence of dementia and 
Parkinson's disease in them. To increase the validity of these data, the information of 
family history was verified by a second first degree relative. lf the patient had been 
hospitalized, the diagnosis was checked in independent medica! records.8 
Data analysis. The strength of association between Alzheimer's disease, smoking and 
other putative risk factors was assessed by the odds ratio (OR) as an estimate of the 
relative risk."' Odds ratios are presenled with 95% confidence intervals (95% Cl). 
Smoking was significantly correlated with alcohol intake (r=0.34; p=0.04) in controls. 
Conditionallogistic regression analysis was used to take the alcohol consumption and the 
level of education as well as the matching variables gender and age into account. 
Modification of the relationship between smoking and Alzheimer"s disease by the 
established risk factors a ge, gender and family history of dementia was tested. Since there 
was a significant interaction between smoking history and family history of dementia of 
the patient (p=0.02), all analyses were stratified for family history of dementia. Trends 
in risk of Alzheirner's disease by categoties of smoking were tested by the Mantel test for 
trend.D 
In the diagnosis of Alzheirner's disease, the Hachinski score was used to exclude 
patients with multi-infarct or vascular dementia. 12 This scale effectively excludes patients 
with evidence of atherosclerotic cardiovascular disease. Because smoking is associated 
with cardiovascular disease, this may have resulted in lower smoking rates in the non-
vascular dementia patients, i.e. Alzheimer patients. To control for this possible bias, we 
performed a separate analysis in which all patients and all controls with a history of 
atherosclerotic cardiovascular disease, including coronary heart disease, stroke and 
hypertension, were excluded. 
Results 
Table 5.3.1 shows the family history of dementia and Parlcinson's disease of the 
Alzheimer patients and their controls. Ofthe patients with Alzheimer's disease, 48% had 
at least one first degree relative with dementia, as compared to 19% ofthe controls (OR 
4.32; 95% Cl2.71-6.82). Significantly more Alzheimer patients than controls had a first-
degree relative with Parkinson's disease (OR 2.90; 95% Cl 1.11-8.49). 
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Tahle 5.3.1 Family history· of dementia and Parldnson's disease of 198 Alzheimer patients 
and 198 agew and gender-matched controls-~ 
Dementia: 
family history + 
family history -
Parkinson's disease: 
family history + 
family history -
Cases 
n=198 
96 
102 
14 
184 
Controls 
n=198 
37 
161 
5 
193 
Odds ratio [95% Cl] 
Crude Adjusted± 
4.12 
[2.61-6.43] 
2.90 
[1.11-8.29] 
4.32 
[2. 71-6.82] 
2.90 
[1.11-8.49] 
• In frrst degree relatives f Adjusted iOr age, gcnder, area. of residcncc, number of frrst degrcc rclatives and education by conditionul rcgression 
analysis 
The proportion of smokers was lower in patients 'Nith Alzheimer's disease than in 
control subjects (table 5.3.2). A significant inverse association was found in patients with 
familial Alzheimer's disease (those with one or more first degree relatives with dementia), 
whereas there was no evidence for an association of smoking with sparadie Alzheimer's 
disease. The inverse association between farnilial AJzheimer's disease and smoking 
remained after restricting the analysis to patients and controls without a history of 
atherosclerotic cardiovascular disease (table 5.3.3: OR 0.16; 95% Cl 0.06-0.45). 
A negative trend for smoking was observed when camparing Alzheimer patients and 
controls: the risk of .Alzheirner's disease decreased as the number of cigarettes smoked 
daily increased (table 5.3.4). After exclusion of patients and controls with a history of 
atherosclerotic cardiovascular disease, the odds ratio for smoking 1-10, 11-20 and more 
than 20 cigarettes daily was 0.81 (95% Cl 0.44-1.49), 0.67 (95% Cl 0.34-1.32) and 0.26 
(95% Cl 0.11·0.61). respectively. A similar trend was observed when camparing patients 
and controls for the number of pack-years they had smoked. The odds ratio was 0.38 
(95% Cl 0.13-1.10) for those whohad smoked 1-10 pack-years, 0.29 (95% Cl 0.08-0.98) 
for 11-30 pack-years and 0.22 (95% Cl 0.06-0.77) for more than 30 pack-years. 
In the 17 families 'Nith a pedigree structure consistent with autosomal dominant 
inheritance of Alzheimer's disease, 33% of the 56 affected siblings had ever smoked, as 
compared to 67% of the 109 unaffected siblings (OR 0.27; 95% Cl 0.11·0.67). Totest 
whether smoking history modified the onset of disease, we used the data of six families 
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Table 5.3.2 Hlstory of smoking befare the ons et of dementia of 193 Alzheimer patients and 
195 controls, stratified for family hlstory of dementia in first degree relatives 
Cases Contra Is O~ds ratio [95% Cl] + 
n=193" n=195" Crude Adjusted 
Family history dementia+ 
Smoking: yes 40 55 0.54 0.35 
no 55 41 [0.31-0.96] [0.16·0.78] 
Family history dementia -
Smoking: yes 49 47 1.11 1.!9 
no 49 52 [0.63·1.93] [0.63-2.25] 
All patients 
Smoking: yes 89 102 0.78 0.70 
no 104 93 [0.52-1.16] [0.43·1.15] 
• Data on smoking history werc missing for fiw paticnts and thrce control subjccts 
+ &sed on unmatched a.nalysis 
+ Adjusted for agc, gender. rcsidcnce. education and intake of alcohol by condition:ll logistic regression 1l.Il:l!ysis 
Table 5.3.3 Hlstory of smoking befare the allSet of dementia of 193 Alzheimer patients and 
195 controls_. stratified Jor family history of dementia,· wilhout patients and controts wilh 
atherosclerolic disease+ 
Cases Controls O~ds ratio [95% Cl] 
n=146 n=122 Crude Adjusted' 
Family history dementia+ 
Smoking: yes 27 41 0.28 0.16 
no 44 19 [0.14-0.59] [0.06-0.45] 
Family history dementia-
Smoking: yes 42 32 1.19 1.66 
no 33 30 [0.61-2.34] [0.67-4.13] 
All patients 
Smoking: yes 69 73 0.60 0.61 
no 77 49 [0.37-0.98] [0.31-1.19] 
• In fust degrcc rcl:ltivcs 
+All pa.tients and controls with ::1 history of eoron:1ry hea.rt disc.'l.SC, stroke or hypertension cxcluded + B:1scd on unm:1tched :ln:llysis 
§ Adjusted for agc, gendcr. residence, cduc.'l.tion and intake of alcohol by conditional Jo gistic rcgression analysis 
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Table 5.3.4 Number of cigarettes smoked daily of 193 Alzheimer patients attd 195 controls, 
stratified for family history of dementia in first degree relatives 
All Family history dementia· + 
Number of CJ.Ses Controls Odds. I':ltiO [95_% C~ Cases Controts Odds.ratio [9~%;), 
cis,;arettes n=193 n-195 Crude Ad1ustcd n=95 n=96 Crude Ad!ust 
0 104 93 55 41 
1-10 47 46 0.91 0.79 20 25 0.60 0.46 
[0.56-1.50] (0.46-1.34] [0.29-1.22} [0.20-1.06] 
11-20 27 30 0.80 0.59 13 16 0.61 0.34 
[0.45-1.45] [0.29-1.21] [0.26-1.40} [0.11-1.05] 
21+ 15 26 0.52 0.39 7 14 0.37 0.18 
[0.26-1.03] [0.17-0.90] [0.14-1.00] [0.05-0.69] 
Chi-square 5.25 7.33 
for trend =0.022 =0.007 
+
• Based on unmutehed analysis 
Adju~ted for agc, gcmkr. n:sidencc, cducation and intake of alcohol by conditionat logistic regn:S>Jion analysis 
Ta};le 5.3.5 Mean age of onset and history of smoÄ:ing in 6 families with autosomal 
dominant inheritance of Alzheimer's disease 
Non-smokers Smokers 
Family Number Onset (years) Number Onsct (years) 
of cases Mean Range of cases Mcan Rancrc 
1005 3 55 55-60 2 62 61-62 
1011 62 1 62 
!066' 3 39 33-49 2 45 41-49 
1072' 58 63 
1083 4 57 55-63 57 
1125 51 I 58 
All 13 54 3$.-63 s 59 4!-63 
·Th.: clinical diagnosis of Al7.hcimer's dis.:a>'<! was confirmcd pathologically in two paticnts of famîly I 066 and I patient of fllmily 
1072. 
in which there were both Alzheimer patients who had ever smoked and patients who had 
never smoked (table 5.3.5). There was a significantly lateronset of 4.17 years in smoking 
as compared to non-smoking patîents from the same family (standard error of the 
difference 1.35; p = 0.03). 
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Discussion 
In this study we observed a strong inverse relationship between smoking and 
A1zheimer's disease. The association was restricted to Alzheimer patients with a positive 
family history of dementia and was independent of cardiovascular history and potenrial 
confaunding variables such as age, gender and alcohol consumption. The risk of 
Alzheimer's disease decreased as the number of cigarettes smoked daily increased. 
Within families in which Alzheimer's disease was apparently inherited as an autosomal 
dominant disorder, we observed that the onset of Alzheimer's disease was later in 
smoking patients than in non-smoking patients. This study also showed farnilial 
aggregation of Parkinson's disease with Alzheimer's disease, even though Alzheimer 
patients with a history of Parkinson's disease were excluded.8 
Befare interpreting these findings, we would like to raise some methodologie issues. 
At present, it is nat possible to distinguish between patients who are primarily of genetic 
origin and those who are primarily of environmental origin. Therefore, we have classified 
patients on the basis of their family history of dementia, assuming that patients with a 
positive family history are more likely to be of genetic origin. This has probably 
introduced misclassification, because relatives of sparadie patients rnay carry the gene and 
express the disease later in life, whereas familial aggregation of Alzheimer's disease rnay 
be due to clustering of non-genetic patients. The most likely effect of this misclassi:fication 
is, that it has made familial and sparadie patients more similar. The difference :in risk 
between familial and sparadie Alzheimer's disease may therefore be Iarger than reported 
in the present study. Another methodologie issue concerns the data collect:ion. Although 
we have measured smoking habits in a symrnetrical way in patients and controls/' there 
is a possibility of bias: (1) the non-response within the control group may have been 
associated with smoking; and (2) relatives of patients with Alzheimer's disease may have 
underreported smoking habits. We consicter it less likely, however, that these types of bias 
have occurred only in patients with a positive family history of dementia ortheir matebed 
controls. Since no association of smoking with sparadie Alzheirner's disease was observed, 
it is unlikely that the association with farnilial Alzheimer's disease can be fu11y explained 
by these sourees of bias. Moreover, the comparison of age of onset between smoking and 
non-smoking patients largely avereames the bias to which camparisans of patients with 
control subjects are prone. Sirree we have included bath incident and prevalent patients 
in our study, another possible souree of bias is that the survival rate may have been 
higher in non-smoking Alzheimer patients than in smoking patients. However, the 
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association between smoking and familial Alzheimer's disease remained significant after 
the exclusion of aU patients and all controls with a history of atherosclerotic 
cardiovascular disease, the most common competing cause of death. Also, the finding of 
a later disease onset in smoking patients as compared to non·smoking patients argues 
against a clear effect of lower survival among smoking patients. A final point concerns 
the uncertainty in the clinical diagnosis of Alzheimer's and Parkinson's disease. The 
validity of the diagnosis of dementia and Parkinson's disease in relatives of patients has 
been discussed elsewhere.8 Por all patients and controls, the data on fami1y history were 
confirmed by a second first degree relative. The diagnosis of Parkinson's disease couJd 
be confirmed by medica! records for 11 patients (79%) and 4 contra Is (80% ). 
Prev:ious studies of the association beween Alzheimer's disease and smoking have 
yielded equivocal results.1o~-u In two studies, a significant positive association between 
smoking and AJzheimer's dîsease was reported, ~~.u but in three studies a significant înverse 
relationship was suggested.14~;:~ Pooling of the data of all forma! case·control studies, 
however, resulted in a significant inverse association (OR=0.78; 95% CI 0.62·0.98).s.15• 
!?,zs.u..::r The advantage of the present study is that it camprises twice as many patients as 
the earlier investigations and therefore allows more careful analyses of subgroups and 
possible sourees of bias. 
The majority of studies of Parkinson's disease have reported a protective effect of 
smoking as well.4 The mechanism underlying the association of smoking with Alzheimer's 
disease and Parkinson's disease is at present unclear. In bath Alzheimer's disease and 
Parkinson's disease nicotinic receptars are reduced.:l&.~ Decreased nicotinic receptor 
binding has been linked to pathological changes characteristic for Alzheimer's disease.J() 
31 Nicotine has been reported to increase the density of nicotinic receptars in the brain.32 
It may be speculated that nicotine from cigarette smoke may compensate the loss of 
nicotinic receptars in Alzheimer's disease and Parkinson's disease and may thus postpene 
the onset of disease. However, it is also possible that preclinical changes in nicotinic 
receptars in Parkinson's disease and familial Alzheimer's disease may have resulted in 
a loss of desire to smoke in these patients.~1 The Jack of association in patients with 
sparadie Alzheimer's disease suggests that smoking may be involved in a mechanism of 
primarily genetic origin. 
Th ere are two implications of our findings. Firstly, they suggest heterogeneity between 
familial and sparadie Alzheimer's disease. Secondly, they suggest a link between 
Parkinson's disease and familial Alzheimer's disease. Although the association of smoking 
with familial Alzheimer's disease and Parkinson's disease may be explained by shared 
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patho1ogical characteristics of different etiology, the familial aggregation of .A.lzheimer's 
disease and Parkinson's disease supports the view of a joint pathogenesis. Bath findings 
point to a genetic link between the disorders. For Parkinson's disease as wen as familial 
.A.lzheimer's disease, it has been suggested that genetic and environrnenta1 factors may 
be implicated.33.:"~ 
We present our findings of an inverse association between smoking and Alzheimer's 
disease with caution, as they are nat yet confirmeà by prospective studies. Although the 
assoc:iation we observed is compatible with a protective effect of smoking for familial 
Alzhe:imer's disease, it has no relevanee for prevention of Alzheimer's disease because 
of the adverse health effects of smoking. These findings may lead to interesting 
speculations, however, as to why bath familial Alzheirner's and Parkinson's disease may 
be inversely related to smoking. It may further suggest a joint etiology of these àisorders. 
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Chapter 5.4 
Interaction between 
genetic and environmental risk factors for 
Alzheimer's disease 
Genetic factors appear to play an important role in Alzheimer's disease. In a 
considerable number of families the disease is apparently inherited as an autosomal 
dominant disorder1 and epidemiologie studies have shown familial aggregation of the 
disease.~3 It has been suggested, however, that Alzheimer's disease may be heterageneus 
and that there rnay be patîents with sparadie Alzheimer's disease, in whom the disease 
may be attributed primarily to environmental causes.<~-<> Other factors that have been 
implicated in A.lzheimer's disease include famiiy history of Down's syndrome, family 
history of Parkinson's disease, late matemal age at birth, head trauma, depression, 
hyperthyroidism, smoking, aJuminurn and education.:!.3 Little is known of the interaction 
between genetic and other putative risk factors for A.lzheimer's disease. The genotype 
and the risk factor may increase the risk of A.lzheimer's disease indepenàently. It is also 
conceivable that the genotype may exacerbate the effect of the risk factor ( or vice versa) 
or that the presence of bath the genotype and the risk factor may be required to increase 
the risk of disease.7 
We have re-analyzed the original data of seven case-control studies of Alzheimer's 
disease to study the interaction between genetic and environmental factors. The data we 
presenthereare basedon 814 patients with A.lzheimer's disease and 894 control subjects. 
Methods 
For this study, all case-control studies of Alzheirner's disease conducted befare January 
1, 1990 were traeed through rnedline search, review papers and persarral contacts."'" 
Van Duijn CM, Ciayton D, Chandra V. Fratiglioni L Graves AB, Hcyman A. Jorm AF. Kokmen E. 
Kondo K. Mortimer JA. Rocca WA. Shalat SL Soininen H. Hofman A Interaction between gcncticand 
cnvîronmemal ri~k faewrs for Alzheimer's disease: a rc·ana\ysis of casc.control studies. Submittcd. 
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We only included studies in which the patients met the criteria for the clinical diagnosis 
of Alzheimer's disease of the National Institute of Neurological and Communicative 
Disorders and Stroke anà the AJzheimer's Disease and Related Disorders Association 
(NINCDS-ADRDA)" or the criteria of the Diagnostic and Statistica! Manual of Mental 
Disorders for pr:imary degeneralive dementia (DSM-lll)." Thus, we identified eleven 
studies. u.zz Four studies were nat included in the present analysis: two studies because 
na data on family history of dementia were collected14'u.t and two other studies because 
the data had notbeen collected syrnmetrically for cases and contra Is, i.e., control subjects 
were interviewed persona1ly, but the pa tient's history was obtained from an informant.11. 
:!1 The seven studies on which this analysis is based have been descnbed in chapter 2.2. 
Selection of risk factors. A great variety of risk factors have been studied in the seven 
case-control studies. In this analysis of interaction among genetic and environmental 
factors we included only those factors which showed a significant association with 
Alzheimer's disease in the overall analysis.9 A second criterion to include a risk factor in 
the present study was that the nurnber of exposed cases and controls should allow 
stratification by family history of dementia in order to assess effect modification. Based 
on these criteria, we examined the interaction of family history of dementia with the 
following factors: family history of Down's syndrome and Parkinson's disease, late 
matemal a ge, history of head trauma. history of depression and history of smoking. For 
medica} history a multitude of disorders have been studied and considerations of bias and 
multiple testing apply particularly to the analysis of these data. We therefore Jimited the 
analysis to disorders that a priori were expected to be associated, i.e., history of head 
trauma and depression. 
For each risk factor, we evaluated the comparability of measurement across studies as 
described earlier."'" As to exposure definition, we restricted the analysis of family history 
to disorders in first degree relatives. For late matemal age, cases and controls in whom 
the mother was aged 40 years ar over at birth were considered exposed. We included in 
the analysis of patient history only exposures occurring at least one year before the 
disease onset. For control subjects we defined the age of onset of the matched case as 
reference and we considered only exposure befare this reference age. To reduce the 
possibility of reeall bias, we restricted the analysis of history of head trauma to that 
invalving loss of consciousness and of episodes of depression to that medically treated. 
Smoking history was analyzed as a dichotomous variable; we classified patients and 
controls as non-srnokers if they had never smoked befare disease onset or the reference 
age, and as smokers if they had ever srnoked. 
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Data analysis. The raw data of all the case-control studies were available for analysis. 
The results we present bere are based on a comparison of cases wîth population or 
neighborhood controls. The associatîon between Alzheîmer's disease and the putative risk 
factors was assessed by the odds ratio (OR) as an estimate of the relative risk. Odds 
ratios are presented with 95% confidence intervals (95% Cl). All studies were matched 
for age and gender and we used conditional Jogistic regression to take the matching 
variables into account.z;~ 
The present analysis is based on a strategy Ottman has outlined to study gene-
environment interaction. This is a general genetie-epidemiologie approach, using family 
history of disease as a surrogate measure of genetic susceptibility in the absence of a 
genetic marker.7 We defined those nat exposed to the risk factor and without a history 
of dementia in first degree relatives as the refen::nce category. Odds ratios were 
estimated (1) for those with a positive family history but nat exposed to the risk factor; 
(2) for those e>:posed to the risk factor but without a family history of dementia; and (3) 
for those exposed to the risk factor having also a positive family history of dementia. If 
the genotype and the risk factor increase the risk of Alzheimer's disease independently, 
the model prediets that genetic susceptibility and risk factor wil! each increase the risk 
of Alzheimer's disease in the absence of the other. If the risk factor modifies the risk of 
a disorder primarily of genetic origin, one would expect the risk for those exposed to the 
risk factor to be increased only in genetically susceptible individuais. Conversely, if the 
genetic factor modifies the risk of a disorder prirnarily of environmemal origin, one would 
expect an increased genetic relative risk only among those exposed to the risk factor, 
while the risk associated with the risk factor is expected to be higher among subjects that 
are genetically susceptible. It is also possible that the gene is causally related to the risk 
factor and that the risk factor increases the risk for the disease. In this case, one would 
also expect an increaseà genetic relative risk only among those exposed to the risk factor, 
while the risk associated with the risk factor is expected to be similar arnong subjects that 
are genetica!ly susceptible and those who are nat. Finally, if bath the risk factor and 
genotype are needed to increase the risk of disease, an increased risk would be found 
only for those exposed to bath factors. Since family history is an imperfect measure of 
genetic susceptibility, we would nat expect to abserve such extreme results. Nevertheless, 
gene-environment interaction should imply slalislical interaction between the effects of 
family history and risk factor, although large sample sizes may be necessary to reach 
statistica! significance.~4 Here we have interpreted statistica} interaction in the 
multiplicative sense. 
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Resu!ts 
Ofthe 814 patients, 399 ( 49%) were men and 415 (51%) were wamen. The mean a ge 
at onset was 66 years (SD=ll years). Three hundred and five (38%) patients had one 
or more first degree relatives with dementia as compared to 140 (16%) controls (OR 3.5; 
95% Cl 2.6-4.6). Table 5.4.1 shows exposure freguencies and the odds ratios for all 
factors studied in this analysis. Smoking history was inversely associated with Alzheimer's 
disease, whereas the other factors încreased the risk of disease. 
Table 5.4.1 Overview of risk factors included in the EURODEM collaborative re-
analysis of interaction between genetic and environmental risk factors for 
Alzheimer's disease 
Risk factor· 
Family history: 
Dementia D.ts-l7.J').~J 
Dov.rn's syndrome13•15'16.19'21 
Parkinson's disease 15' 19 
Patient history: 
Maternal age 40+ years15• 1"'~1 
Head trauma15'1"'1"'21 
Depressionm1 
SmokingJ:l,Js-n.t.-...~1 
Exposure frequency 
Cases Controls 
305/814 140/894 
20/588 7/615 
20/312 8/294 
47/446 
60/622 
15/273 
423/821 
28/446 
35/622 
12/378 
526/907 
Odds ratio 
95 %confidence 
interval+ 
3.5 
[2.6-4.6] 
2.7 
[1.2-5.7] 
2.4 
[1.0-5.8] 
1.7 
[1.0-2.9] 
1.8 
[1.1-2.7] 
1.7+ 
[0.8-3.9] 
0.8 
[0.6-1.0] 
• Rcfcrcnccs of studies with d:tt:l. :tvailable on this risk factor 
+Risk estîmates may diffcr slightly from estimates published earlicr.~ since this analysis is performcd within a subset 
of studies that have collected data on family history of dementia 
+ Depression was signi!icantly associated with Alzheimer's discase in the overall analysis (odds ratio 1.8; 1.2+2.9), when 
studies without family history dat:l. were included11 
130 
Interaction genetic and cnvironmen tal factors 
Odds ratios for family history of Down's syndrome and family history of Parkinson's 
disease, stratified by family history of dementia are given in table 5.4.2. In the absence 
of a family history of dementia, the odds ratios for those with a first degree relative with 
Down's syndrome (OR 2.6; 95% Cl 0.8-8.5) and for those with a first degree relative with 
Parkinson's disease (OR 2.4; 95% Cl 0.8-7.0) were increased although nat statistically 
significant. For bath risk factors the odds ratio tended to be higher for those with a 
positive family history of dementia. The effect was strengest for family history of Down's 
syndrome; the odds ratio of 4.2 (95% Cl 0.9-20.0) was 1.6 times higher for those with a 
:first degree relative with dementia as compared to those with no family history of 
dementia. The interaction was nat statistically significant. 
Table5.4.2 Family history of Down's syndrome and Parkinsons disease and the riskfor 
Alzheimer's disease, effect modification by family history of dementia: The EURODEM 
collaborative re-analysis of case-control studies 
Family history of 
Down's syndrome: 
+ 
Odds ratio+ 
Parkinson's disease: 
+ 
Odds ratio+ 
Farnily history dementia 
+ 
1 3.3 
reference [2.4-4.4] 
2.6 13.8 
[0.8-8.5] [3.0-63.8] 
2.6 4.2 
[0.8-8.5] [0.9-20.0] 
3.6 
reierenee (2.4-5.6] 
2.4 12.0 
[0.8-7.0] [1.4-101.4] 
2.4 3.3 
[0.8-7.0] [0.4-28.2] 
Odds ratio 
family 
history 
dementia· 
3.3 
[2.4-4.4] 
5.3 
[0.8-36.9] 
3.6 
[2.4-5.6] 
5.0 
[0.5-54.7,] 
Odds rntio [95% confid.::ncc intcrv~l] for thos<.: with ~ positiv.: family history of d<.:mentia, comput<.:d within stratum of 
risk factor 
+ Odds rntîo [95% confidenc<.: interval] for those expo~ed to risk fuetor, computed within ~tratum of family hi~tory of 
dementia 
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Tabie 5.4.3 Matemal a ge, head trauma and depression and the risk [ar Alzheimer's disease, 
effect modiftcation by family history of dementia: 1he EURODEM collaborative re-analysis 
of case-control studies 
Risk factor Family history dementia 
+ 
Matemal age 40+: 1 3.6 
reference [2.5-5.1] 
+ 2.0 6.0 
[1.1·3.5] [2.1·16.9] 
Odds ratio+ 2.0 1.7 
[1.1-3.5] [0.6-4.8] 
Head trauma: 1 2.9 
reference [2.2·3.9] 
+ 1.9 5.0 
[1.1-3.2] [2.1-12.1] 
Odds ratio+ 1.9 1.7 
[1.1-3.2] [0.7-4.2] 
Depression: 1 3.9 
reference [2.4-6.5] 
+ 2.1 7.9 
[0.8-1.7] [0.8-78.7] 
Odds ratio+ 2.1 2.0 
[0.8-1.7] [0.2-19.8] 
Odds ratio 
family 
history 
dementia· 
3.6 
[2.5-5.1] 
3.0 
[1.0-10.0] 
2.9 
[2.2-3.8] 
2.6 
[1.0-7.4] 
3.9 
[2.4-6.5] 
3.8 
[0.3-44.9] 
Odds ratio [95% confidcncc interval] for those with a posîtivc family history of dementia. computcd within stratum of 
risk factor 
+ Odds rutio [95% contidence interval] forthese cxposcd to risk factor. computcd within stratum of family history of 
dementia 
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Table 5.4.3 gives the odds ratios for late matemal age, history of head trauma and 
history of depression, stratified by family history of dementia. Family hlstory of dementia 
remained significantly associated with AJzheimer's disease in the absence of the other risk 
factors. For late matemal age, history ofhead trauma and history of depression the odds 
ratio virtually did nat change when stratifying by family history of dementia, indicating 
that the risk for family Iristory of dementia and these risk factors are multiplicative. 
The inverse association between history of cigarette smoking and Alzheimer's disease 
tended to be strenger for those with a positive family history of dementia (table 5.4.4). 
For those with na family history of dementia there was na evidence for an association 
between smoking history and Alzheimer's disease (OR 0.9; 95% Cl 0.7-1.2). For those 
with a positive family history an inverse relationship was observed (OR 0.6; 95% Cl 0.4-
1.0). The odds ratio for family history of dementia tended to be lower in smokers (OR 
2.8; 95% Cl 2.1-4.0) as compared tonon-smokers (OR 3.9; 95% Cl 2.6-5.7), although the 
two odds ratios did nat differ significantly. 
The high exposure frequency made it possible to perfarm an analysis of smoking 
history stratified further by the number of affected first degree relatives (table 5.4.5). The 
effect of smoking was most pronounced for those with two ar more affected relatives. 
Table 5.4A Smoking and the risk for Alzheimer's disease, effect modifîcation by family 
history of dementia: The EURODEM collaborative re-analysis of case-control studies 
Risk factor Family history dementia Odds ratio 
family 
+ history 
dementia· 
History of smoking: 
1 3.9 3.9 
reference [2.6-5.7] [2.6-5.7] 
+ 0.9 2.5 2.8 
[0.7-1.2] [1.8-3.6] [2.1-4.0] 
Odds ratio+ 0.9 0.6 
[0.7-1.2] [0.4-1.0] 
Odds ratio [95% confidence interval] for thosc with a positivc family history of dementia, computcd within stratum of 
risk factor 
+ Odds ratio [95% confidencc interval] for those exposcd to risk factor, computcd wîthin stratum of family history of 
dementia 
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Table 5.4.5 Smoking and the risk for Alzheimer's disease, effect modification by family 
history of dementia: The EURODEM collaborative re-analysis of case-control studies 
History Nurnber of affected re1atives Odds ratio+ Oàds ratio+ 
of smoking 1 affected 2+ affected 
0 l 2 relative relatives 
1 3.0 10.9 3.0 10.9 
reference [2.0-4.7] [2.6-46.9] [2.0-4.7] [2.6-46.9] 
+ 0.8 2.0 4.8 2.5 6.0 
[0.6-1.1] [1.3-3.0] [1.8-13.2] [1.7-3.5] [2.2-16.1] 
Odds ratio+ 0.8 0.7 0.4 
[0.6-1.1] [0.4-1.1] [0.1-2.6] 
·Data on the number of affected rcbtivcs wcre not collcctcd in two studics13·17 
+ Qdds ratio [95% confidcncc interval] for these with .:1 positivc family history of dementia, computed within stratum 
of risk factor 
+ Odds ro.tio [95% confidcncc interval] for these exposcd to risk factor, computcd within stratum of famîly history of 
dementia 
The odds ratio for those with two or more affected relatives was 1.9 times higher among 
non-smokers (OR 10.9; 95% Cl 2.6-46.9) as compared to smokers (OR 6.0; 95% Cl 2.2· 
16.1). However, the difference between the odds ratios was nat statistically significant. 
Discussion 
This study shows that family history of Down's syndrome, family history of Parkinson's 
disease, late matemal age) head trauma and depression are associated with an increase 
in the risk for Alzheimer's disease in the absence of a family history of dementia, while 
family history of dementia rernains strongly associated with AJzheimer's dîsease regardless 
of the presence or absence of these factors. As to the interaction between smoking and 
family history of dementia, there was no evîdence for an association between hîstory of 
smoking and Alzheimer's disease for those with no first degree relatives with dementia. 
The risk for family history of dementia tended to be lower in smokers as compared to 
non-smekers) although the difference was nat statistically significant. This effect was most 
pronounced for those with two or more affected first degree relatives. 
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The resu1ts of this re~analysis of case-control studies must be interpreted hearing the 
crude measurement of genetic susceptibility in mind. The use of family history of 
dementia as an indicator in the absence of a genetic marker suitabie for epidemiologie 
studies certainly incurs misclassification. Unaffected relatives may simply nat have 
expresse à the disease at the time of the study and patients classified as having "sporadic" 
Alzheimer's disease may in truth be gene carriers. Therefore the finding of an effect of 
a risk factor for those without a family history of dementia does nat exclude the 
possibility that the risk factor operates only in L'1ose genetically susceptible. Yet, if the 
association in patients with "sporadic'' Alzheimer's disease is to be explained by 
misclassification of genetically susceptible individuals, odds ra ti os must be higher for those 
with a positive family history. On the other hand, familial aggregation of Alzheimer's 
disease may result from clustering of patients with non-genetic disease and such 
misdassification may have reduced the statistica! power to show interaction between 
genotype and other factors. Another issue in familial Alzheimer's disease is related to the 
growing evidence that more than one gene may be implicated :in Alzheimer's disease.15· 
26 If a risk factor interacts with only one specific genotype, the use of family history as an 
indicator for genetic susceptibility may result in little statistica! power to show such a 
mechanism. Moreover, due to genetic heterogeneity it is unlikely that we are able to 
assess a mechanism in which a gene exacerbates the effect of an env:ironmental factor 
without increasing the risk for Alzheimer's disease by itself. Tne predicted lack of 
association with Alzheimer's disease for those with this gene but without the risk factor 
is likely to be blurred by the increase in risk for Alzheimer's disease for those with a 
positive family history due to other genes having an independent effect. A final point to 
be discussed when studying interaction with risk factors conferring only small or more 
moderate relative risks is that very large studies are necessary to achieve sufficient power 
to detect interaction.;, Despite the pooling of all case~control studies conducted to date, 
one may argue that the sample size of this analysis has been toa small. 
The findings should also be interpreted in light of the validity of the case-control 
studies on which the re-analysis is based.!J.:!l> Selection bias may have occurred in the first 
place because in all studies the control series had a higher non-response than the case 
series. Bias may have also resulted from the fact that the case series comprised a mixture 
of prevalent and incident cases. Although we performed a separate analysis for incident 
cases that did nat suggest major differences in the risk estimates, we cannot fully exclude 
the possibility that the findings are biased by differential survival.!J~ Despite the 
symmetrie data-coneetion in cases and controls, reeall bias may have occurred. This 
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applies particularly to data on family history, history of head trauma and history of 
depression. As biased reeall is more likely to occur when assessing disorders in relatives 
more distantly re1ated, we have restricted the analysis of family history to disorders in 
first degree relatives.~ For history of head trauma, we restricted the analysis to that 
invalving ]oss of consciousness in order to reduce the possibility of reeall bias.::<O The 
association between depression and Alzheimer's disease was also shown within the cohort 
study based on rnedical records of the Roehester register, which suggests that the 
assoc:iation can nat be asenbed fully to reeall bias. 1s..~1 
For family history of Down•s syndrome, family history of Parkinson•s disease, late 
maternal age, history of head trauma and history of depression a consistent increase in 
risk for Alzheimer's disease was observed across the individual case-control studies, 
although nat always statistically significant.2')..~~ The mechanism through which these risk 
factors may be implicated in Alzheimer's disease has been discussed earlier."'-" The 
present analysis showed that each factor increased the risk for Alzheimer's disease in the 
absence of a positive family history of dementia. These findings argue against the rnadeis 
in which (1) the risk factor merely exacerbates the genorype: and (2) the risk factorand 
the genotype are bath required to increase the risk for Alzheimer's disease. As family 
history of dementia remairred strongly associated with Alzheimer's disease in the absence 
of other risk factors, the results are most consistent with a model in which the genetic 
factor and these risk factors may increase the risk for Alzheimer's àisease regardless of 
each atbers presence. For late matemal age, history of head trauma and history of 
depression, the similarity in relative risks for those with and without a family history of 
dementia suggests that there is na interaction with the genotype. The risk for Alzheimer's 
disease for those with a family history of Down ·s synàrome as well as for those with a 
family history of Parkinson 's disease tended to be higher when havihg a positive family 
history of dementia in addition. These findings are compatible with a genetic link 
between the dîsorders. However, for bath disorders the interaction was not statistically 
significant, but this may be due to the small number of exposed patients and controls. 
Studies of the association between Alzheimer's disease and history of smoking have 
yielded equivocal results.17.JJ Pooling of the data of all forma] case-control studies resulted 
in a significant inverse association.).l This finding is supported by the Iower incidence of 
late-onset AJzheirner's disease among smokers as cornpared to non-smokers in a 
prospective follow-up study.35 The possibility that al der smokers who develop Alzheimer's 
disease may be sereerred out of the case series due to conàitions secondary to smoking 
should be considered as an explanation.33·).1 Yet, the finding of a trend (albeit non-
136 
Interaction genetic and cnvironmen tal factors 
significant) towards an increased effect of smoking w:ith increasing number of affected 
relatives argues against this explanation, as it is unlikely that this type of bias has 
occurred specifically in patients with familial Alzheimer's disease. The observation that 
pathoiogical changes observed in Alzheimer's àisease are associated with a decrease in 
nicotinic receptor density~7 makes the inverse association w:ith smoking biologically 
plausible ( see also chapter 5.3). Smoking increases the density of these receptors" and 
may thus deiay the onset of dementia, resulting in a 1ower risk for Alzheimer's disease 
forsmokers when camparing cases and a ge- and gender-matebed controls. In the present 
anaiysis, the effect of cigarette smoking tended be strenger with increasing number of 
affected first degree relatives, suggesting that smoking interacts with a genetically 
determined process. This finding agrees with the delay in onsetage observed in smoking 
patients as compared to non-smoking patients from families in which the disease is 
apparently inherited as an autosarnar dominant disorder ( chapter 5.3). The small non-
significant decrease in risk for patients with no family history suggests heterogeneity in 
the etiology or pathology of familial and sparadie Alzheimer's disease. 
Although the findings of our study are compatible with a role of severa1 risk factors 
for Alzheimer's disease independent of genetic susceptibility, we interpret our findings 
with caution. Despite the large number of patients in the analysis, the validity of case~ 
control studies of PJzheimer's disease conducted to date is limited by the possibility of 
reeall bias and selection bias. Furthermore, we recognize the possibility of 
misclassification in genetic susceptibility and the relatively srnall sample size for studying 
interaction. These probieros may be sufficient to account for our failure to find statistica! 
significant evidence for interaction. Prospective fellow-up studies incorporating biologie 
markers of genetic susceptibility would have a greater chance of success, but even tb en, 
large studies would be required to dernonstrate gene-environment interaction. 
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Chapter 6 
General discussion 

Chapter 6.1 
Introduetion 
A genetie-epidemiologie study aims at answering the following questions:'·' (1) Does 
the disease cluster in families? (2) If yes, can the farnilial aggregation be explained by 
genetic or shared environmental factors? (3) lf there is evidence fora genetic component, 
can we identify the genetic mechanisrn(s)? (4) If genes are implicated in the genetic 
mechanism, on which chromosarnes are these genes located? (5) Do environmenta1 
factors interact with genes to modify the ex-pression of disease? 
Research on the role of heredity in familial aggregation and the mode of inheritance 
requires pedigree research, whereas the study of the role of genetic and environmental 
factors in the occurrence of disease requires research of unselected populations. This 
thesis camprises several popuiatien studies as well as pedigree studies. In chapter 6.2 the 
limitations of the design of the studies will be reviewed in light of the interpretations of 
the findings and recommendations for further research. Chapter 6.3 discusses the 
inference that can be drawn from our findings with regard to the knowledge of risk 
factors for Alzheimer's disease along with recomdations for further research. 
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Methodologie issues 
Diagnosis 
At present, there is na qualitative biologîc marker for Alzheimer's disease. According 
to the criteria for the clinical diagnosis, Alzheimer's disease is a diagnosis by exclusion 
of other specific causes of dernentia.L~ Perhaps the most difficult distinction to be made 
is with vascular dementia, as there is sti11 debate on the diagnosis of this type of 
dementia."'" The definite diagnosis of Alzheimer's disease can only be established by 
pathologie confirmation.1 Autopsy studies have shown that the accuracy of the clinical 
diagnosis of Alzheimer's disease based on the NINCDS-ADRDA criteria varies from 
85% to 100%.'"" Neuropathologie changes characteristic for Alzheimer's disease 
camprise neuritic plaques and neurofibrillary tangles. Extracellular amyloid fibrils 
composed of the amyloid protein (A4 protein) make up the core of the neuritic 
plaques.13·14 Neurofibrillary tangles consist ofintra-neuronal paired helical filaments, which 
are in part cornposed of altered farms of the microtubule-associated protein tau. 15•1" Bath 
these pathologie changes have also been observed in normal aging, albeit to a lesser 
extent. 17_,q 
As to the clinical diagnosis of Alzheimer's disease, in an early stage there is 
considerable chance for misclassification because ofthe insidious onsetY In particular for 
late-onset Alzheimer's disease, the cut-off points to separate dementia from normal aging 
and Alzheimer's disease from other types of dementia may be considered arbitrary."'" 
Many of the methodologie problems that will be discussed in this chapter are related to 
the diagnosis of the disease. Another problem in studies of Alzheimer's disease is related 
to the measurement of genetic susceptibility as a determinant. confaunder or effect 
modifier. Since the disease onset has been shown to be similar within families ( chapter 
5.2), particularly gene-carriers of the late-onset farm have a high chance of dying befare 
the expression of disease. This problem is referred to as censoring. As concern about the 
diagnosis and censoring apply to a lesser extent to early-onset Alzheimer's disease than 
to Jate-onset Alzheimer's disease, there is a strong point to be made to focus etiologie 
research on the early-onset farm. Following this reasoning, we have conducted a 
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popuiation-based study of risk factors for early-onset Alzheimer's disease, which is 
presented in this thesis. 
A final issue to be considered related to the diagnosis of Alzheimer's disease is that 
although no clinical symptoms can be detected, the underlying disease process may 
already be in progress. Thus, although exposures are considered befare the first 
symptoms of disease, risk factors may still relate to the progression of an ongoing process 
rather than be a cause of the disease. It is also conceivable that the risk factor merely is 
an early expression of the disease. Therefore, a risk factor should be viewed of as a 
measure of association, which may reflect a causa! or non-causal relationship. 
Bias 
This thesis is based upon observational research. In epidemiologie terrns, there are 
two principal types of observational studies: case-control studies and cohort studies. In 
a case-control study, present or previous exposure to a putative risk factor is measured 
after the onset of disease în patients and is compared tothelevel of exposure of subjects 
without the disease. Cohort studies fellow people known to be ex-posed to the possible 
risk factor and campare the occurrence of disease to these who were nat exposed. A 
pedigree study is conceptually a hybrid between a case-control and a cohort study. The 
risk of disease is eeropared v.rithin two cohorts, i.e., relatives of cases and controls, the 
exposure being the disease status of the proband. However, selection of study subjects 
and data-coHeetion generally fellow the case-control design. Therefore, the same 
problems of bias rnay apply to the case-control studies and the pedigree studies presented 
in this thesis. There are various ways in which the validity of these studies of Alzheimer's 
disease may be compromised:13·~4 
• Firstly, the studies presented in this thesis comprised a mixture of prevalent and 
incident cases. It is well known, that if prevalent cases are studied, i.e., when cases are 
nat already included in the study at first occurrence of Alzheimer's disease, selection bias 
may result frorn mortaHty and migration related to the disease.15 This would not be the 
case when subjects were incident or newly diagnosed. AJthough a separate analysis on 
incident cases that was performed in the re-analysis of case-control studies did nat alter 
any of the conclusions (chapter 2.2), we cannot fully exclude the possibility of bias. 
Another putative souree of bias concerns the diagnosis of Alzheimer's disease, which was 
in most cases based on clinical data without pathological confirmation. Therefore 
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misclassification may have occurred. This type of misclassification vvill most likely 
attenuate a true association. 
• Secondly, bias may have occurred in the selection of controlsin several ways. Spurious 
associations may occur if the control subjects have been drawn from a different study-
base or study-population than the cases. Insome of the studies included in the re-analysis 
of case-control studies, the case-series was hospital-based whereas the control series was 
drawn from the general population. However, a separate analysis in which cases were 
compared to hospital controls gave essential1y similar results and did nat change any of 
our conclus.ions ( chapter 2.2). Among control subjects, the non-response may have been 
associated with other risk factors than among cases. Such bias can nat be adjusted for in 
the data analysis. 
• Thirdly, there is ample opportunity for inforrnation bias in studies of Alzheimer's 
disease. There may have been non-differential as well as differential measurement error 
of either the disease outcome or the exposure. Non-differential misclassification, i.e., b.ias 
operating similar in cases and cantrols, is aften considered ta be a minor problem in 
epidemiology as it wil! most likely lead to an underestimation of the strength of 
assaciation rather than create a spurious assaciatian. One may argue, however, that such 
bias introduced by the use of surrogate inforrnams in retrospective studies of Alzheimer's 
disease rnay have reduced the statistica} power to show an association considerably. 
Moreover, non-differential misclassification may be a seriaus prablem if the degree of the 
misclassification varies across subgroups, thus creating a pattem that may give rise to 
erroneous speculations abaut heterogeneity of the àisease.~ Misclassification in the 
diagnosis of Alzheimer's disease when studying effect modification by onset age may 
serve as an example. It is well recognized that the diagnosis of Alzheimer's disease 
becomes less accurate with increasing onset age~ and this must be considered as a 
possible explanation for a weaker association of a risk factor for late-onset Alzheimer's 
disease as compared ta early-onset Alzheimer's disease. Differentlal misclassification 
between cases and controls, which may create spuriaus associations, is also a problem in 
studies of A.lzheimer's disease. Most abvious in this case may be the possibilîty of reeall 
bias as exposures may have occurred decades befare the anset of àisease and informants 
of cases may be more willing to reealleet such bistorical data than informantsof controls. 
In studies of Alzheimer's disease differential bias may operate also in the measurement 
of disease outcome, as the probability of being diagnosed with AJzheimer's disease may 
vary within a popuiatien according to, for example, socio-economie status, education or 
gender.~ 
146 
General discussion - Methodologie issues 
o Founhly, a poînt of criticism concerns the possibility of confounding. As little is known 
of the etiology of Alzheimer's disease, it is difficult to exclude the possibility that an 
unmeasured confaunder may explain the relationship to a risk factor. Residual 
confaunding may have occurred when putative confounders, e.g. genetic susceptibility, 
have been measured with sa much error that effective control bas been impossible in the 
data analysis phase.~ 
Meta-analysis 
Case~control studies of Alzheimer's disease have nat yielded consistent evidence for 
risk factors. A major concern in the interpretation of these findings has been the 
re1atively small sample size of the individual studies. The low statistica! power of such 
studies to detect a significant association may explain some of the apparently conflicting 
results. Ta tackle this problem, we conducted a paoled analysis of all formal case-control 
studies of Alzheimer's disease conducted befare January 1, 1990. 
Meta-analysis bas become an important feature in modern scientific research and bas 
already been applied successfully in therapeutic trials.z.. However, unlike a meta-analysis 
of blinded randomized trials, there rnay be large differences in methodology .in case-
control studies making a meta-analysis nat straightforward. In order to campare results, 
a re-analysis of the raw data is in practice inevitable. Th ere are two ways in which case-
control studies may be paoled into one single effect estimate: (I) the risk estimates from 
the individual studies, analyzed in a camparabie way, may be paoled into a single risk 
estimate; the rationale of this analysis is that the effect measures may vary across studies, 
and (2) the raw data of the studies may be paoled and analyzed; thus we assume there 
is a fixed effect. We have paoled the studies according to the latter approach ( chapter 
2.2). 
A re-analysis of observational studies must be juàged on its own merits.::> Indeed, it is 
clear that the large sample size of a paoled analysis wil! increase the statistica! power to 
detect risk factors conferring only moderately increased risks. Furthermore, pooling of 
the data wiJl result in more precise risk estimates and will enable subgroup analyses. 
However, the guality of the paoled analysis is fully determined by the guality of the 
individual studies1 which, as discussed earlier, may be criticized in the case of the case-
control studies of Alzheimer's disease. Considerations with regarà to the validity rnay be 
withdrawn if consistency of findings across studies conducted with different methodology 
147 
Chapter 6.2 
by different research groups can be established. Although it is possible that all studies 
have been biased in the same direction, the finding of consistency does support the 
evidence fora true relationship with Alzheimer's disease. Therefore, an important goal 
of the re-analysis of case-control studies has been to test whether odds ratios differed 
across studies. If consistency can be assessed, or heterogeneity can be explained, pooling 
of the data of single studies may be considered more valuable. 
Gene-environment interaction 
Same additional comments should be made with regard to misclass:ification in genetic 
susceptibility based on family history of dementia when studying gene-environment 
interaction as suggested by Ottman.~ This approach assumes that the disease under 
investigation has multiple causes, which may be of genetic or envjronmental origin. Table 
6.2.1 shows how a gene may interact with other risk factors and what associations are to 
be expected in a case-control study for each mechanism. In the first model, bath the 
presence of the risk factor and the genotype are necessary to increase the risk of disease. 
Such a mechanism prediets an increased risk of the disease only for these exposed to 
bath factors. In the second model, the risk factor modilies the risk of a disorder primarily 
of genetic origin. Thus, one would expect the risk for those exposed to the risk factor to 
be increased only in genetically susceptible individuals. In the third model, the gene does 
nat cause the disease directly, but is involved in the expression of the risk factor. In this 
case, one would expect that the gene does nat increase the risk of the disease within the 
strata of the risk factor, while the risk associated with the risk factor is expected to be 
similar regardless of the absence or presence of the gene. The fourth model shows a 
mechanism in which the genetic factor modifles the risk of a disorder primarily of 
environmental origin. In this circumstance, one would expect an increased relative risk 
for the genetic factor only among those exposed to the risk factor, while the risk 
associated with the risk factor is expected to be strenger among subjects who are 
genetically susceptible. In the fifth model, the genotype and the risk factor increase the 
risk of A!zheimer's disease independently of each other. This model prediets that genetic 
susceptibility and risk factor will each increase the risk of Alzheimer's disease if the other 
is absent. 
Ottman bas suggested that family history may be used as an indicator of genetic 
susceptibility.27 As aresult of non-differentlal misclassification, the strengthof association 
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Table 6.2.1 Gene-environment interaction: predicted observations for the odds ratio" in 
case-control studies as suggested by Ottman17 
Genetic susceptibility 
Model + 
Risk factor Risk factor 
+ + 
1. Gene and risk factor bath required 
Gene 
I ,.. Disease + 1 1 1 
Risk 
factor 
2. Risk factor exacerbates gene 
Gene ... Disease ++ + 1 1 
r 
Risk 
factor 
3. Gene increases expression risk factor 
Risk factor ... Disease + 1 + 1 
r 
Gene 
4. Gene exacerbates risk factor 
Risk factor ,.. Disease ++ 1 + 1 
r 
Gene 
5. Gene and risk factor increase in risk 
in the absence of each other 
Gene ~ Disease +?- + + 1 
Risk Factor ~ Disease 
1 denotes no associatîon with the dîsd.Se, + denotes an increase in odds rntio whereas + + denotes a strenger 
associa.tion duc to effect modi:ficatîon 
for genetic factors as well as for other risk factors is likely to be underestimated.:$ 
Therefore, less extreme results are expected than outlined in table 6.2.1. However, as 
pointed out in chapter 5.4, nat only will misclassification in genetic susceptibility based 
on family history data result in a reduction of the statistica! power, it will also distart 
studies of gene-environment interaction when the disease is genetically heterogeneous, 
as may be the case for Alzheimer's disease. If we assume that there exists at least one 
dominant gene, which increases the risk of Alzheimer's disease in the absence of ether 
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risk factors, it follows that the risk associated with family history of dementia will always 
be increased. In the situation that a risk factor interacts with another gene, it wiJl be 
difficult to distinguish the roodels 1 and 2 and the rnadeis 3, 4 and 5, as in models 1, 3 
and 4 the predicted Jack of association forthese with this gene but without the risk factor 
is like1y to be blurred by the increase in risk for Alzheîmer's disease for those with a 
positive family history due to the dominant gene. Thus, in the circumstance of genetic 
heterogeneity, the finding that the strength of association is similar among those with and 
without a positive family history may be compatible with model 3 and model5. Similarly, 
the finding of a stronger association among those with a positive family history in such 
a situation may be compatible with model 4 and model 5. 
It is obvious that studies of gene-environment interaction wilJ strongly gain value when 
biologie markers for genetic susceptibility become available. However, when studying 
interaction with risk factors conferring only small or more moderately e]evated relative 
risks, very large studies are necessary to achieve sufficient power to detect interaction,Z9 
even if biologie genetic markers are available. In such case, risk estimates may be 
compared rather than to test for statistica} interaction. To overcome the problem of 
statistica] power, twin studies may be used nat only to investigate risk factors for 
Alzheimer's disease,:w but in actdition they may serve as a vehicle for studies of gene-
environment interaction. The difference in onset age between concordant affected 
identical twins may be linked to environmental factors. To date, a limited nurnber aftwin 
studies have been performed, although a number of studies are in progress. As a 
corollary of such twin studies, it is suggested in this thesis that this approach may be 
extended to families in which early-onset Alzheimer's disease is apparently inherited as 
an autosomal dominant disorder ( chapter 5.2). As the onsetage of AJzheimer's disease 
within decadesappears to be genetically determined within a family (chapter 5.2), it is 
conceivable that environmental factors may have been implicated in patients that fall 
outside the family-specific a ge of ons et range. These patients may represent phenocopies, 
that is patients with the disease who do nat have the genotype. It is also possîble that 
environrnental factors have merely altered the genetically determined age of onset in 
these patients. To distinguish between these rnechanisms, studies of interaction between 
genetic and environmental factors should preferably be conducted among families in 
which linkage to genetic markers or the underlying mutation is known. 
Finally, two points are to be addressed bere concerning the relative risk as a measure 
of strengthof association between a risk factorand the àisease. The first point concerns 
the use of the odds ratio, which rnay be considered an estimate for the relative risk when 
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the disease under study is rare. The rare disease assumption is likely to break down in 
a study among a high risk popuiatien such as carriers of a major dominant gene for 
Alzheimer's disease. Therefore, the odds ratio as derived from a case-control study may 
be used as a measure of association, but will most likely overestimate the relative risk 
because the rare disease assumption is nat met unless the study is lirnited to incident 
cases diagnosed in a short period of time.31 Secondly, as the relative risk is dependent on 
the prevalenee of the disease,!S bias may occur when camparing the relative riskfora risk 
factor between two populations with a different baseline risk, such as gene carriers and 
non-gene carriers. 
Future approach 
A case-control study can be considered an efficient way to study risk factors for a 
chronic disease as compared to the following up a complete population.!S This design is 
widely used in scientific disciplines ether than epidemiology. However, case-control 
studies are rather susceptible for reeall bias and exposure suspicion bias, when exposures 
are assessed by interviews. Therefore, there is a need to confirm risk factors that have 
emerged in case-control studies of AJzheimer's disease conducted to date in prospective 
fellow-up studies, in which exposure to the risk factor is measured befare the onset of 
disease. Future studies also have to resolve the problem of selection bias, in particular 
related to the in dusion of prevalent cases. A feasibJe way to evereome bath types of bias 
may be to incorporate studies of risk factors in incidence studies.~ Such studies are 
already in progress.3~ Although data collection of events that occurred in the past (e.g. 
medical history) may still be subject to measurement error, an important advantage is 
that bias will no Jonger be associated \V'ith case-control status. An evident drawback of 
this design is that it only aiiows to study risk factors acknowledged at baseline 
measurement, unless exposure can be rneasured in stared blood samples. Therefore, in 
order to test a new hypothesis, a retrospective case-control study of incident cases may 
be a more efficient design. 
There are several methodologie issues to be anticipated :in follow-up studies of 
Alzheimer's disease. As the onset of Alzheimer's disease is insidious,1 cases are always 
diagnosed some time after the disease onset. Thus, selection bias may occur in studies 
of incident cases with a late-onset disorder like Alzheimer's disease due to mortality or 
migration during follow-up, albeit to a lesser ex1ent than i11 a study of prevalent cases.~ 
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ln particu1ar, this may occur in the old age category, in which the highest percentage of 
new cases will emerge while rnortality in this group is highest and may be associated with 
putative risk factors as well as with Alzheimer's disease. The magnitude of this problem 
will be determined mainly by the time between the baseline measurement and the follow~ 
up examination. To enable a complete follow-up, this period ls to be as short as possible. 
Yet, as the disease progresses s1owJy in most cases, one may also piea for a Jonger period 
of follow~up in order to exclude the possibilîty of the presence of sub~clinical disease at 
the baseline measurement. A rather costly and time-consurning salution rnay be to 
examine the popuiatien several times with short periods of follow-up between the 
examina ti ons. Since there is a high likelibood that mortality will occur during the peri ad 
of follow-up, a complete ascertainmem of incident cases requires consideration of the 
occurrence of Alzheimer's disease among those who died befare the follow-up 
examination. As death certificates have proven to be unreliable to assess Alzheimer's 
disease,33 forrnal attention should be given to criteria for the diagnosis of Alzheimer's 
disease based on informant interviews of relatives and of physicians. Another point of 
concern is that bias may occur when the disease is diagnosed eariier in those exposed to 
certain risk factors (e.g. head trauma ar other medical conditions).z:~ An important aspect 
of the diagnosis of disease to be considered is therefore the definition of onset age. 
A different approach that may be fruitful to follow in prospective follow-up studies 
may be to study risk factors associated with cognitive decline. Clearly, a study of cognitive 
declîne wili overcome probieros related to the diagnosis of Alzheimer's disease and the 
defînition of onset age, which limit at present the interpretation of studies conducted in 
the elderly. Although such a design will nat yield information on the risk of any type of 
dementia specifically, such studies rnay be relevant frorn a public health point of view. 
Potentia! pitfalls, however, result frorn the rneasurement of the level of cognitive function 
as well as cognitive decline, which may be determined by cohort effects and factors such 
as pre~morbid intelligence, education and socio-economie status. Furthermore, the 
association between baseline level and change in cognitive function requires attention in 
the study design as well as in the data-analysis. 
There are tv.ro strong points to link studies of heredity to epidemiologie incidence 
studies. Firstly, in order to study the extent of genetic involvement,. an unseJected 
popuiatien of cases should be investigated and this condition is met in a study of patients 
derived from a population~based incidence study. Secondly, the growing body of evidence 
for a role of non~genetic factors in familial aggregation of Alzheimer's disease (see 
chapter 3.3) implies that the power of studies of inheritance may be increased 
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considerab1y by taking into account the .influence of other risk factors as putative 
confounders. Regressive rnadeis may be used to conduct such analyses.34 
Studies of segregation of Alzheimer's disease conducted to date have been limited to 
first degree relatives. In future research, larger pedigrees including more distant relatives 
shou]d preferab1y be studied to provide evidence on the number of major gen es involved35 
and to disentangle poiygenic and environmemal effects. A specific methodologie issue to 
be addressed in genetie-epidemiologie studies is the use of family history of dementia as 
an indicator for genetic susceptibility in the absence of a biologie genetic marker. To 
increase the reliability, one would prefer to assign a probability to each case that the 
disease is of genetic crigin varying frorn 0 to 1 rather than to use a dichotomous outcome 
such as family history positive ar negative. To establish such a measurement requires an 
ex'tensive study of pedigree data and risk factors simultaneously. Farrer and coworkers 
are at present conducting such a study (personal communication). In light ofthe evidence 
for genetic heterogeneity (see chapter 3.3), it may be argued that at present studies of 
gene-environment interaction should preferably be conducted among families in which 
linkage to genetic markers ar the underlying mutation is known, as interaction may be 
specific to the mutation involved. Age of ons et may be an important measure of outcome 
in such studies. 
It may be concluded that long term follow-up studies, preferably population-based, of 
families well characterised from an epidemioiogic and genetic point of view, are needed 
to study the genetic transmission of Alzheimer's disease. 
Conclusions 
The validity of the case-control studies of risk factors for Alzheimer's dîsease 
conducted to date is limited. Therefore the risk factors that have emerged from these 
studies need to be confirmed in prospective follow-up studies of incident cases in which 
exposure to the risk factor is measured at baseline. Although this design may resolve the 
problems of reeall bias and e'1'osure suspicion bias, difficulties related to selective 
mortality of cases require consideration in follow~up studies. To clarify the mode of 
inheritance, segregation of A.lzheimer's disease should be studied in extensive pedigrees 
including several generations. At present, popuiatien studies on the interaction between 
hereditary and environmental factors are lirnited by the Jack of a biologie genetic marker 
suitable for popuiatien studies. 
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Genetic and environmental 
risk factors for Alzbeimer's disease 
The scope of this chapter is to place the evidence for risk factors for Alzhehner's 
disease provided in this thesis in a perspective of the current know1edge of the etîology 
of Alzheimer's disease. The evidence wil! be discussed for: (1) genetic factors, including 
farnily history of dementia and related disorders as well as the possible underlying genetic 
mechanisrn and origin; (2) environmental risk factors, including all factors that are nat 
inherited such as parental age, medical history, smoking, alcohol consurnption and 
occupationai exposures; and (3) gene-environment înteraction. 
Genetic factors 
Family history of dementia 
There is little doubt that Alzheimer's disease aggregates within families. There has 
been debate, however, on whether the strength of familial aggregation of Alzheimer's 
disease may vary with age of onset. It has been suggested that familial aggregation of 
Alzheimer's disease may be specific to patients with early-onset of d:isease.1 
As expected, the collaborative re-analysis of case-control studies of Alzheimer's disease 
supported familial aggregation of dementia (chapter 3.2) as did the study of risk of 
possible Alzheimer's disease in first degree relatives of patients with early-onset 
Alzheimer's disease ( chapter 3.3). The observations of the re-analysis of case-control 
studies presented in chapter 3.2, showed an association between family history of 
dementia and early-onset as wellas late-onset AJzheimer's disease. Among patîents with 
an onset of disease after 80 years, there were significantly more subjects with one or 
more first àegree relatives with dementia as cornpareà to controls. However, the risk 
decreased with increasing onset a ge. The lower risk of late-onset Alzheimer's disease was 
due to a lower prevalenee of dementia arnong parents of cases with late-onset 
A1zheimer's àisease. As environmental exposures are likely to be more similar among 
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siblings than for parents and siblings, it may be speculated tbat familial aggregation of 
late onset Alzheimer's disease may in part be of non-genetic or multifactorial origin. 
Although there is concern that such a pattem may also be created by selective censoring 
( chapter 3.2), the view of genetic heterogeneity derives support from a study of risk in 
first degree relatives of patients with familial Alzheimer's disease.2 This study showed that 
when the eensering age is taken into account, the risk among relatives of patients with 
late-onset Alzheimer's disease was significantly higher than expected for an autosomal 
dominant disorder, suggesting that environmental factors may play a role in familial 
aggregation. 
Family history of Down's syndrome 
There is much evidence fora link between Alzheirner's disease and Down's syndrome, 
since neuropathologie changes of the Alzheimer type as well as dementia are frequently 
found in patients with Down's syndrome.:;.s Another finding suggesting chromosome 21 
may be implicated in Alzheimer's disease is the higher frequency of patients with Down's 
syndrome that bas been observed in the family of patients with Alzheimer's disease.1 As 
reviewed in chapter 3.2, studies of family history of Down's syndrome have yielded 
equivocal results, which may in part be explained by the relatively low ra te of occurrence 
of Down's syndrome. A significant increase in risk of A.Izheimer's disease for those with 
a first degree relative with Down's syndrome was shown in the re-analysis of case-control 
studies (chapter 3.2). A previous study of familial aggregation of Down's syndrome and 
Alzheimer's disease suggested that the risk of early-onset Alzheimer's disease was only 
increased.1 This hypothesis was rejected by the re-analysis; there was evidence for familial 
aggregation in early-onset as well as late-onset patients. This finding is of particular 
interest because it suggests a link with chromosome 21 for bath early-enset as well as 
late-onset Alzheimer's disease. To date there is debate whether the late-onset farm is 
linked to cbramosome 21.' A potential souree of bias which needs to be addressed in 
future studies is the age of the mother at birth of the relative with Down's syndrome, 
which was nat available in the present studies. 
Familial aggregation ofDown's syndrome and Alzheimer's disease was observed in the 
absence of a first degree relative with dementia (chapter 5.4). The risk of Alzheimer's 
disease for those with a family history of Down's syndrome tended to be higher for tbose 
with a positive family history of dementia (chapter 5.4). This finding is compatible with 
a genetic link between the disorders. The association with the sparadie farm may be 
explained by misclassification of gene-carriers. Another exp1anation may be inferred from 
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a hypothesis put forward by Potter,' suggesting that accumulation of trisomy 21 cells 
during Jife may underlie familial as well as sparadie Alzheimer's disease.7 According to 
this view, there may be an increased frequency of nondisjunction of chromosome 21 
during mitosis in patients with AJ.zheimer's disease resulting in trisomy 21 in somatic cells. 
This may lead to the Alzheimer's disease pathology through the same mechanism by 
which patients with Down's syndrome develop the disease. Nondisjunction during meiosis 
in these patients would genera te trisomy 21 germ cells, thus increasing the risk ofDown's 
syndrome in the offspring. Such a process may occur sporadically, perhaps induced by 
factors such as late matemal a ge or neurotoxins.7 Non-disjunction mayalso be influenced 
by genetic factors, e.g., by mutations in or near the centromere,7 resulting in a strenger 
association among these with a positive family history of dementia. Patients with 
Alzheimer's disease whose lymphocytes were mosaic for trisomy 21 but who did nat have 
the phenotype of Down's syndrome have been reported and in one case, the patient had 
a Down's child.'' Cytogenetic studies of aneuploidy in Alzheimer's disease have yielded 
contradicting results, 1o.15 however, non-disjunction does not need to occur in all cells and 
may therefore easily go undetected.7 Future cytogenetic studies, using interphase 
techniques and various tissue sections of patients from families in which Alzheimer's 
disease and Down's syndrome aggregate, may be used to test this hypothesis. 
Family history of Parkinson's disease 
Alzheimer's disease and Parkinson's disease share several neuropathologie 
characteristics.16 It has been suggested that these disorders may have a camman 
pathogenesis.17 This hypothesis was supported by the re-analysis of case-control studies, 
that suggested familial aggregation of Alzheimer's disease and Parkinson's disease 
( chapter 3.2). The association tended to be strenger in men as eeropared to wamen. 
Although the risk of Alzheimer's disease for these with a positive family history for 
Parkinson's disease was increased in the absence of a first degree relative with dementia, 
the risk tended to be higher for these who had a positive family history of dementia as 
wel! (chapter 5.4). The stronger association with family history of Parkinson's disease 
among men and among those with a positive family history of dementia may be exp1ained 
by the hypothesis that Parkinson's disease rnay be of rnultifactorial origin, meaning that 
genetic as weli as environmental factors are required to increase the risk of the disease.18 
The strenger association in these with a positive family history of dementia may be 
explained by a genetic link between Alzheimer's disease and Parkinson's disease, while 
the strenger association in men may be explained by environmental factors to which men 
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in particular are exposed, for examp1e occupational exposures. Such a mechanism 
remains to be resolved in genetie-epidemiologie studies. 
Genetic mechanism 
As presented in chapter 3.2, the re-analysis of case-control studies showed a difference 
in risk for those with two ar more first degree relatives with dementia as compared to 
those with one affected relative. Such a trend was observed for early- as well as late-onset 
Alzheimer's disease and may point at heterogeneity. The view of heterogeneity in early-
onset Alzheimer's disease was supporteà by a segregation analysis using data of fust 
degree relatives of 198 patients with early-onset Alzheimer's disease (chapter 3.3). This 
analysis confirmed a role of a major dominant gene in early-onset Alzheimer's disease. 
Our data suggested, however, that it is unlikely that a major dominant gene effect 
accounts for the total varianee in transmission of Alzheimer's disease. Other genetic 
mechanisms or environmental factors may account for the familial aggregation of disease 
in a considerable number of cases. Similar findings have been reported for a populatîon 
comprising patients with early-onset as well as late-onset Alzheimer's disease.19 
Genetic origin 
Linkage between early-onset A.lzheimer's disease and markers on the proximal long 
arm of chromosome 21 was first reported in 1987.~ In the same year the gene coding for 
the amyloid precursor protein (APP), a precursor of the A4 protein deposited in the 
brains of patients with Alzheimer's disease anà Down's syndrome, was located to the 
sameregion of chromosome 21.::1 As two studies excluded the APP gene as the cause of 
Alzheimer's diseasezz.:::~ and since genetic heterogeneîty in early-onset Alzheimer's disease 
was nat yet considered at that time, molecular genetic research concentrated on the 
search for other mutations on cbramosome 21. Although in the following years a number 
of studies confirmed linkage to cbromesome 21, linkage was excluded by others.Z4-28 After 
pooling the data of 48 families in which Alzheimer's disease was apparently inherited as 
an autosomal dominant disorder, linkage to cbramosome 21 was confirmed for early-
onset Alzheimer's disease but excluded for late-onset Alzheimer's disease.28 For the latter 
patients, linkage to chromosome 19 has been reported.;:<l At present it is unclear what 
proportion of the families with Alzheimer's disease is linked either to chromosome 19 or 
to chromosome 21. 
In view of the growing eviàence for genetic heterogeneity, the possibility that a 
mulation in the APP gene may lead to Alzheimer's disease in a subset of families with 
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early-onset Alzheimer's disease was reconsidered by Goate and coworkers.:;o In 1991 they 
reported a mulation in exon 17 (transcript APP770) of the APP-gene in two families that 
showed linkage to APP on chrornosome 21. This mutation was a]so found in four other 
families in which early-onset Alzheirner's disease was inherited as an autosornal dominant 
disorder.30.31 To assess the role of the APP717 mutation as a cause of early-onset 
Alzheimer's disease in the general population, we screened 100 patients with fru-nilial and 
sparadie Alzheimer's disease but faileà to show the mutation reported by Goate et al 
(chapter 3.4). Our finding suggests that this APP717 mutation is nat a camman cause of 
early-onset Alzheimer's disease in the Dutch population. However, it cannot be excluded 
that other mutations in the APP gene may be involved in Alzheimer's disease. To date, 
two ether mutations at codon 717 of the APP-gene were reported.3::.)J 
For Hereditary Cerebral Haemmorhages With Amyloidosis of the Dutch type 
(HCHWA-D) a mutation has been detected in exon 17 of the APP-gene, at residue 693 
(APP ",).~"' HCHW A-D brains are characterized by B-amyloid angiopathy, but amorphous 
plaques have been shown as well. Since a great number of patients w:ith Alzheimer's 
disease have B-amyloid angiopathy, it has been suggested that the E-amy1oid in the senil.e 
plaques may be of vascu1ar origin.:\6 It is of interest that in one of the Rotterdam families 
(family 1302), intra-cerebral bleedings and dementia appeared to segregate tagether 
(unpublished findings). In this family, there was one subject with intra-cerebral 
haemmorhage (a ge 40 years) due to amyloid angiopathy confirrned at biopsy. In this 
pa ti ent, amyloid reactive senile plaques were found in actdition to the arnyloid angiopathy. 
None of the rnutations in the APP gene reported to date were detected in this patient. 
In this five generation family, one other living patient was known with intra-cerebral 
bleedings, while four others suffered from a slowly progressive dementia, probably of the 
Alzheimer type. No massive bleedings were observed in the patients with dementia. As 
the intra-cerebral bleedings and the dementia appeared to segregate tagether in this 
family, it is tempting to specula te that in this family cerebral haemrnorhage and dementia 
rnay have the same genetic origin. However, in the absence of pathologie confirmation, 
it is at present impossible to distinguish whether the patients with dementia suffer from 
dementia due to B-amyioid angiopathy or from Alzheimer's disease. 
DNA repair 
Another possible mechanisrn irnplicateà in the pathogenesis of .AJzheimer's disease is 
DNA repair. Increased levels of DNA-damage have been found in cortex tissue of 
patients with AJzheimer's disease.~7 This finding may be the result of an increased level 
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of exposure to DNA darnaging agentsin patients, but it is also conceivable that patients 
with Alzheimer's disease may have a decreased DNA repair capacity. As reviewed in 
chapter 3.5, studies of DNA repair using fibroblast or lymphoid celllines of patients with 
Alzheimer's disease have yielded equivocal results.:lS-4..1 We observed a delay in DNA 
repair of single~strand breaks induced by N-ethyl-N-nitrosourea in freshly isolated 
lymphocytes of patients from families in which Alzheimer's disease is apparently inherited 
as an autosomal dominant disorder ( chapter 3.5). Th ere was no evidence for a decrease 
in DNA repair capacity in the other patients, suggesting DNA-repair may only be 
implicated in inherited early-onset Alzheimer's disease. However, as pointed out in 
chapter 3.5, our study must be considered as exploratory and our findings remain to be 
confirmed by independent studies. 
Environmental factors 
Parental age 
The ro1e of parental age in AJzheimer's disease is debated.44 To date 12 studies have 
reported on this issue, yielding contradicting results.~s.56 Four studies have reported a 
significant association to late matemal age,45.4<>.5l.53 while two studies reported a significant 
increase in risk for young matemal age as well as young paternal age.50.s6 Of the latter 
studies, the most recent one showed that the association with young matemal age 
disappeared when adjusting for paternal age, while the association with paternal age was 
specific for late-onset Alzheimer's disease.5t> As a corollary of these contradicting fîndings, 
there are two competing hypotheses on the underlying mechanism. For late matemal age, 
the association has been e\-plained by the link with Down's syndrome. This hypothesis 
prediets that the risk of Alzheimer's disease follows the risk of Down's syndrome, which 
increases slowly with increasing matemal age until age 30 years and rapiàly thereafter.44 
According to the second more speculative hypothesis, the association of late-onset 
Alzheimer's disease with young paternal a ge may be explained by genetic imprintin~, i.e., 
patients have inherited an increased predisposition to the disease through a particular 
parent.56 
The findings of the re-analysis of case-control studies as presented in chapter 4.2 did 
nat show an association with patemal age, when matemal age and paternal age were 
studied simultaneously and data were analyzed stratified by gender and onset age. The 
findings provided weak support for an association between Alzheimer's disease and late 
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matemal age. Although the risk of Alzheimer's disease was significantly increased among 
subjects whose mother was 40 years or o1der at birth, the association was mainly 
determined by one study. At the same time, there was also evidence for an increased risk 
of early-onset Alzheimer's disease foryoung matemal age (19 years or younger), although 
this association could also be attributed to the strong relation observed in one study. In 
the paoled analysis, there was no evidence for an increase in risk of Alzheimer's disease 
for matemal age at birth between 20 and 40 years. 
The persistent discrepancies between the findings on this putative risk factor give rise 
to the hypothesis that, as opposed to the idea of two competing hypotheses on the role 
of parental age in Alzheimer's disease, the association may be determined by two 
different mechanisms: (1) young parental age may be a risk factor for Alzheimer's 
àisease, through an unknown mechanism, perhaps related to genetic imprinting and (2) 
late maternal age may be associated with an increase in risk of Alzheimer's disease, 
perhaps due to a chromosome 21 linked mechanism.7 These two potential mechanisms 
may outbalance each ether and therefore :it is conceivable that their effects can only be 
shown at bath extremes of the parental a ge distribution, which in most studies comprised 
only a limited number of subjects. In such a situation, camparisen of means of parental 
age wîll be of little use and a large nurnber of patients need to be studied to show a 
significant assodation :in the e:x1remes of the dis tribution of parental age. Another issue 
to address in future research :is related to the assessment of the parental age at birth. 
Although agreement between the next of kin interview and direct :interview was shown 
to be high (88% )," the informants could nat provide us with data on parental age for 
17% of the cases and 11% of the controls. Finally, studies of the role of the sex of the 
transmitting parent on age of onset in aftspring (imprinting) and changes in age of onset 
in offspring (anticipation) may be of interest in light of the contradicting findings on the 
role of matemal and paternal age in Alzheimer's disease. 
Head trauma 
The similarity in pathology bas led to the hypothesis of a camman pathogenesis of 
Alzheimer's disease and dementia pugilistica (punch drunk syndrome ).5"" Head trauma 
was studied in chapter 4.2, based on the re-analysis of case-control studies, and in chapter 
4.3, based on the Dutch case-control study. In the re-analysis of case-control studies, an 
association with Alzheimer's disease could be shown only in men. Although the 
association was strengest for head trauma that occurred within ten years befare the 
disease onset, a significant e1evation in risk was also observed in the re-analysis for head 
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trauma that occurred more than ten years befare the onset of àisease. By contrast, the 
Dutch study suggested that the risk of Alzheimer's disease was increased only within the 
ten year period befare the disease onset, in men and wamen. These findings suggest a 
short lag-time between the head trauma and the occurrence of disease. No association 
was found with head trauma that occurred early in life. This finding is compatible with 
the view that head trauma may interact with a sub-clinical disease process. It :is also 
conceivable that head trauma may interact with an age-related process, e.g. a decrease 
in regeneratien capacity of the brain at old age. 
Despite the apparently consistent findings of epidemiologie studies (reviewed in 
chapter 4.3), there are several reasans for challenging the interpretation of a causa! 
relationship. There is considerable scope for reeall bias for events that occurred long 
befare the disease onset. For head trauma occurring close to the disease onset, we cannot 
exclude the possibility that the head trauma may be a consequence of an early stage of 
the dementia. Furthermore, the only prospective fellow-up study based on data obtained 
from medical records of the Roehester register showed only a slight non-significant 
elevation in risk (chapter 4.2). Therefore, todetermine the etiologie significanee of the 
relation between head trauma and Alzheimer's disease, the association remains to be 
confirmed in a prospective fellow-up study. 
Medica! history 
A great variety of disorders have been linked with Alzheimer's disease, but many of 
these associations appeared in one or two studies and were nat rep1icated in others. As 
pointed out in chapter 4.2, eautien is warranted when interpreting the findingsof the re-
analysis of case-control studies on meàical history. Bias, multiple testing and data 
dredging apply particularly to these analyses.30 Moreover, as exposures are usually rare 
and the precision in assessing the disease history ar previous treatment is generally low, 
it may be argued that a perhaps more fruitful approach to study medica! history may be 
to conduct a prospective fellow-up study based on historica! cohorts defined within a 
morbidity register, e.g. using the medical records of the Roehester register ( described in 
chapter 2.2). 
There is some evidence for an association between Alzheimer's disease and history of 
hypothyroidism. In the Roehester study, an increase in risk was observed for history of 
hypothyroidism, albeit non-significant. However, exposure frequency was low in cases 
(10/392) and controls (6/392). The re-analysis of case-control studies confirmed this 
finding ( chapter 4.2). The association between Alzheimer's disease and hypothyroidism 
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may be of partienlar interest because of the role of the tbyroid hormone on maturation 
of the nervous system and on neuritic outgrowth.61-63 The thyroid hormoneis furthermore 
related to ether horrnanes and trapbic factors that have been implicated in Alzheimer's 
disease.64 There are several arguments which plea for cautious interpretation: (1) earlier 
studies yielded contrameting results," (2) the classification for type of tbyroid disorder 
may be criticized as it was based on functional status as reported by informants, who, 
with the exception of the Roehester study, were nat medically trained, (3) altbough an 
association could be shown to hypothyroidisrn, from a statistica! point of view skepticism 
on this relationship results from the lack of an assoc:iation to all thyroid diseases 
combined, and ( 4) hypothyroidism can be a cause of secondary dementia and such cases 
may not have been recognized. Therefore, it is acknowledged that this finding is to be 
considered as tentative. The association with hypothyroidism must be confirmed 
preferably in a prospective fo!low-up study of well-defined, non-demenled cases witb 
hypothyroidism. 
Increased levels of acute-phase proteins have been reported in patients with 
Alzheimer's disease.65-67 lt bas been demonstrated that the production of acute-phase 
proteins is in part mediated by lyrnphokines such as interleukin-I and interleukin-6." As 
presented in chapter 4.4, serum levels of inter]eukin-6 were nat associated with 
Alzheimer's disease. However, this finding does nat exclude the possibility that 
interleukin-6 is locally elevated within the brain and may in this way be related to 
Alzheimer's disease. 
Psychiatrie bistory 
In the re-analysis of case-control studies, history of depression that was medically 
treated emerged as a risk factor for Alzheimer's disease, in particular for the late-onset 
farm ( chapter 4.2). There were two findings that overruled concern of bias with regard 
to thls relationship. Firstly, the association was present in tbe Roehester study, which 
avereames tbe problem of reeall bias as this prospective study is based on medica! 
records. Secondly, a significant association was observed for episodes of depression that 
occurred more than ten years befare the disease onset, suggesting a true association 
rather than the depression being the result of the dementia. 
There are several possible explanations for the association between history of 
depression and Alzheimer's disease possible.tfj Anti-depressant treatment is to be 
considered as an explanation, as it may alter neurotransmitter functioning. Because in our 
study there were only limited data available on type of medication and duration of use, 
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we can nat excbde this possibi!ity. Another explanation may be a joint etiology of bath 
disorders. Systems disrupted in depression may also be involved in Alzheimer's disease. 
lt is also conceivable that the depression is an early symptom of Alzheimer's disease, that 
may occur befare the first symptoms of dementia. As patients with depression may 
already have subtle cognitive deficits, it is also possibJe they may reach more quick.ly the 
threshold for the diagnosis of dementia. These explanations are nat exclusive. They all 
assume heterogeneity in the pathogenesis of early- and late-onset Alzheimer's disease in 
order to explain for the association to late-onset Alzheimer's disease specifically. 
Despite the evidence for an association to history of depression, further studies on 
incidence of AJzheimer's disease in confirmed cases with depression are needed to study 
the re!ation with specific types of depression (bipolar, unipolar). Furthermore, the role 
of electro-convulsive therapy and prior medica ti on, in particular those with anticholinergic 
effects, need to be addressed. The difference between early- and late-onset Alzheimer's 
disease requires further investigation in light of the possibility of genetic heterogeneity 
between the early- and Jate-onset farm. 
Smoking, alcohol and occupational exposures 
There is some evidence from clinical trials that nicotine may imprave information 
processing and attention in Alzheimer patients.70'71 The mechanism underlying this 
association may be related to the decreased nicotinic receptor binding, which has been 
linked to the Alzheimer type pathology.nn Nicotine has been reported to increase the 
density of nicotinic receptars in the brain.74 We may specula te that nicotine from cigarette 
smoke may compensate the loss of nicotinic receptars in AJ.zheimer's disease and may 
thus delay the progression of .A.lzheirner's disease. Such a mechanism would predict an 
inverse association between smoking and .A.lzheimer's disease. Indirectly, this hypothesis 
derives support from the fact that a decrease in nicotinic receptor binding bas a!so been 
observed in patients with Parkinson's disease, while the major:ity of studies of Parkinson's 
disease have reported an inverse association with smoking.75 
The fust evidence fora possible inverse association with smoking history was obtained 
in the Dutch case-control study of early-onset AJzheimer's disease ( chapter 5.3). In this 
study, we were able to show that it was unlikely to ex-plain the relation by (1) selection 
bias due to the exclusion of patients with evidence of atherosclerotic cardiovascular 
disease in the clinical diagnosis of Alzheirner's disease, and (2) by differential survival of 
smoking and non-smoking patients. The findings of the Dutch study were supported by 
the re-analysis of case-control studies ( chapter 4.2). Furthermore, in the re-analysis 
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(chapter 4.2) as wel! as in the Dutch study (chapter 5.3) there was evidence fora dose-
response relationship when smoking was analyzed stratified accordîng to the number of 
pack-years smoked. An inverse relationship between smoking and Alzheimer's disease 
could on1y be shown among patients with a positive family history of dementia. Th ere was 
no association among those with na first degree relatives with dementia in the Dutch 
case-control study ( chapter 5.3) or in the re-analysis of case-control studies (chapter 5.4), 
suggesting that smoking may interact with a genetically determined process. 
The roie of smoking in Alzheimer's disease reguires further study. Ta fully evereome 
the problem of bias due to mortality related to smoking, a preferably popuJation-based 
study of incident cases has to be conducted. Although the association we observed is 
compatible with a protective effect of smoking for farnilial Alzheimer's disease, it bas no 
relevanee for prevention of AJzheimer's disease because of the actverse health effects of 
smoking. Moreover, we cannot exclude the possibility that preclinical changes in for 
instanee nicotinic receptars may have resulted in a loss of desire to smoke in patients 
with familial .A.lzheimer's disease. 
There was no evidence in the re-analysîs of case-control studies for an increase in risk 
of Alzheimer's disease for alcohol intake ar for occupational exposure to lead or solvents 
( chapter 4.2). These findings should be treated with caution. Cases with high alcohol 
intake rnay have been excluded when applying the criteria for possible or probable 
AJzheimer's disease and this may have led to an underestimation in risk.7" The freguency 
of exposure to lead and solvents was low, even when the studies were pooled, and 
exposure definition bas been imprecise forthese putative neuroto>dns.77 
AJuminurn 
Aluminumsilicates are found in the cores of senile plaques and :in neurones containing 
neurofibrillary tangles.n However, it rernains to be establisheà if the presence of 
aJuminurn is a cause ar a consequence of the disease. Case reports of subjects exposed 
to high doses of aJuminurn which led to high concentrations in the brain suggest that the 
exposure does nat lead to pathologie changes specific for Alzheimer"s disease.7'1-81 Yet, 
several studies reported an association between aJuminurn intake through drinking water 
and the risk of Alzheimer's disease, despite the fact that water contributes oniy a small 
percentage of aJuminurn intake.~-&1 However, there is considerable scope for bias in these 
observational studies. In the earliest study, dementia was assessed by death certificates,~ 
a methad which has been shown to be unreliab1e.ss.66 The $tudy by Martyn et al83 may be 
criticized because the diagnosis of .A.lzheimer's disease was based on cr-scan readings 
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without clinical examinatien of the patients. Further, the association was mainly due to 
an increase in risk for the highest exposure category, without showing convincing evidence 
fora dose-response relationship. Finally, the findings of a relationship in the most recent 
stud~ could nat be replicated after re-measurement of the aJuminurn content of the 
àrinking water (personal communication). 
A roJe of aJuminurn in Alzheimer's disease was supported by three other findings. 
Firstly, a higher risk of Alzheimer's disease was observeà for miners who were treated 
with aluminum powder.87 Secondly, a case-control study based on informant interviews 
reported an increase in risk of Alzheimer's disease for subjects using aJuminurn 
containing antiperspirants.88 Thirdly, a sJower progression of the disease in patients with 
Alzheimer's disease treated with aJuminurn binding chemieals was reported, suggesting 
aluminum may be involved in the progression of the disease.89 On the other hand three 
case-control studies that have investigated the role of aJuminurn containing antacids failed 
show an association.51,90'91 
AJthough a number of studies provided evidence fora relationship of aJuminurn with 
Alzheimer's disease, one cannot escape the condusion that the role of aluminum in 
Alzheimer's disease remains to be clarified. In particular, the interaction with genetic 
susceptibility or other risk factors may be of interest, as it remains to be resolved how 
aJuminurn îs able to pass the blood-brain harrier. It is possible that genetic factors and 
environrnentai factors (e.g. head trauma) may enable aluminurn to enter the brain. On 
the ether hand, it is also conceivable that aluminium merely exacerbates the effect of 
ether risk factors, asthereis evidence that aluminium is implicated in the progression of 
Alzheimer's disease. 
Education 
Education may be related to Alzheimer's disease through several mechanisms.-r.. It is 
conceivable that highJy educated subjects have greater cognitive or neuronal reserves than 
poorly educated subjects and therefore can lose more neurons due to AJzheimer's disease 
befare showing symptoms of the disease. lt is also possible that the highly educated 
practice their cognitive skilis more intensively during their lives than these with a low 
education and it has been suggested that Jack of intellectual stimulation may lead to an 
increased risk of neuronalloss and Alzheimer's disease.Q3 A third possibility is that low 
education may mereiy be related to socio-economie status and that lifestyle and 
occupational exposures may be underlying the association with AJzheimer's disease. 
AJthough education has been linked to cognitive decline and dementia in a large 
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number of studies, the interpretation of these findings bas been hampered by the 
possibility of assessment bias.92 When the ascertainment of patients is accomplished 
through screening for cognitive impairment, an association with education rnay result 
from the fact that the scores of those screening tests may in part be determined by the 
subjeet's level of education. As an example of the difficulties encountered when 
interpreting findings on the re1ation between Alzheimer's disease anà education, may 
serve the findings of a population-based prevalenee study conducted in Shanghai China.~ 
This study showed an association between education and AJ.zheirner's disease, which was 
mainly determined by wamen in the old a ge category. The interpretation of this finding 
is nat straightforward as education-dependent cut-off points for the screening instrument 
were used and effect modification by gender may be explained by inadequacy of the 
screening test in wamen. Another exarnp1e may be the findings of the Dutch case-control 
study, as reported in chapter 2.1. The findings were compatible with the view of an 
inverse association between AJ.zheimer's disease and education, astherewas an increased 
risk for those who received less thanseven years of education (chapter 2.1). However, 
we cannot rule out the possibility that bias bas occurred due to selective non-response 
among control subjects with low education. 
It rnay be concluded that the ev:idence for an association of education wîth Alzheimer's 
disease is still weak. The major difficulty to averearoe is to deal wîth methodologie 
problems, in particular that of assessment bias in population-based prevalenee and 
incidence studies. Furthermore, the hypothesis that life-style, occupational or medica! 
exposures may explain the relationship needs to be examined in future studies. 
Gene-environment interaction 
For family history of Down's syndrome, family history of Parkinson's disease, late 
matemal age, hîstory of head trauma and history of depression, the association with 
Alzheimer's disease was observed regardless of the absence or presence of a fust degree 
relative with dementia (chapter 5.4). An additional analysis using the data of the re-
analysis of case-control studies showed that hypothyroidism and young matemal age were 
also associated with an increased risk of AJzheimer's disease for those with and without 
a positive family history of dementia (unpublished data). Because family history of 
dementia remained strongly associated with AJzheimer's disease in the absence of other 
risk factors, these findings are consistent wîth a model in which genetic and 
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environmental risk factors may increase the risk of Alzheimer's disease independently of 
each other. For late matemal age, history of head trauma, history of depression and 
historf of hypothyro.idism, the strength of association did not vary when stratifying for 
family history of dementia, suggesting there is no interaction with a genetic factor. 
However, as pointed out in chapter 6.2, due to misclassificatîon resulting from the use 
of family history of dementia as an indicator for genetic susceptibility, the possibility that 
genetic factors may underlie these environmental factors cannot be excluded. Such a 
mechanism .is conceivable in particular for history of depression and histo:ry of 
hypothyroidism. Tbe risk for family history of Down's syndrome, for family history of 
Parkinson's disease and for young matemal age tended to be higher for those who had 
a positive family history of dementia. However, in all cases the interaction was not 
statistically significant, but this may be due to the small number of e:;..:posed patients and 
controls. There is sorne evidence suggesting that smoking may merely interact with a 
genetically determ.ined process. An association was found only among those with one or 
more first degree relatives with dementia (chapter 5.3 and 5.4). The re-analysis of case-
control studies showed that the risk associated with family history of dementia tended to 
be Jower forsmokers as compared to non-smokers ( chapter 5.4). Although no significant 
differences could be established, this effect was most pronounced for those with two or 
more affected relatives. The Dutch genetie-epidemiologie study of early-onset Alzheimer's 
disease showed that the disease onset was significantly later in smoking patients as 
compared to non-smoking patients from families in which the disease is apparently 
inherited as an autosomal dominant disorder ( chapter 5.3). Because there is familial 
a~oregation of Alzheimer's disease and Parkinson's disease and Parkinson's disease bas 
been found to be inversely associated with smoking as well, it rnay be speculated that 
smoking may modify the risk of a genetic factor that is invoived :in Alzheimer's disease 
as wen as Parkinson's disease. 
Condnsions 
The findlngs of this thesis may be summarised as fellows: 
1. There is evidence for familial aggregation of early-onset as well as late-onset 
Alzheimer' s disease. 
2. Not all patients with ear1y-onset Alzheimer's disease can be exp1ained by autosomal 
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dominant inheritance, i.e., there rnay be other genetic or environmental factors 
implicated. 
3. There is some evidence for a genetic link between Alzheimer's disease and Down's 
syndrome and between AJzheimer's disease and Parkinson's disease. 
4. In all likelihood, there is more than one mutation involved in Alzheimer's disease, the 
one in exon 17 of the amyloid precursor protein gene3(1 being a rare cause. 
5. Decreased DNA repair may be implicated in inherited Alzheimer's disease. 
6. Parental age may be involved in Alzheimer's disease through several mechanisms. 
7. History of head trauma, history of depression and history of hypothyroidism may 
increase the risk of A1zheimer's disease regardless of the genetic susceptibility. 
8. Smoking may be inversely related to Alzheimer's disease, through a mechanism of 
genetic origin. 
Case-control studies have shown a great variety of risk factors to be associated with 
Alzheimer's disease. Many of these associations appeared only in one ar two studies and 
were nat replicated by ethers. Given the exploratory design of the epidemiologie studies 
conducted to date, at present there appears to be a need for studies designed to test 
specific hypotheses. As evidenced by the recent findings of several mutations in the 
amyloid precursor protein gene that are associated with A1zheimer's disease, it is like1y 
that Alzheimer's disease may be divided into many smaller subgroups based on genetic 
characteristics. As a consequence, interaction between genetic and environmental factors 
may becorne an important feature in epidemiologie studies and special attention should 
be paid to geneticaspects in the design of the study. An important assumption underlying 
current research on Alzheimer's disease is that we are dealing with a single disorder. One 
of the key questions to be answered is whether this assumption holds1 Ta resolve this 
issue, a strong link between the genetie-epidemiologie and molecular biologie approach 
is likely to be profitable. 
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Summary 
The aim of the investigations presented in this thesis was to study the role of various 
genetic and environmental factors in Alzheimer's disease, as well as the interaction 
between genetic and environmental risk factors (chapter 1). Risk factors for Alzheimer's 
disease were studied in a Dutch genetie-epidemiologie study of 198 patients with early-
enset Alzheimer's disease ( diagnosis befare 70 years) and 198 age- and gender-matched 
controls, and in a re-analysis of all forma! case-control studies conducted to January 1, 
1990, comprising a tata! of 1385 cases and 1739 age- and gender-matched controls. The 
design of the studies was described in ( chapter 2). 
In chapter 3, genetic factors were addressed. Familial aggregation of AJzheimer's 
disease and related disorders was studied in the re-analysis of case-control studies 
(chapter 3.2). When pooling the raw data of the studies, the risk of Alzheimer's disease 
for those with at least one first degree re1ative with dementia was significantly increased. 
Stratification according to age of onset of AJzheimer's disease showed that the risk 
decreased with increasing onset age. However, among patients with an onset of disease 
after 80 years, there were still significantly more subjects with one or more fust degree 
relatives with dementia as compared to controls. The risk of early-onset as well as late-
onset Alzheimer's disease was lower for patients who had one first degree relative with 
dementia as compared to those who had two or more affected relatives. Furthermore, 
the re-analysis showed an increased risk of Alzheimer's disease for those with a positive 
family history of Down's syndrome as we]] as for those with a positive family history of 
Parkinson's disease. The risk ofpossible Alzheimer's disease and the genetic transmission 
of disease were studied in first degree relatives of the 198 Dutch patients with early-onset 
Alzheimer's disease (chapter 3.3). Among first degree relatives of patients, the risk of 
Alzheimer's disease (0.39) was lower than expected for an autosomal dominantly 
inherited disorder, although the risk estimate did nat differ significantly from the 
expected risk (i.e., 0.50). Segregation analysis suggested that familial aggregation of 
Alzheimer's disease is most likely in part explained by a dominant major gene effect. 
Other genetic ar environmental factors may play a role in the etiology as well. A sample 
of 100 cases out of the 198 Dutch cases with early-onset Alzheimer's disease was 
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screened for a mulation within exon 17 (transcript APP770) of the amyloid precursor 
protein gene ( chapter 3.4). The study comprised 14 unrelated cases from families in which 
AJ.zheimer's disease was apparently inherited as an autosomal dominant disorder. None 
of the patients showed the mutation. This finding suggests that the mutation in the 
amyloid precursor protein gene is nat a camman cause of early onset Alzheimer's 
disease in the general population. As increased levels of DNA damage have been 
reported in Alzheimer's disease, DNA repair may be implicated in the pathogenesis. 
DNA repair after treatment of lymphocytes with alkylating agents was stuclied in 43 
patients with early-onset Alzheimer's disease and 48 controls ( chapter 3.5). Our study 
showed a delay in DNA repair of single-strand breaks induced by N-ethyl-N-nitrosourea 
in patients from families in which Alzheimer's disease was apparently inherited as an 
autosomal dominant disorder. There was no evidence for a decrease in DNA repair 
capacity in the other patients, suggesting DNA-repair may only be implicated in inherited 
Alzheimer's disease. However, our study must be considered as exploratory. 
Environmental ris!< factors were addressed in chapter4. The evidence for non-inherited 
risk factors for Alzheimer's disease was reviewed in chapter 4.2, based on the findings of 
the re-analysis of case-control studies. There was weak: evidence for an association of late 
matemal a ge at birth ( 40 years or older) with A!zheimer's disease. Although overall a 
significant elevation in risk was shown, this finding was mainly determined by one study. 
In addition, there was evidence for a relation between young matemal age (19 years ar 
younger) and early-onset Alzheimer's disease, but also this finding could be attributed to 
one study. No association was shown with paternal age, when adjusting for matemal age. 
In the re-analysis of case-control studies concerning medical history, history of 
hypothyroidism and history of depression emerged as two possible risk factors for 
Alzheimer's disease. An association between head trauma and Alzheîmer's disease could 
be shown only in men. Although the association was strengest for head trauma that 
occurred within ten years befare the disease onset, a significant elevation in risk was 
observed also for head trauma that occurred more than ten years befare the onset of 
disease. By contrast, the Dutch study of early-onset Alzheimer's disease suggested that 
the risk of Alzheimer's disease was încreased only for head trauma that occurred within 
the ten year period befare the disease onset, in men and wamen. No assocîation was 
found for head trauma that occurred early in life (chapter 4.3). In the re-analysis, an 
inverse relationship between smoking and Alzheimer's disease was observed ( chapter 4.2). 
An inverse relationship could only be shown among those with a positive family history 
of dementia. Furthermore, there was evidence for a dose-response relationship when 
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subjects were classified according to the number of pack-years they had smoked. The 
findings of the Dutch case-control study of early-onset Alzheimer's disease were very 
similar ( chapter 5.3). Increased levels of acute-phase proteins have been reported in 
patients with Alzheimer's disease. It bas been demonstrated that the production of acute-
phase proteins is in part mediated by interleukin-6. Serum levels of interleukin-6 were 
nat associated with Alzheimer's disease in a study of 97 patients with early-enset 
Alzheimer's disease and 79 controls (chapter 4.4), but this finding does nat exclude the 
possibility that interleukin-6 is locally elevated within the brain. 
Gene-environment interaction was discussed in chapter 5. In chapter 5.2, age at onset 
was examined for 139 memhers of 30 families in which early-enset Alzheimer's disease 
( onset befare 60 years) was apparently inherited as an autosomal dominant disorder. Age 
of onset was more similar within than between families. Although onset age within 
decades is most likely genetically determined in patients from such families, the relatively 
wide spread in onsetage observed within these families as well as within sets of identical 
twins suggests that environmental factors may influence the family-specific onset age. The 
issue of interaction between genetic and environmental risk factors was addressed in the 
re-analysis of case-control studies (chapter 5.4). For late matemal age, history of head 
trauma and history of depression, an association with Alzheimer's disease was observed 
regardless of the absence ar presence of a first degree relative with dementia. Since 
family history of dementia remained strongly associated with Alzheimer's disease in the 
absence of other risk factors, these findings are consistent with a model in which genetic 
and environmental risk factors may increase the risk of Alzheimer's disease 
independently. The risk of Alzheimer's disease for family history ofDown's syndrome and 
for family history of Parkinson's discase tended to be higher for those who also had a 
positive family history of dementia. These findings support the view of a genetic link 
between Alzheimer's disease and Down's syndrome and between Alzheimer's disease and 
Parkinson's disease. However, in bath cases the interaction was nat statistically significant. 
There was some evidence that smoking may be related specifically to a genetically 
determined process. The risk of Alzheimer's disease associated with family histQry of 
dementia tended to be lower in smokers as compared to non-smekers. This effect was 
most pronounced for these with two ar more affected relatives. When camparing 
smoking patients to non-smoking patients from families in which the disease was 
apparently inherited as an autosomal dominant disorder, the onset of disease was 
significantly later in smokers (chapter 5.3). 
The inference that can be drawn upon our findings was discussed in chapter 6.2 
179 
Chapter 7 
(methodologie issues) and chapter 6.3 (forrnal aspects). The quality of the case-control 
studies conducted to date may be criticized. In order to detemrine the etiologie 
significance, risk factors that have emerged in these studies remain to be confirmed, 
preferably in prospective follow-up studies. At present, research on the interaction 
between hereditary and environmental factors is limited by the Jack of biologie genetic 
markers suitable for population studies. 
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Het doel van de onderzoeken beschreven in dit proefschrift was mogelijke 
risicofactoren voor de ziekte van Alzheimer op te sporen (hoofdstuk 1). Erfelijke en 
omgevingsfactoren, alsmede hun onderlinge interactie, zijn bestudeerd in twee 
onderzoeken. Het eerste was een genetisch-epidemiologisch onderzoek bij 198 patiënten 
bij wie de ziekte van Alzheimer op jonge leeftijd (voor het 70ste levensjaar) werd 
gediagnostiseerd en 198 op leeftijd en geslacht gematchte controle personen. De 
patiënten en controles waren afkomstig uit de vier noordelijke provincies en de regio 
Rotterdam. Het tweede onderzoek betrof een her-analyse van alle patiënt-controle 
onderzoeken naar risicofactoren voor de ziekte van .Alzheimer, die voor 1 januari 1990 
zijn uitgevoerd. Deze analyse betrof zowel patiënten bij wie de ziekte van Alzheimer op 
jonge leeftijd begon als patiënten bij wie de ziekte zich pas op oudere leeftijd 
manifesteerde. De opzet van de twee onderzoeken werd besproken in hoofdstuk 2. 
In hoofdstuk 3 werd de rol van erfelijke facmren onderzocht. Het vóórkomen van de 
ziekte van Alzheimer in de familie werd nagegaan in de her-analyse van patiënt-controle 
onderzoeken (hoofdstuk 3.2). Het risico op de ziekte van Alzheimer was duidelijk 
verhoogd voor personen met één of meer eerste graads verwanten met dementie. Het 
risico nam af met het toenemen van de leeftijd waarop de ziekte begon. Echter ook 
patiënten bij wie de ziekte na het 80ste levensjaar begon hadden vaker eerste graads 
verwanten met dementie dan controle personen. Het risico op de ziekte van Alzheimer 
was lager bij patiënten met één familielid met dementie dan bij patiënten met twee of 
meer eerste graads familieleden met dementie. Daarnaast kwamen bij eerste graads 
familieleden van patiënten met de ziekte van Alzheimer vaker familieleden met het 
syndroom van Down en met de ziekte van Parkinson voor dan bij eerste graads 
verwanten van de controle personen (hoofdstuk 3.2). De wijze van erfelijke overdracht 
van de ziekte van Alzheimer werd onderzocht bij de eerste graads familieleden van de 
198 Nederlandse patiënten bij wie de ziekte van Alzheimer voor het 70ste levensjaar 
werd vastgesteld (hoofdstuk 3.3). Bij de eerste graads verwanten was het risico op de 
ziekte van Alzheimer (0.39) lager dan verwacht voor een aandoening die autosomaal 
dominant wordt overgedragen (0.50), hoewel de geobserveerde waarde niet significant 
van de verwachte waarde verschilde. Met behulp van segregatie analyse kon worden 
aangetoond dat het clusteren van de ziekte van Alzheimer in families slechts ten dele te 
verklaren was door een dominant overgedragen gen. Daarnaast spelen andere erfelijke 
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of niet erfelijke factoren mogelijk een rol. Bij een aantal families is een mutatie in exon 
17 (transcript AJ?P770) van het amyloid precursor eiwit gen aangetoond, die mogelijk de 
ziekte van Alzheimer veroorzaakt. Bij 100 patiënten uit het Nederlandse onderzoek werd 
deze mutatie nagegaan (hoofdstuk 3.4). De onderzoekspopulatie bevatte ondermeer 14 
niet verwante patiënten afkomstig uit families waarin het overervingspatroon erop wees 
dat de ziekte van Alzheimer mogelijk erfelijk is bepaald. Bij geen van de 100 patiënten 
kon de mutatie worden aangetoond. Deze bevinding suggereert dat het een zeldzame 
oorzaak van de ziekte van Alzheimer betreft. Bij patiënten met de ziekte van Alzheimer 
zijn verhoogde niveaus van DNA-schade waargenomen. Het is mogelijk dat het DNA-
herstel mechanisme een rol speelt in de ziekte van Alzheimer. DNA-herstel werd 
nagegaan bij 43 patiënten bij wie de ziekte voor het 70ste levensjaar begon en bij 48 
controle personen (hoofdstuk 3.5). Een verminderd herstel van DNA-breuken 
geïnduceerd door N-ethyl-N-nitrosourea werd waargenomen hij patiênten afkomstig uit 
families waarin de ziekte leek te worden overgedragen als een autosomaal dominante 
aandoening. Bij de overige patiënten waren er geen aanwijzingen voor een verminderd 
DNA-herstel. De resultaten van dit exploratieve onderzoek dienen bevestigd te worden 
door onafuankelijke onderzoeken. 
In hoofdstuk 4 werd de rol van omgevingsfactoren onderzocht. In hoofdstuk 4.2 werd 
een overzicht gegeven van de rol van niet-erfelijke en omgevingsfactoren, zoals gevonden 
in de her-analyse van patiënt-controle onderzoeken. Een verhoogd risico op de ziekte van 
Alzheimer kon worden aangetoond voor personen van wie de moeder 40 jaar of ouder 
was bij de geboorte, hoewel dit effect voornamelijk werd bepaald door de resultaten van 
66n onderzoek. Tevens was er een verband met een jonge leeftijd van de moeder bij de 
geboorte (19 jaar of jonger), maar ook deze relatie kon worden toegeschreven aan bet 
effect waargenomen in 6én onderzoek. In de medische voorgeschiedenis kwamen 
schildklierziekte (hypothyroïdie) en depressie als mogelijke determinanten van de ziekte 
v2n Alzheimer naar voren. Een verband tussen de ziekte van Alzheimer en ongevallen 
met het hoofd kon alleen worden aangetoond bij mannen. Hoewel het verband het 
sterkst was voor ongevallen met het hoofd die binnen een periode van tien jaar voor het 
begin van de ziekte optraden, werd in deze analyse ook een significant verhoogd risico 
gevonden voor ongelukken met het hoofd die meer dan tien jaar voor de eerste 
ziekteverschijnselen optraden. In het Nederlandse onderzoek kon daarentegen geen 
verban à worden aangetoond met ongelukken met het hoofd die meer dan tien jaar voor 
het begin van de ziekte optraden (hoofdstuk 4.3). Tenslotte werd er een inverse relatie 
gevonden tussen roken en de ziekte van Alzheimer in de her-analyse van patiënt-controle 
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onderzoeken (hoofdstuk 4.2). Een inverse relatie kon alleen worden aangetoond bij 
patiënten met een positieve familie-anamnese voor dementie. Verder waren er 
aanwijzingen voor een dosis-effect relatie. De bevindingen van het Nederlandse 
onderzoek waren zeer vergelijkbaar (hoofdstuk 5.3). Verhoogde waarden van acute-fase 
eiwitten zijn waargenomen bij patiënten met de ziekte van Alzheimer. De aanmaak van 
deze eiwitten is deels bepaald door interleuk.ine-6. Serum waarden voor interleukine-6 
waren echter vergelijkbaar bij 97 patiënten en 79 controle personen (hoofdstuk 4.4). 
In hoofdstuk 5 werd de interactie tussen erfelijke en omgevingsfactoren nagegaan. De 
leeftijd bij eerste ziekteverschijnselen werd onderzocht bij 139 familieleden afkomstig uit 
30 families waarin de ziekte autosomaai dominant leek te worden overgedragen 
(hoofdstuk 5.2). Alleen families waarin de eerste ziekteverschijnselen reeds voor het 60ste 
levensjaar optraden werden bestudeerd. De leeftijd bij eerste ziekteverschijnselen was 
meer vergelijkbaar binnen families dan tussen families. Deze bevinding suggereert dat het 
begin van de ziekte waarschijnlijk erfelijk is bepaald. De aanzienlijke spreiding in de 
leeftijd bij eerste ziekteverschijnselen tussen patiënten uit dezelfde familie en tussen 
identieke tweelingen doet echter vermoeden dat ook omgevingsfactoren een rol spelen. 
Tenslotte werd de interactie tussen erfelijke en omgevingsfactoren onderzocht in de her-
analyse van patiënt-controle onderzoeken (hoofdstuk 5.4). De leeftijd van de moeder bij 
de geboorte van de patiënt, ongelukken met het hoofd, depressie en hypothyroïdie waren 
geassocieerd met de ziekte van Alzheimer bij zowel patiënten met als zonder een 
positieve familie-anamnese voor dementie in eerste graads familieleden. Een positieve 
familiegeschiedenis voor dementie was geassocieerd met de ziekte van Alzheimer 
onafhankelijk van deze risicofactoren. Deze bevindingen suggereren dat erfelijke en 
omgevingsfactoren afzonderlijk het risico op de ziekte van Alzheimer kunnen 
beïnvloeden. Het risico op de ziekte van Alzheimer voor personen met een positieve 
familiegeschiedenis voor het syndroom van Down en voor de ziekte van Parkinson was 
hoger voor personen die tevens een positieve familiegeschiedenis voor dementie hadden. 
Hoewel in beide gevallen geen significant verschil tussen personen met en zonder een 
positieve familie-anamnese voor dementie kon worden aangetoond, suggereren deze 
bevindingen een gemeenschappelijke, wellicht erfelijk bepaalde, etiologie. Er waren 
aanwijzingen dat roken specifiek een rol speelt in een erfelijk bepaald proces. De her-
analyse van patiënt-controle onderzoeken liet zien dat het risico op de ziekte van 
Alzheimer voor personen met een positieve familie-anamnese voor dementie lager was 
voor rokers dan voor niet rokers. Dit effect was het sterkst bij personen met twee of 
meer eerstegraads verwanten met dementie. In de Nederlandse families was het begin 
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van de ziekte later bij patiënten die in het verleden hadden gerookt dan bij patiënten die 
nooit hadden gerookt (hoofdstuk 5.3). 
De implicaties van de onderzoeken beschreven in dit proefschrift werden besproken 
in hoofdstuk 6. Hierbij werd ingegaan op methodologische aspecten (hoofdstuk 6.2) en 
de rol van erfelijke en omgevingsfactoren (hoofdstuk 6.3). Geconcludeerd werd dat gezien 
de kwaliteit van de tot nu toe uitgevoerde patiënt-controle onderzoeken, de risicofactoren 
bevestigd dienen te worden bij incidente patiënten, bij voorkeur in een prospectief 
opgezet onderzoek. Onderzoek naar interactie tussen erfelijke en omgevingsfactoren 
wordt vooralsnog beperkt door het ontbreken van biologische genetische merkers die 
geschikt zijn voor bevolkingsonderzoek. 
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